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Abstract 
Underuse of medical care and prescription drug adherence are health behaviors 
affected by financial pressures, demographic and socioeconomic characteristics, and 
health status of Medicare beneficiaries. Cost-related underuse is the avoidance of needed 
medical care or prescription drugs due to financial concerns about the cost of the 
treatment. The purpose of this project is to determine the characteristics associated with 
cost-related underuse and to evaluate how health policy changes and prescription drug 
coverage may affect that behavior. The project aims are threefold: (1) determine the 
change over time and relationship between prescription drug coverage and the underuse 
of other medical care due to cost within the Medicare population; (2) examine the effect 
of enrollment in the Medicare Part D partial Low Income Subsidy (LIS), a program that 
provides scaled premium assistance and a flat 15% co-insurance, on adherence within 
drug classes associated with cost-related underuse; and (3) test the effects of financial, 
patient, and disease characteristics on prescription drug adherence within the Medicare 
partial LIS population. This study will provide a broader understanding of the policy 
levers, such as the Medicare Part D Low Income Subsidy, that impact prescription drug 
behavior and underutilization of medical care by Medicare beneficiaries. 
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Project Introduction 
This dissertation investigates adherence and cost-related underuse within the 
Medicare population and focuses on prescription drug-taking behaviors, medical care 
utilization, drug coverage, and pharmacy assistance programs, such as the Medicare Part 
D Low Income Subsidy (LIS) or Extra Help program. This study provides a broader 
understanding of cost-related underutilization within the Medicare population to inform 
evaluation of the Medicare Part D program and to improve the quality of health within 
the Medicare population. The findings of this project integrate into the broader medical 
sociology, health policy, and applied health services research literatures that examine 
prescription drug adherence and will be useful to health policy makers and practitioners 
providing care to the Medicare population. 
The project goals are threefold: (1) determine the change over time and the 
relationship between prescription drug coverage and the underuse of other medical care 
due to cost within the Medicare population; (2) examine the effect of enrollment in the 
Medicare Part D partial LIS benefit, a program that provides scaled premium assistance 
and a flat 15% co-insurance, on adherence within drug classes associated with cost-
related underuse; and (3) test the effects of financial, patient, and disease characteristics 
on prescription drug adherence within the Medicare partial LIS population. These three 
study aims examine prescription drug behavior that may be affected by cost constraints 
and evaluate the responses of this behavior to health policy changes and prescription drug 
plan coverage.  
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Literature Background on Cost-Related Underuse of Prescription Drugs 
Prescription drug adherence as a health behavior concept has an extensive health 
services and clinical research literature.1 The traditional focus has been the physician-
patient dyad, and research findings from this perspective typically suggest patient 
education strategies to correct non-adherent behaviors.2 The issue of cost-related 
underuse is a relatively recent area of research and broadens the traditional scope of study 
to include characteristics of the health insurance market and medical care system.3 
Conceptually, a person who experiences cost-related underuse would be an adherent 
patient net the cost constraint and this suggests public policy and programs as possible 
solutions rather than behavioral or attitudinal interventions. Within this broad literature, 
the conceptual terms of compliance, adherence, concordance, and underuse have all been 
used to describe the attitudes and health behaviors of patients who do not follow medical 
treatment regimens as prescribed. While some4–6 distinguish ideological differences 
between the applications of the different terms, I use the term underuse to describe sub-
optimal medication taking behaviors self-reported from survey data such as skipping 
doses or splitting pills and non-adherence/adherence to describe health behavior measures 
using clinical data or administrative claims.  
Medication underuse and non-adherence by the elderly is an important topic in 
health services research and health policy analysis.6 Underutilization of prescription 
drugs in the elderly population is more prevalent due to higher rates of chronic conditions 
that require medications7,8 and more households with fixed incomes.9 The most common 
definition of underutilization of prescription drugs within the health survey literature is 
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not filling or obtaining medication from the pharmacist.10 However, underuse may result 
from a range of behaviors that do not follow the medication-taking regimen, such as 
increasing the spacing of dosages, skipping doses, or splitting pills to lengthen the 
prescription fill.7,11 A comparison of rates of prescription medication underuse due to cost 
reasons (as measured by self-report survey questions of not filling a prescription during 
the previous time period, delaying initiation of medication use, skipping or splitting pills) 
in the community-dwelling, adult population range from 1.6 to 22 percent and averaged 
4.2 percent within the Medicare-only population prior to the implementation of the 
Medicare Part D benefit.10 Rates vary due to question wording, look-back periods, survey 
source, and sample.10,12  
The health consequences of underuse include increases in co-morbidity,13 worse 
management of illness,14,15 and increased risk of mortality.16 Health system consequences 
for service delivery from prescription drug underutilization include increasing rates of 
hospitalizations, use of the emergency departments, and demand for home health care 
services.16 At the population level, the relationship between cost-related underuse and the 
lack of prescription drug coverage within the Medicare benefit was one of the driving 
forces for the passage of the Part D legislation.17–19  
Prescription drug utilization and drug plan coverage patterns by the Medicare 
population have been studied extensively.17,18,20–27 Descriptive analyses have documented 
racial and socioeconomic differences in utilization and drug plan enrollment rates19,28–31 
and types of medications used by subpopulations stratified by health or co-morbidity 
conditions.23,32–34 The relationship between race/ethnicity and cost-related underuse of 
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prescription drugs has been shown to be related to financial pressures, such as 
income.17,35 Given that many of the elderly population are retired with fixed incomes, a 
large number of studies focus on the underuse of prescription medications due to cost 
reasons36–38 based on limited out-of-pocket spending budget constraints. 
Several studies of non-Medicare populations have shown that differing levels of 
coinsurance rates and co-payment levels may reduce prescription drug utilization and 
increase non-adherence.36,39 Stuart and Zacker40 show that dual- eligible beneficiaries 
residing in states with Medicaid drug co-payments have lower overall utilization than 
dual beneficiaries in states without co-payments. Ku41 finds that co-payment differences 
of even a $1 between brand and generic for beneficiaries with incomes less than $5000 is 
equivalent to a $10 difference for beneficiaries with household incomes of $50,000.  
The relationship between prescription drug non-adherence and the use of other 
medical care has typically been examined from the perspective of impact on total health 
care costs: better drug adherence results in net savings from not using other more costly 
health services or, conversely, poorer adherence results in more costly hospitalizations 
and emergency services.16 These offset studies typically focus on a single drug class 
related to a chronic condition, such as congestive heart failure,42 myocardial infarction,43 
stroke,44 cancer,45 or depression.46 Data used for the analyses in these studies is 
frequently administrative claims that allow sequencing of procedures and prescription 
fills to estimate changes in co-payments and service utilization. Self-reported underuse of 
medical care within the Medicare population and its relationship with prescription drug 
coverage has not been examined using this same framework. 
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Policy Background of Medicare Part D Low Income Subsidy Program 
Non-adherence and cost-related medication underuse are important areas of study 
within the Medicare population. Concerns about underutilization and the importance of 
drug coverage were demonstrated by the implementation of the Part D program on 
January 1, 2006, which marked one of the largest coverage expansions in Medicare 
program history. The outpatient prescription drug benefit allows beneficiaries to choose 
to enroll in either stand-alone Prescription Drug Plans (PDP) or Medicare Advantage 
Plans with Part D (MA-PD). Part D coverage is a benefit that has phases based on total 
out-of-pocket and utilization costs with four different stages: the deductible, initial 
coverage, the benefit gap, and catastrophic coverage. Congress designed the phased 
benefit in order to attract private plans to offer prescription drug coverage. Enrolled Part 
D beneficiaries move through the different stages based on out-of-pocket costs and total 
drug spending during the calendar year. The importance of the study of cost-related 
underuse is a primary concern during the benefit gap or “donut hole,” which is the Part D 
benefit phase when the beneficiary is responsible for the full cost of the medication and 
plan premium. During the gap phase, the Medicare beneficiary is facing the same cost 
constraints as someone without drug coverage but the person has the additional cost of 
continuing to pay the monthly premium. For private plans offering the Medicare 
prescription drug coverage, the catastrophic coverage phase provides re-insurance of 
high-cost beneficiaries. 
The Part D benefit design provides different incentives for plans to address 
beneficiary adherence levels, in general, apart from the benefit phase feature. PDPs or 
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stand-alone drug plans have little or no financial incentive to improve or monitor 
adherence because better adherence would result in increased drug utilization; any 
medical utilization offsets would benefit the Medicare program and not PDP profits. MA-
PDs, in comparison, do have incentives to improve drug adherence to prevent other more 
costly health care utilization because the plan is responsible for coverage of the 
beneficiaries other Medicare-covered medical care; therefore, better adherence levels for 
MA-PD enrollees have the potential to result in net plan savings or better profits. As 
such, the examination of drug adherence within the Medicare population is an important 
research area for all Part D enrollees and not just those select numbers that encounter the 
donut hole or benefit gap feature.  
The Low Income Subsidy (LIS) program is one of the “safety net” features of the 
Part D program that allows Medicare beneficiaries who qualify based on assets and 
income levels to be eligible to receive premium subsidies and reduced cost sharing. The 
LIS program is administered by the Social Security Administration (SSA), which is 
responsible for the eligibility determination and program enrollment in coordination with 
state Medicaid programs. Medicare beneficiaries who are dually-enrolled in the Medicaid 
program are deemed or auto-enrolled into the LIS program. Other non-dual beneficiaries 
may apply to qualify for enrollment. LIS Medicare beneficiaries are not subject to benefit 
phase constraints, such as the donut hole, and account for close to two-thirds of all 
prescription drug enrollees that reach the catastrophic coverage benefit phase.47 The LIS 
program has 8 categories of enrollment that vary based on the premium subsidy amount 
and the cost sharing proportion.  
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LIS categories differentiate deemed and non-deemed beneficiaries and the 
premium subsidy and cost-sharing amounts as shown in Table 1.48 The deemed LIS 
enrollees are Medicare beneficiaries who are enrolled in the Medicare Savings Programs 
(MSP), or more commonly known as the Medicare-Medicaid duals, and are automatically 
assigned their corresponding LIS category based on their MSP qualification status. The 
MSP program has different Medicaid coverage categories based on the individual’s asset 
and income level. Deemed LIS enrollees are autoenrolled in a stand-alone PDP but may 
elect to enroll in an MA-PD. Non-deemed enrollees must apply for the LIS program and 
categorical assignment is based on their SSA income level without asset-level 
certification. The last category in Table 1 is for enrollees in the Part D program that are 
not in the LIS program and they do not received any premium subsidies or cost sharing 
but may enroll in a plan with gap coverage. The partial LIS group examined in research 
aims 2 and 3 of this project are categories 6 through 8. 
For 2006 and 2007, programmatic summary statistics show that roughly 25 
million beneficiaries or 54% of the total Medicare population enrolled in the Part D 
program.49 Of those enrolled in Part D, 72% in 2006 and 69% in 2007 were enrolled in 
the stand-alone PDPs.49 Approximately 10 million beneficiaries or 40% of the enrolled 
Part D Medicare population in 2006 and 2007 were enrolled in the Low Income Subsidy 
program and roughly 85% of LIS enrollees were deemed or auto-enrolled.49 The average 
time from deductible to the benefit gap in 2006 and 2007 was approximately 6 months 
and the average time in catastrophic coverage was 4 months.50 For the LIS enrolled Part 
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D population, approximately 44% exceeded the initial coverage limit in 2006 and 2007; 
for the non-LIS enrolled population, approximately 24% reached the benefit gap phase.50  
Project Aims 
The project has three specific research aims: (1) examine the change over time of 
prescription drug and medical care underutilization within the Medicare population, (2) 
evaluate the effect of the Medicare Part D Low Income Subsidy (LIS) program for those 
enrolled within the partial LIS benefit on cost-related underuse of medications, and (3) 
determine the effects of differing premium subsidization amounts and race/ethnicity on 
prescription drug adherence controlling for other financial, patient, and diagnostic 
characteristics within the partial LIS population. Both survey and administrative data are 
used to address these research aims.  
The first research objective examines cost-related underutilization of prescription 
drugs and medical care and its relationship with prescription drug coverage. This study 
aim examines the possible policy solutions for minimizing cost-related underutilization. 
Using both descriptive and statistical analysis of the Medicare Current Beneficiary 
Survey (MCBS), the findings from this research objective compare over time the 
phenomena of cost-related underutilization for both medical care and prescription drugs 
as self-reported by the Medicare beneficiary. The key question is to determine if 
prescription drug behavior is similar to other health care behaviors or if it is unique. The 
findings from this study examine responsiveness of cost-related underuse to an extension 
of prescription drug coverage and whether this pattern is similar for prescription drugs 
and medical care. The statistical analysis uses longitudinal data to examine the 
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relationship of prescription drug underutilization and underuse of medical care and the 
effect of prescription drug coverage over time. 
The second research objective evaluates the effect of partial LIS enrollment on 
adherence within the three drug classes most likely to have cost-related underuse reported 
in the MCBS data: statins, gastrointestinal agents, and anti-diabetics. Using 
administrative enrollment and claims data, this research aim examines Part D enrollees’ 
prescription drug adherence levels before and after enrollment in the Low Income 
Subsidy program to evaluate whether the additional income assistance, through cost 
sharing and premium assistance, improves adherence with prescribed drug therapy 
regimens. The dependent variable is the calculated administrative drug adherence 
measure. The Medicare claims and enrollment administrative data are collected from 
2006 through 2010 and allow analysis of the initial implementation period of the Part D 
program. The analytic sample is composed of Medicare beneficiaries who first enrolled 
in the Part D benefit and later enrolled in the LIS program between 2006 and 2010 to 
allow examination of pre-LIS enrollment and post-LIS enrollment adherence levels. 
Independent variables used in the analysis include financial, patient, and diagnostic 
characteristics. The implications of the findings from this research aim provide an 
evaluation of whether the LIS program enrollment improves medication adherence and 
decreases cost-related underuse of prescription drugs for Medicare beneficiaries.  
The third research objective compares the different levels of premium assistance 
provided to partial LIS enrollees based on their income and asset levels and race/ethnicity 
of the beneficiary in the examination of prescription drug adherence levels. The partial 
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LIS program has 3 different categories of eligibility with the same cost sharing but 
differing premium subsidization amounts based on income. Cost-sharing levels are a flat 
15% coinsurance level. Premium assistance ranges from notched levels at 75%, 50%, and 
25% assistance. Similar to the second research aim, administrative enrollment and claims 
data are used for this research aim. The purpose of this research aim is to examine 
race/ethnicity and the effects of the differing cost sharing and premium subsidization 
levels on medication adherence for select therapeutic classes, such as gastrointestinal 
agents, anti-diabetics, and statins. The 2006-2010 administrative enrollment and claims 
data are used to construct the analytical cohort of all partial LIS enrollees. The findings 
from this study objective provide information on the effectiveness of the partial LIS 
program for increasing prescription drug adherence by the Medicare population enrolled 
in the Part D benefit and needing the additional financial assistance provided by cost 
sharing and premium subsidization. Taken together, the importance of these last two 
research aims is to examine the two primary policy levers, cost sharing and premium 
assistance, for reducing cost-related underuse of prescription drugs within the Medicare 
population. 
Conceptual Model of Prescription Drug Non-Adherence 
Given over 50 years of academic research on adherence,6 prescription drug 
underutilization due to cost is a relatively recent focus within the extensive drug 
adherence literature. Starting in the late 1990s with Soumerai, et al.39 examination of 
cost-related underuse within the Medicaid population in response to increases in co-
payments and benefit caps, researchers have expanded the literature from a focus on the 
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clinical patient-physician dyad to a broader health services conceptual model that 
incorporates the health environment context. Piette, et al.51 accurately summarize the next 
generation of studies that focus on the bridge between the economic barriers conceptual 
model and the adherence conceptual model as shown in Figure 1. 
The cost-adherence conceptual model links compliance and cost-related underuse 
in the same model.51,52 The direct effect of financial pressures, such as drug coverage, 
cost-sharing, subsidy programs, income level, interacts with drug regimen characteristics, 
such as number of prescriptions and refill frequency, and is moderated by patient, drug, 
health, and health system characteristics and mediated by clinician and health system 
factors. Patient characteristics are measures of socio-demographic traits, cognitive ability, 
or health literacy and attitudes. Diagnosis characteristics are health measures such as 
disease burden or disability status. Drug characteristics include therapeutic class, side 
effects, drug form, and immediacy of benefits. The patient, diagnosis, and drug 
characteristics have a direct effect on drug non-adherence and are the main components 
of the traditional drug adherence conceptual model. The health system factors include 
pharmacy access, cost assistance programs, or coordination of care programs and have 
both mediating and moderating effects in the conceptual model. Clinician factors are 
measures of the patient-physician dyad relationship. The traditional adherence model 
focused on the patient, drug and diagnosis characteristics and the mediating effects of the 
clinician factors. 
The cost-adherence conceptual model informs the research design of this 
dissertation project, but the data sources used in the analysis do not have variables that 
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match all of the separate model concepts. Nonetheless, the model is useful for this project 
because it addresses the behavior influences that affect the drug adherence decision 
process. The conceptual model also highlights the groups of key variables and 
relationships that need to be measured and tested in the statistical models for the research 
aims. The primary conceptual area that captures the main exposure variables in the 
empirical models tested in this project is financial pressures, such as income and drug 
coverage, and patient and diagnostic characteristics are also tested. 
Financial characteristics examined in this project that are associated with cost-
related underuse include prescription drug coverage, premium and cost-sharing 
assistance, and income and asset levels of the Medicare beneficiary. Following the 
conceptual model, it is expected that obtaining prescription drug coverage or having 
higher income levels decreases the financial pressure for the Medicare beneficiary and 
increase prescription drug adherence or reduces the likelihood of cost-related 
underuse.34,37,38,52–55   
Patient characteristics examined in this project include demographic variables, 
such as age, sex, and race/ethnicity. In addition, Study 1 includes socioeconomic 
variables such as education level, employment status, and metropolitan status. Patient 
characteristics account for individual differences, such as patient-physician 
communication patterns, patient beliefs about the efficacy of treatment,  patient abilities 
to understand medical advice, or differences in patterns of medical care seeking 
behaviors and having a usual source of care.30,56,57 Older Medicare beneficiaries are less 
likely to experience cost-related underuse than younger beneficiaries.58–61 Women are 
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more likely to experience cost-related underuse than men.62–64 Cost-related underuse has 
been shown to vary by race/ethnicity groups within the Medicare population,56,65–67 and it 
is expected that non-white racial groups or Hispanic ethnicity are more likely to have 
cost-related underuse.64,68,69 
Diagnostic characteristics associated with cost-related underuse that are examined 
in this project include chronic conditions or measures of co-morbidity.  Having multiple 
chronic conditions increases the number of prescription medications used to treat 
Medicare beneficiaries, known as polypharmacy,2,12,54,70 and it is expected to increase the 
likelihood of cost-related underuse and poorer adherence.34,71,72  Study 1 also includes 
self-reported mobility limitations and these limitations are expected to increase the 
likelihood of cost-related underuse.63,73 
One limitation of the Piette, et al.51 cost-adherence conceptual model is that it 
does not distinguish between decreases due to overutilization and decreases that are 
adverse underutilization.74 Increased financial pressures, such as higher co-payments, 
may have a beneficial effect of decreasing overutilization. The drug characteristics have a 
moderating effect in the model, so the degree to which overutilization is related to 
particular types of drugs would be captured in the model, but the distinction needs to be 
clear in the operationalization of the drug non-adherence that decreases in utilization may 
be reflecting decreases in overutilization. To address this possible conceptual model 
limitation, Studies 2 and 3 examine therapeutic classes most likely to have cost-related 
underuse within the Medicare population, and Study 1 examines survey questions that 
ask about needed medical care and prescribed medications. 
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The research aims of this project address different sections of Piette’s conceptual 
model. The first research aim expands the conceptual model by examining other health 
outcomes, such as cost-related underuse of medical care. The second aim examining 
pre/post partial LIS enrollment focuses on the health systems factors by examining how a 
safety net policy lever, which provides premium subsidization and cost-sharing, may 
reduce financial pressures and affect prescription drug adherence. The third research aim 
concentrates on the financial pressures and patient characteristics by comparing 
adherence levels by the income and premium subsidization groups and individual-level 
characteristics, such as race and ethnicity. For each of the research aims, the explanatory 
variables tested within the empirical models are grouped within their corresponding 
conceptual area as related to financial pressures, patient, and diagnostic characteristics. 
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Table 1: Low Income Subsidy Categories 
LIS Category Deemed 
Premium 
Subsidy 
Co-Payment  
Cost-Sharing 
1 Yes 100% No Co-Payment 
2 Yes 100% Low ($1-$3) 
3 Yes 100% High ($5-$7) 
4 No 100% High ($5-$7) 
5 No 100% 15% Co-payment 
6 No 75% 15% Co-payment 
7 No 50% 15% Co-payment 
8 No 25% 15% Co-payment 
9 No None No Cost Sharing 
Source: Centers for Medicare and Medicaid Services (CMS). 2011. “Chapter 13 – 
Premium and Cost-Sharing Subsidies for Low-Income Individuals” in Medicare 
Prescription Drug Benefit Manual. Baltimore, MD: U.S. Department of Health & Human 
Services. 
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Figure 1. Cost-Adherence Conceptual Model 
 
Source: Piette JD, Heisler M, Horne R, Alexander GC. 2006. “A Conceptually Based 
Approach to Understanding Chronically Ill Patients’ Responses to Medicare Cost 
Pressures.” Social Science & Medicine 62(2006):849. 
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Study 1: Cost-Related Underuse Before and After Medicare Part D  
Summary for Study 1 
Research Objective: The primary purpose of this study is to examine rates of 
prescription drug and medical care underutilization due to cost within the Medicare 
population and to compare these rates before and after the implementation of the 
Medicare Part D benefit. 
 
Study Design: The Medicare Current Beneficiary Survey (MCBS) Access to Care 
modules are used to compare a longitudinal cohort from 2005 to 2007. Underutilization is 
defined as self-reported behaviors to extend prescribed medications, such as skipping 
doses, splitting pills and not acquiring medication fills, or as foregoing needed medical 
care by the beneficiary during the previous 12 months. Explanatory variables include 
prescription drug coverage, demographic and socioeconomic characteristics, chronic 
conditions, mobility measures, and geography. Logistic regression is used to test cost-
related underuse following the implementation of Part D in 2007 in a stratified analysis of 
Medicare beneficiaries that experienced underuse in 2005 and those that did not.  
 
Population Studied: Community-dwelling, continuously-enrolled Medicare population 
from 2005 to 2007. 
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Principal Findings: Medicare beneficiaries had a reduction in cost-related underuse of 
medical care from 7.6 percent (95% confidence interval(CI), 6.8-8.3) in 2005 to 5.8 
percent (95% CI, 5.1-6.6) in 2007 and had a larger reduction in cost-related underuse of 
prescription drugs from 13.4 percent (95% CI, 12.1-14.7) in 2005 to 9.1 percent (95% CI, 
8.1-10.1) in 2007. Medicare beneficiaries who did not experience cost-related underuse 
of prescription drugs in 2005 had a 0.06 (95% CI, 0.06-0.07) probability of newly 
experiencing cost-related underuse of prescription drugs in 2007, and of those 
beneficiaries not obtaining prescription drug coverage had a marginal probability increase 
of 0.02 (95% CI, 0.003-0.04) in the likelihood of underuse compared to those with 
continuous drug coverage from 2005 to 2007. In comparison, beneficiaries who did not 
experience cost-related underuse of medical care in 2005 had a 0.04 probability (95% CI, 
0.04-0.05) of newly experiencing it in 2007, and compared to those with continuous drug 
coverage, those with new prescription drug coverage had a marginal probability increase 
of 0.012 (95% CI, 0.0004-0.02) and those with no drug coverage in both 2005 and 2007 
had a marginal probability increase of 0.014 (95% CI, 0.003-0.03) in the likelihood of 
medical care underuse in 2007. 
 
Conclusions: The findings suggest the implementation of Part D was associated with an 
overall decline in cost-related underuse within the Medicare population, and those that 
did not experience underuse in 2005 and continued to lack drug coverage in 2007 were 
more likely to newly experience underuse in 2007.  
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Introduction  
Following the implementation of Medicare Part D in 2006, cost-related underuse 
continued to be a concern, especially for Medicare beneficiaries who encountered the 
coverage gap.26 Possible consequences for those Medicare beneficiaries that adopted cost 
saving strategies, such as not filling prescriptions or taking medications less frequently 
than the prescribed dosage, were potentially adverse effects that affected their health and 
treatment regimens.38 While there are several corollary concerns that relate to 
underutilization, such as issues of medical knowledge needed for understanding treatment 
regimens,75,76 doctor-patient communication about reasons for the prescribing the 
medication,37 and understanding drug interaction effects77 that are not addressed in this 
study, the underutilization of prescription medications due to cost reasons continues to be 
a major issue for the health of the Medicare population.71,78,79 
Prescription drug underutilization within the elderly population has received a 
vast amount of study.12,17,80 Most studies are cross-sectional surveys or compliance 
evaluations. Longitudinal rates of prescription drug underutilization within the Medicare 
population have not been examined with the same detailed analysis. Similarly, the 
relationship between prescription drug coverage and the underuse of other medical care is 
not as well-studied in the Medicare population. Given that the implementation of 
Medicare Part D was the largest, recent benefit expansion, it remains important to 
investigate baseline rates of underuse by Medicare beneficiaries to examine the health 
behavioral response to the policy change.  
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Background on Medicare Part D Implementation 
 The initial implementation of the Medicare Part D benefit was associated with 
reductions in cost-related underuse of prescription drugs.81–86 More recently, however, 
these initial gains have eroded for the Medicare disabled population79 and those with 
multiple chronic conditions.71 These recent increases in cost-related underuse do not have 
a clear reason for the change, such as coverage benefits. The Part D benefit structure 
remains the same for the disabled Medicare population that are deemed, and the donut 
hole coverage gap began to close starting in 2011, which benefits high drug utilization 
groups such as those with multiple chronic conditions. If the trend reversal is related to 
increased financial pressures experiences from the recession, it would be expected that 
cost-related underuse would decline as the economy recovers; however, if the trend 
reversal is related to increased financial pressures from increasing drug prices, then the 
reversal of the trend would be expected to continue.  
 Research examining the relationship between Medicare Part D and medical care 
are broadly grouped as the “offset” studies because they focus on how prescription drug 
therapy use offsets or reduces the utilization of other medical care, mainly higher cost 
care.87 For example within the Medicaid population, a 1% increase in prescription drug 
use relates to a 0.04% to 0.17% decrease in inpatient and outpatient costs.88 Offset effects 
within the Medicare population following the implementation of Part D are mixed. Some 
find no effect,89,90 and others find positive effects of reduced hospitalizations91 or 
declines in non-drug medical costs,92 especially when drug adherence is factored into the 
model.72,93 One recent analysis found the implementation of Medicare Part D reduced 
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non-urgent and unnecessary emergency department visits.94 Offset studies examine 
administrative claims data for medical care and prescription drugs but have not examined 
self-reported underuse of medical care from survey data. The relationship between 
Medicare Part D coverage and self-reported cost-related underuse of medical care has not 
been examined previously and is a unique contribution to the research literature by this 
study. 
Research Design  
Data 
The dataset used for this analysis is survey data for a national Medicare sample. 
The Medicare Current Beneficiary Survey (MCBS) is a multi-purpose panel survey 
composed of four rotating cohorts interviewed in person, three times per year over a four-
year period. The Computer Assisted Personal Interview (CAPI) is conducted in-person at 
the beneficiary’s place of residence. Survey instruments on access and self-reported 
health measures are administered during the fall interview round. Health care utilization 
and coverage information is collected each round following the initial interview, which is 
used for training the panelist in how to track the data that is reported in the subsequent 
rounds. The sample is constructed from the enrolled Medicare population and includes 
community and facility beneficiaries in all 50 states, the District of Columbia and Puerto 
Rico. The primary sampling units are based on zip code clusters, and the strata are 
beneficiary age groups. MCBS divides the collected data into two different modules for 
each calendar year: Access to Care and Cost and Use. The Access to Care module 
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contains that fall round survey instruments, and the Cost and Use modules contains the 
health care utilization and associated costs reported during each survey round. An 
entering cohort is trained during the first fall survey round on how to collect utilization 
and cost information that is reported in each of the subsequent interview rounds. For this 
reason, panelists may be tracked through four Access to Care modules containing fall 
round survey data and three Cost and Use modules for the calendar year medical care 
utilization following that first fall round interview and training. Each module contains the 
survey weights and variance correction variables for the complex survey design. In 
addition, the Access to Care module contains two-, three-, and four-year backwards 
longitudinal weights. MCBS has been continuously fielded since 1991 and allows the 
examination of historical behavioral data prior to the implementation of Medicare Part D. 
For this study, the 2005 and 2007 Access to Care modules are used to construct a 
longitudinal panel. 
The benefits of using the MCBS data are threefold. First, the panel allows 
longitudinal study of prescription drug behavior and underutilization of medical care. 
Second, the sample is a national representative sample of the entire enrolled Medicare 
population that includes the disabled and facility dwelling beneficiaries who are typically 
absent in other survey samples. Lastly, the survey also includes self-reported health 
conditions and utilization for both the Fee-for-Service (FFS) and Medicare Advantage 
(MA) populations.  The use of self-reported health conditions and health behaviors from 
survey questionnaires, such as those used by MCBS, have been shown to be valid and 
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reliable measures of health95–97 and prescription drug behavior98,99 compared to measures 
from administrative claims data and medical charts. 
Study Sample 
 A retrospective longitudinal cohort was constructed from the Access to Care 
modules from 2005 through 2007 to examine cost-related underuse before and after the 
implementation of the Medicare Part D benefit. The study examines cost-related underuse 
of medical care following the implementation of Medicare Part D. Cost-related underuse 
of prescription drugs provides a comparison for the medical care results and contributes 
to previous findings of cost-related underused of prescription drug by examining the 
stratified Medicare population based on prior underuse. Previous findings examining the 
two-year longitudinal cohort from 2005-2006 cohort found a reduction in prescription 
drug cost-related underuse following Medicare Part D.83,84 Limitations of using a shorter 
panel, such as the 2005-2006 cohort, are twofold. First, MCBS fields the survey 
instruments during the fall so the question look-back periods for the underutilization 
measures include a portion prior to the January 1 start date of the Part D benefit. 
Secondly, the initial implementation of Medicare Part D had open enrollment through 
May of 2006, so an examination of Part D drug coverage may only coincide for a partial 
period of overlap. The 2005-2007 panel cohort does not have these limitations. For the 
2005-2007 cohort, Medicare Part D has been shown to be related to declines in 
prescription drug underuse,81,82 but the relationship between Part D coverage and the 
underuse of medical care has not been previously examined during this same period. 
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 Figure 2 provides the detailed flow chart showing the construction of the 
analytical sample used in this study. The total sample size for the 2005-2007 MCBS 
cohort is 6,654 respondents. The retention rate between the 2005 and 2007 fall round 
interviews was 94.0% for the longitudinal cohort.100 Most of response decline is due to 
mortality (approximately 5%). The overall survey response rate for this cohort is 63.9% 
for the entire panel rotation including the initial refusal rate.100 Approximately 82% of the 
Medicare beneficiaries agree to participate in the survey when they are initially contacted 
and retention declines following that initial agreement are mainly from decedents and 
respondent moves outside of the CAPI survey clusters that are not tracked.100  
In construction of the analytical cohort used in this study, respondents that were 
facility-dwelling respondents or refused to reply to the selected survey questions were 
excluded from the analysis. MCBS survey respondents that were residing in a nursing 
home or long-term care facility during the fall survey rounds in 2005 or 2007 
(unweighted N = 478) are excluded from the analytical sample because facility 
respondents are not directly interviewed, and different survey instruments that do not 
include questions of prescription drug or medical care underuse are completed by a proxy 
respondent for panelists by the designated contact within the residential facility. The 
second exclusion criteria from the cohort are the small number of respondents with 
missing data (unweighted N = 72) because of item non-response to the question or they 
did not complete the entire interview round that included the questions used in the 
analysis. Since the MCBS is a complex survey design, all respondents (unweighted N = 
6,654) are included to have complete strata and cluster information for the Taylor 
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linearization calculations of standard errors but only the analytical subpopulation 
(unweighted N = 6,104) provide the information used in the analysis variables. The final 
analytical sample represents 33,119,862 Medicare beneficiaries continuously enrolled in 
the Medicare program from 2005 through 2007 and residing in the community. 
Outcome Variables 
Cost-related underuse is measured separately for medical care and prescription 
drugs. Table 2 provides the survey instrument questions for the measures used to 
construct the cost-related underuse outcomes from the MCBS Community Core survey 
instruments.101 Underutilization of medical care is reported in the Access to Care module 
and occurs when the survey respondent does not seek medical care due to concerns about 
the cost of the care at any time during the previous 12 months. Respondents that report 
“yes” are coded as experiencing cost-related underuse of medical care, and “no” replies 
are coded as not experiencing it. Respondents that refuse to answer the question or “don’t 
know” are coded as missing data for cost-related underuse of medical care. Prescription 
drug cost-related underuse is constructed from three survey questions.82–84 Cost-related 
underuse is coded if a respondent reports not acquiring a prescribed medication during 
the previous 12 months because of the medication cost, or reports “often”/”sometimes” 
taking smaller doses of a medication to extend the length of the fill, or reports 
“often”/”sometimes” skipping doses to extend the medication coverage length. The 
respondents are coded as not experiencing cost-related underuse if they do not report any 
of those behaviors or as having missing data if they refuse or “don’t know.” 
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 For analytical purposes, the Medicare population is stratified by their underuse 
behavior in 2005 and the outcome measures are constructed based on their underuse 
behavior in 2007.  The stratification allows an examination of cost-related underuse of 
medical and prescription drugs in 2005 to compare underuse in 2007 within the 
subpopulation. Survey respondents in the analytical sample have separate cost-related 
underuse outcomes for prescription drugs and medical care based on their behavior 2005 
and 2007. For those that experience cost-related underuse in 2005, they either continued 
to experience it in 2007 or resolved the underuse issue and did not experience cost-related 
underuse in 2007. For those that did not experience cost-related underuse in 2005, they 
continued to not experience it in 2007 or they experienced cost-related underuse in 2007 
as a new health behavior issue.  
Explanatory Variables 
Financial Characteristics. Prescription drug coverage is queried during the Fall 
interview round from the administration of the Supplemental Health Insurance 
instrument.100 Panelists are asked about prescription drug coverage for up to 5 different 
supplemental insurance plans that they have listed during the previous year’s survey 
rounds. For dual Medicaid covered panelists and Tricare enrollees, the panelists are asked 
if their enrollment covers prescriptions drugs. The survey instrument also asks about any 
other public plan coverage of prescription drugs and enrollment. Drug coverage in 2005 
is compared to drug coverage in 2007 to create a four-category variable that indicates 
continued coverage for those with drug coverage in both 2005 and 2007, new coverage 
for those without any drug coverage in 2005 but with coverage in 2007, no coverage for 
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those without any drug coverage in both 2005 and 2007, and lose coverage for those with 
drug coverage in 2005 but without any reported coverage in 2007. Drug coverage is 
expected to reduce financial pressure and the likelihood of experiencing cost-related 
underuse. 
The second financial characteristic measures self-reported income above or below 
$25,000. Income is the one question with the highest refusal response rate100 and many 
survey respondents do provide any additional detail on income level beyond the first 
question of whether they are above or below $25,000. Income is part of the questionnaire 
instruments conducted during the fall round each year. Panelists that refuse to answer the 
income question in subsequent years have their previous year reply carried forward as 
their income response for that year.100 For these reasons, income is coded from the 2005 
Access to Care module, at baseline, for analysis because it is not possible to distinguish 
reliable smaller intervals of income for all panelists nor determine no change in income 
between years from responses that are carried forward because of current refusal. It is 
expected that Medicare beneficiaries with higher income levels are less likely to 
experience cost-related underuse. 
Patient Characteristics. Demographic, socioeconomic, and geographic variables 
are measured as patient characteristics. Demographic variables include age, 
race/ethnicity, and gender. Age is coded into 5 categories to group the younger, disabled 
Medicare population (less than 45 years and 45-64 years) and older, age-qualified 
Medicare populations (65-69 years, 70-74 years, 75 years and older). Race/ethnicity is 
self-reported by the panelists and combines the race and Hispanic ethnicity questions into 
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one variable for White, Non-Hispanic; Black, Non-Hispanic; Hispanic, All Races; and 
Other, Non-Hispanic comparison groups. Male and female are the two gender codes. 
Socioeconomic variables include education level and current employment status. 
Geography is the rural/urban status of the county of residence. All patient characteristics 
are from the baseline in the 2005 Access to Care module. 
Diagnostic Characteristics. Health status measures of diagnostic characteristics 
include self-reported health, chronic conditions, and mobility measures. These measures 
are coded from the baseline responses in the 2005 Access to Care. It is expected that 
those with worse health, more chronic conditions, less mobility are more likely to 
experience cost-related underuse of medical care or prescription drugs. 
Self-reported health is a Likert scale question rating health from poor to excellent 
and recoded into two categories to compare self-reported good/very good/excellent health 
with fair/poor health. This measure is coded at baseline in 2005. 
Chronic conditions are measured as a count variable of all of the self-reported 
chronic conditions in 2005 and grouped into three categories for comparison: those with 
none or one chronic condition, those with two or three chronic conditions, and those with 
four or more self-reported chronic conditions in their medical history.84  The chronic 
conditions include self-reported histories with rheumatoid arthritis, non-rheumatoid 
arthritis, emphysema, asthma, chronic obstructive pulmonary disease (COPD), diabetes 
(either Type 1 or Type 2), stroke or brain hemorrhage, hypertension, hardening of 
arteries, myocardial infarction, heart attack, angina pectoris, coronary heart disease, any 
non-skin cancer, or skin cancer. 
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Depression has been shown to be associated with cost-related underuse of 
prescription drugs.46,54,60,86 It is coded as an indicator variable for self-reported history of 
depression or not in the 2005 Access to Care module. 
Mobility measures include instrumental activities of daily living (IADL) and 
activities of daily living (ADL). IADLs and ADLs are grouped into three comparative 
categories for none, one, or two or more. IADLs include any difficulty using telephone, 
doing light housework, doing heavy housework, preparing meals, shopping, or managing 
money. ADLs include any difficulty bathing or showering, dressing, eating, getting in or 
out of bed or chair, walking, or using the toilet. Mobility measures are coded from the 
2005 baseline survey responses. 
Statistical Analysis 
 Descriptive analysis of the rates of cost-related underuse of medical care and 
prescription drugs in 2005 and 2007 are compared using a paired t-test for differences in 
proportions. The bivariate and multivariate results are presented for each of the 
subpopulations stratified by underuse behavior in 2005 for prescription drugs and 
medical care, separately.  Rates by the stratified underuse subpopulations are calculated 
for each of the outcome measures of cost-related underuse in 2007 and compared for 
financial, patient, and diagnostic characteristics from the 2005 baseline year for both 
medical care and prescription drugs using bivariate χ2 test statistics. The same 
explanatory variables are then used to estimate a logistic regression for the categorical 
outcome variables. Adjusted odds ratios are calculated from the logit parameters and 
provided with the 95% confidence interval. The adjusted Wald test of joint probability of 
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the variables for financial, patient, and diagnostics characteristics are equal to zero as a 
set within the logistic regressions is also calculated. The average marginal probabilities at 
the means of the explanatory variables are calculated to allow comparisons of financial, 
patient, and diagnostic variables and presented with their corresponding 95% confidence 
interval. All descriptive, bivariate, and logistic regression analyses are completed using 
Stata 12 SVY procedures for complex surveys and subpopulations. Results with p<0.05 
are discussed in the finding section below. 
Findings  
Descriptive Analysis of Cost-Related Underuse 
 Figure 3 shows that community-dwelling Medicare beneficiaries who were 
continuously enrolled from 2005 through 2007 had a reduction in cost-related underuse 
of medical care from 7.6 percent (95% confidence interval(CI), 6.8-8.3) to 5.8 percent 
(95% CI, 5.1-6.6) in the years before and after the implementation of the Medicare Part D 
benefit. Cost-related underuse of prescription drugs during this same time period had a 
larger reduction from 13.4 percent (95% CI, 12.1-14.7) in 2005 to 9.1 percent (95% CI, 
8.1-10.1) in 2007 for the continuously enrolled, community-dwelling Medicare 
population. Cost-related underuse of medical care and prescription drugs both declined 
during the expansion of Medicare to include the Part D prescription drug benefit in 2006. 
The net 1.8 (=7.6-5.8) percent reduction in medical care cost-related underuse was a 23.7 
(=1.8/7.6) percent change from 2005 to 2007. In comparison, cost-related underuse of 
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prescription drugs had a 32.1 percent change or a net 4.3 percent reduction from 2005 to 
2007. 
Cost-Related Underuse of Prescription Drugs 
 Table 3 presents the distribution of the financial, patient, and diagnostic 
characteristics by cost-related underuse of prescription drugs in 2007 for the Medicare 
subpopulation that experienced cost-related underuse of prescription drugs in 2005.  Of 
the 13.4 percent of the Medicare population that experienced cost-related underuse of 
prescription drugs in 2005 (Figure 3), 71.3 percent or 3,007,675Medicare beneficiaries 
resolved their cost-related underuse by 2007 and 28.7 percent (1,211,449 beneficiaries) 
continued to experience cost-related underuse of prescription drugs in 2007.   
Continued, unresolved cost-related underuse of prescription drugs compared to 
resolved underuse in 2007 was associated with 2005 baseline measures of patient and 
diagnosis characteristics.  Older Medicare beneficiaries age 75 or more years (32.8 
percent) were more likely to resolve their cost-related underuse than not (16.8 percent 
unresolved). Similarly, disabled Medicare beneficiaries that experienced cost-related 
underuse of prescription drugs in 2005 were more likely to continue to experience it in 
2007 with 38.7 percent ages 45 to 64 years with unresolved compared to 19.7 percent 
with resolved underuse and 12.2 percent less than 45 years with unresolved compared to 
6.1 percent with resolved.  Persons with better self-reported health in 2005, the baseline 
year, were more likely to resolve their underuse of prescription drugs, 31.9 percent, than 
have unresolved cost-related underuse, 16.3 percent.  Medicare beneficiaries with 
depression were more likely to have unresolved cost-related underuse of prescription 
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drugs, 47.9 percent, than resolved, 28.4 percent.  Those without any instrumental 
activities of daily living mobility limitations were more likely to have resolved underuse, 
61.0 percent, than continued, unresolved cost-related underuse, 47.0 percent. 
   Table 4 shows the logistic regression of resolved compared to unresolved cost-
related underuse of prescription drugs in 2007 for the Medicare population that 
experienced cost-related underuse of prescription drugs in 2005. The adjusted Wald test 
of joint probability shows that the set of variables measuring patient characteristics 
(F(13,466)=2.58, P>|F|=0.002) and diagnosis characteristics (F(8,471)=2.22, 
P>|F|=0.025) are associated with differences between resolved and unresolved cost-
related underuse of prescription drugs in 2007.  Compared to Medicare beneficiaries ages 
75 years and older, disabled beneficiaries less than 45 years (adjusted odds ratio 
(AOR)=0.36; 95% CI, 0.18-0.72) and ages 45 to 64 years (AOR=0.40; 95% CI, 0.22-
0.71) are less likely to resolve cost-related underuse of prescription drugs, controlling for 
all other financial, patient, and diagnostic characteristics.  Medicare beneficiaries with 
good to excellent self-reported health in 2005 are more likely to have resolved cost-
related underuse of prescription drugs (AOR=1.88; 95% CI, 1.26-2.79).  Of those that 
experience underuse in 2005, beneficiaries with depression are less likely to resolve the 
underuse in 2007 (AOR=0.66; 95% CI, 0.44-0.97). 
Table 5 provides the distribution of the financial, patient, and diagnostic 
characteristics by newly experienced cost-related underuse of prescription drugs or not in 
2007 for the Medicare population that did not self-report prescription drug cost-related 
underuse in 2005.  The 86.6 percent of the continuously enrolled from 2005 to 2007, 
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community-dwelling Medicare population that did experience cost-related underuse of 
prescription drugs in 2005 (Figure 3) had 1,619,170 beneficiaries, 5.6 percent, self-
reported underuse of prescription drugs due to costs in 2007.  The remainder of the 
subpopulation cohort (27,281,568 beneficiaries or 94.4 percent) continued to not 
experience cost-related underuse of prescription drugs in 2007.   
Newly experienced cost-related underuse of prescription drugs in 2007 for those 
that did not have any in 2005 is associated with income, gender, race/ethnicity, age, self-
reported health status, the chronic condition of depression, and mobility limitations.  
Medicare beneficiaries with incomes less than $25,000 were more likely to experience 
cost-related underuse (61.6 percent) than continue to not (53.5 percent) in 2007.  Females 
were more likely, 61.2 percent, to have new cost-related underuse of prescription drugs 
than those that did not have any cost-related underuse, 54.0 percent.  Of those with new 
cost-related underuse of prescription drugs, a higher proportion (11.7 percent) were 
black, non-Hispanic and a lower proportion (4.6 percent) were Hispanic than their 
comparable proportions without any cost-related underuse (black, non-Hispanic 7.5 
percent; Hispanic 7.4 percent).  White, non-Hispanic Medicare beneficiaries and other, 
non-Hispanic race/ethnicities had similar proportions with no cost-related underuse 
compared to new cost-relate underuse of prescription drugs (white, non-Hispanic 80.5 
percent none, 78.6 percent new cost-related underuse; other, non-Hispanic 4.5 percent 
none, 5.1 percent new).  Medicare beneficiaries ages 75 years and over were less likely to 
experience cost-related underuse of prescription drugs (31.7 percent new cost-related 
underuse, 42.0 percent no cost-related underuse).  Disabled Medicare beneficiaries aged 
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45 to 64 years were 20.0 percent of those with new cost-related underuse and 9.1 percent 
of those without any cost-related underuse of prescription drugs in 2007. The other three 
age groups have similar proportions with new and no cost-related underuse (less than 45 
years 3.0 percent with none, 4.7 percent with new; ages 65 to 69 years 23.0 percent none, 
23.3 percent new; ages 70 to 74 years 22.9 percent no cost-relate underuse, 20.3 percent 
new cost-related underuse of prescription drugs). Those that continued to not experience 
cost-related underuse of prescription drugs had better health (47.7 percent) than those that 
newly experienced underuse (29.5 percent).  Medicare beneficiaries with depression were 
a larger proportion (29.7 percent) of those with new cost-related underuse than those that 
did not experience cost-related underuse of prescription drugs in 2007 (16.8 percent).  
Medicare beneficiaries that did not experience cost-related underuse in 2005 were more 
likely to continue no cost-related underuse in 2007 if they did not have any IADLs (73.0 
percent no underuse, 63.8 percent new underuse) or ADLs (74.1 percent no underuse, 
65.3 percent new underuse). 
The logistic regression results of new compared to no cost-related underuse of 
prescription drugs in 2007 for the subpopulation that did not have any cost-related 
underuse of prescription drugs in 2005 are provided in Table 6.  The adjusted Wald test 
of joint probability for the variable sets measuring patient characteristics 
(F(13,466)=2.68, P>|F|=0.001) and diagnosis characteristics (F(8,471)=4.18, 
P>|F|=0.000) shows that these sets of variables are associated with the likelihood of 
experiencing new cost-related underuse in 2007 compared to those that did not.  
Controlling for all other financial, patient, and diagnostic characteristics, Medicare 
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beneficiaries that did not have any prescription drug coverage in 2005 or 2007 were more 
likely to experience cost-related underuse of prescription drugs in 2007 (AOR=1.52; 95% 
CI, 1.08-2.14) than those with continuous drug coverage in 2005 and 2007 for those 
Medicare beneficiaries that did not have any cost-related underuse of prescription drugs 
in 2005.  Male beneficiaries (AOR=0.70; 95% CI, 0.54-0.92) are less likely to experience 
new cost-related underuse than female beneficiaries. Compared to Medicare beneficiaries 
ages 75 years and over, disabled Medicare beneficiaries less than 45 years (AOR=1.81; 
95% CI, 1.13-2.89) and ages 45 to 64 years (AOR=2.20; 95% CI, 1.50-3.23) are more 
likely to experience new cost-related underuse of prescription drugs, and newly enrolled 
aged Medicare beneficiaries from ages 65 to 69 years (AOR=1.44; 95% CI, 1.09-1.89) 
are also more likely to have new cost-related underuse of prescription drugs.  Medicare 
beneficiaries with self-reported good to excellent health status are less likely to 
experience new underuse that those with fair or poor health (AOR=0.59; 95% CI, 0.43-
0.81).  Of those without any cost-related underuse of prescription drugs in 2005, 
beneficiaries with a medical history of depression are more likely to experience cost-
related underuse in 2007 (AOR=1.53; 95% CI, 1.09-2.15). 
Table 7 presents the adjusted marginal probability of cost-related underuse of 
prescription drugs in 2007 constructed from the stratified population logistic regression 
models in Tables 4 and 6.  The average marginal effect (AME) is the adjusted marginal 
probability and is an estimated change in probability given a unit change in the variable 
while holding all other explanatory measures at their corresponding mean values. 
Overall, the predicted probability of resolved cost-related underuse of prescription drugs 
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in 2007 is 0.77 (95% CI, 0.74-0.81) for those Medicare beneficiaries that experienced 
cost-related underuse of prescription drugs in 2005, and the predicted probability of new 
cost-related underuse of prescription drugs in 2007 is 0.06 (95% CI, 0.06-0.07) for those 
Medicare beneficiaries that did not experience cost-related underuse of prescription drugs 
in 2005. 
Medicare beneficiaries that did not have any prescription drug coverage in 2005 
or 2007, compared to those with continuous drug coverage, had an increased probability 
of new cost-related underuse in 2007 (AME=0.02; 95% CI, 0.003-0.04) for those 
Medicare beneficiaries that did not report cost-related underuse in 2005.  All other 
financial characteristics in the stratified population models are not associated with 
differences between experiencing or not experiencing cost-related underuse of 
prescription drugs in 2007.   
Patient characteristics associated with cost-related underuse of prescription drugs 
in 2007 include age for those Medicare beneficiaries that experienced cost-related 
underuse in 2005 and gender, race/ethnicity, and age for those Medicare beneficiaries that 
did not have cost-related underuse in 2005.  Male beneficiaries have a lower probability 
of new cost-related underuse in 2007 (AME= -0.02; 95% CI, -0.03 - -0.005) than female 
beneficiaries.  Compared to white, non-Hispanic beneficiaries, Hispanic beneficiaries 
have a lower probability of new cost-related underuse (AME= -0.02; 95% CI, -0.04 - -
0.005).  In comparison to Medicare beneficiaries ages 75 years and older, disabled 
Medicare beneficiaries less than 45 years have a lower probability of resolved cost-
related underuse (AME= -0.19; 95% CI, -0.32 - -0.05)and a higher probability of new 
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cost-related underuse of prescription drugs (AME=0.03; 95% CI, 0.001-0.06). Compared 
to the same reference age group, Medicare beneficiaries ages 45 to 64 years have a lower 
probability of resolved underuse (AME= -0.17; 95% CI, -0.28 - -0.06) and a higher 
probability of new underuse (AME=0.05; 95% CI, 0.02-0.08). Medicare beneficiaries 
ages 65 to 69 years have a higher probability of new cost-related underuse of prescription 
drugs in 2007 (AME=0.02; 95% CI, 0.003-0.03) compared to beneficiaries ages 75 years 
and older. 
Both self-reported health status and medical histories of depression are diagnosis 
characteristics associated with cost-related underuse in 2007.  Compared to those with 
fair or poor health, Medicare beneficiaries with better health have a higher probability of 
resolved cost-related underuse of prescription drugs (AME=0.10, 95% CI, 0.04-0.16) and 
a lower probability of newly experiencing underuse in 2007 (AME= -0.03; 95% CI, -0.04 
- -0.01).  Beneficiaries that have a medical history of depression have a lower probability 
of resolved underuse (AME= -0.07; 95% CI, -0.15 - -0.002) and a higher probability of 
new cost-related underuse of prescription drugs in 2007 (AME=0.03; 95% CI, 0.003-
0.05).  
Cost-Related Underuse of Medical Care 
 Table 8 presents the distribution of the financial, patient, and diagnostic 
explanatory variables by resolved and unresolved cost-related underuse of medical care 
in 2007 for those Medicare beneficiaries that experienced cost-related underuse of 
medical care in 2005. Of the 7.6 percent of the Medicare population continuously 
enrolled from 2005 to 2007 (Figure 3) who experienced cost-related underuse of medical 
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care in 2005, 68.0 percent or 1,613,091 Medicare beneficiaries resolved the underuse and 
did not experience cost-related underuse of medical care in 2007. Compared to the 2007 
resolution rate, 71.3 percent (Table 3), of those who experienced cost-related underuse of 
prescription drugs in 2005, a smaller percentage resolved cost-related underuse of 
medical care in 2007 but the estimated 760,100 (Table 8) Medicare beneficiaries who 
continued to experience cost-related underuse of medical care in 2005 and 2007 (or 32.0 
percent) is numerically smaller than the number, 1,211,449 (Table 3), who continued to 
experience cost-related underuse of prescription drugs in 2005 and 2007. 
 As shown in the bivariate comparisons in Table 8, prescription drug coverage and 
age are associated with resolved and unresolved cost-related underuse of medical care in 
2007 for those Medicare beneficiaries that experienced cost-related underuse of medical 
care in 2005. Of those that resolved cost-related underuse of medical care in 2007, 48,0 
percent had continued drug coverage in both 2005 and 2007 (compared to 41.0 percent 
with unresolved), 25.0 percent had new drug coverage in 2007 and no coverage in 2005 
(compared to 25.3 percent with unresolved), 21.4 percent had no drug coverage in 2005 
or 2007 (compared to 32.1 percent with unresolved), and 5.6 percent did not have drug 
coverage in 2007 who had coverage in 2005 (compared to 1.6 percent with unresolved).  
Older Medicare beneficiaries were more likely to have resolved cost-related underuse of 
medical care with disabled Medicare beneficiaries ages 64 years and younger accounting 
for the majority, 58.7 percent (42.1 + 16.6 percent), of those with unresolved cost-related 
underuse of medical care compared to 39.4 percent (28.3 + 11.1 percent) ages 64 years 
and younger with resolved. 
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 Table 9 presents the logistic regression results of resolved cost-related underuse 
of medical care in 2007 for those that experienced underuse in 2005.  Compared to 
Medicare beneficiaries who did not have prescription drug coverage in 2007 but had 
coverage in 2005, beneficiaries that had no drug coverage in both 2005 and 2007 were 
less likely to have resolved underuse of medical care (AOR=0.19; 95% CI, 0.05-0.77), 
controlling for all other financial, patient, and diagnostic characteristics.   
 Table 10 shows the distribution of the financial, patient, and diagnostic 
explanatory variables by those who had no cost-related underuse of medical care and 
those who newly experienced cost-related underuse in 2007 for those Medicare 
beneficiaries who did not have cost-related underuse of medical care in 2005.  Of the 
30,746,671 Medicare beneficiaries continuously enrolled and community dwelling from 
2005 to 2007 and who did not experience cost-related underuse of medical care in 2005, 
3.4 percent, or 1,056,827 beneficiaries, had cost-related underuse of medical care in 
2007.  The bivariate test statistics show that financial, patient, and diagnostic measures 
are related to new cost-related underuse of medical care in 2007 for those that did not 
have underuse in 2005. 
 Both income level and prescription drug coverage are related to cost-related 
underuse of medical care in 2007 for those Medicare beneficiaries that did not have any 
cost-related underuse in 2005.  Of those with new cost-related underuse of medical care, 
21.0 percent had new drug coverage in 2007 that did not in 2005 (compared to 13.6 
percent with no cost-related underuse) and 22.3 percent did not have any drug coverage 
in 2005 or 2007 (compared to 17.6 percent with no cost-related underuse). Of those with 
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no cost-related underuse of medical care 60.4 percent had continuous drug coverage in 
2005 and 2007 compared to 50.2 percent of those with new cost-related underuse.  
Medicare beneficiaries with income below $25,000 are more likely to have new cost-
related underuse of medical care, 81.3 percent, than those with incomes above $25,000, 
18.7 percent.  Those who did not experience any cost-related underuse of medical care 
had 53.4 percent with income below $25,000 and 46.6 percent with income above this 
level. 
 Patient characteristics related to new cost-related underuse of medical care 
include race/ethnicity, age, and education. Medicare beneficiaries who self-identify as 
white, non-Hispanic are 80.3 percent of those with no cost-related underuse of medical 
care and 71.6 percent of those with new cost-related underuse of medical care.  Almost 
twice the rate of black, non-Hispanic Medicare beneficiaries had new cost-related 
underuse, 14.9 percent, than had no cost-related underuse of medical care, 7.8 percent.  In 
stark contrast, Medicare beneficiaries ages 75 years and older were 42.4 percent of those 
with no cost-related underuse and 22.0 percent of those with new cost-related underuse of 
medical care while disabled Medicare beneficiaries younger than 64 years were 11.9 
percent of those with no cost-related underuse (9.1 + 2.8 percent) and 45.3 percent (36.9 
+ 8.4 percent) of those with new cost-related underuse of medical care. More than 35 
percent of those with new cost-related underuse of medical care had some college 
education compared to 23.8 percent of those with no cost-related underuse, but those with 
a highest level of education as a high school diploma were 31.5 percent of those with no 
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cost-related underuse and 23.9 percent of those with new cost-related underuse of 
medical care. 
 All diagnosis characteristic measures are related to new cost-related underuse of 
medical care in 2007 for those that did not have cost-related underuse in 2005. Medicare 
beneficiaries with good to excellent self-reported health in 2005 baseline year were 46.6 
percent of those with no cost-related underuse and 25.5 percent of those with new cost-
related underuse of medical care in 2007. Of those with new cost-related underuse, 30.1 
percent had medical histories of four or more chronic conditions, and 21.7 percent of 
those with no cost-related underuse had four or more chronic conditions. Those with a 
medical history of depression were more likely to have new cost-related underuse of 
medical care, 41.3 percent, than those with no cost-related underuse, 17.0 percent. 
Medicare beneficiaries without any mobility limitations are more likely to have no cost-
related underuse of medical care in 2007 with 72.7 percent with no IADLs and 74.2 
percent with no ADLs having no cost-related under in 2007 compared to 53.5 percent 
with no IADLs and 54.6 percent with no ADLs with new cost-related underuse of 
medical care in 2007. 
Table 11 has the logistic regression results of financial, patient, and diagnostic 
characteristics one the likelihood of new cost-related underuse of medical care in 2007 
for the Medicare population that did not have any cost-related underuse of medical care 
in 2005. The adjusted Wald test statistic of joint probability for the set of measures for 
financial characteristics (F(4,475)=11.77, P>|F|=0.000), patient characteristics 
(F(13,466)=5.88, P>|F|=0.000) and diagnosis characteristics (F(8,471)=5.41, 
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P>|F|=0.000) show that as a group of variables the sets are associated with new cost-
related underuse of medical care. Controlling for all other explanatory measures, 
Medicare beneficiaries with new drug coverage (AOR=1.6; 95% CI, 1.1-2.5) or 
continued lack of drug coverage (AOR=1.7; 95% CI, 1.1-2.6) are more likely to have 
new cost-related underuse of medical care compared to those Medicare beneficiaries with 
continuous drug coverage from 2005 to 2007. Those with incomes over $25,000 are less 
likely to have new cost-related underuse of medical care (AOR=0.3; 95% CI, 0.2-0.5) 
than those with incomes below $25,000. Compared to Medicare beneficiaries age 75 
years and older, beneficiaries ages 70 to 74 years (AOR=1.7; 95% CI, 1.0-2.9), ages 45 to 
64 years (AOR=4.8; 95% CI, 2.8-8.3), or less than 45 years (AOR=3.6; 95% CI, 2.1-6.0) 
are more likely to have new cost-related underuse of medical care in 2007. Medicare 
beneficiaries with some college education in comparison to those without a high school 
degree are more likely to experience new cost-related underuse (AOR=2.0; 95% CI, 1.3-
3.1). Beneficiaries with medical histories with depression are more likely to experience 
new cost-related underuse of medical care (AOR=1.7; 95% CI, 1.2-2.4). 
Table 12 presents the adjusted marginal probability of resolved and new cost-
related underuse of medical care by financial, patient, and diagnostic characteristics. 
Predicted probability of resolved cost-related underuse of medical care in 2007 is 0.74 
(95% CI, 0.67-0.80) for those Medicare beneficiaries that experienced cost-related 
underuse of medical care in 2005. Compared to those Medicare beneficiaries with drug 
coverage in both 2005 and 2007, beneficiaries that drop coverage (have drug coverage in 
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2005 but do not in 2007) have a higher probability of resolved cost-related underuse of 
medical care in 2007 (AME=0.14; 95% CI, 0.01-0.26).  
As shown in Table 12, the predicted probability of new cost-related underuse of 
medical care in 2007 is 0.04 (95% CI, 0.04-0.05) for the stratified population of Medicare 
beneficiaries that did not have any cost-related underuse of medical care in 2005. 
Compared to those with continued drug coverage in both 2005 and 2007, Medicare 
beneficiaries with new drug coverage in 2007 (AME=0.012; 95% CI, 0.0004-0.02) or no 
drug coverage in 2005 or 2007 (AME=0.014; 95% CI, 0.003-0.03) had higher probability 
of new cost-related underuse of medical care in 2007. Medicare beneficiaries with 
incomes over $25,000 had a lower probability of new cost-related underuse than 
beneficiaries with incomes below $25,000 (AME= -0.03; 95% CI, -0.04 - -0.02). In 
comparison to Medicare beneficiaries ages 75 year and older, disabled Medicare 
beneficiaries had higher probabilities of new cost-related underuse of medical care (ages 
45 to 64 years AME=0.05; 95% CI, 0.03-0.08; less than 45 years AME=0.04; 95% CI, 
0.02-0.06). Those with some college education compared to those without any high 
school education had a 0.02 higher average marginal probability of cost-related underuse 
of medical care (95% CI, 0.01-0.03).  Medicare beneficiaries with medical histories with 
depression had a higher probability of new cost-related underuse of medical care than 
those without depression (AME=0.01; 95% CI, 0.004-0.03).  
Discussion 
 Cost-related underuse is a complex phenomenon. As the findings for those newly 
experiencing cost-related underuse from this study suggest, financial pressures persist, 
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even with the largest benefit expansion within the Medicare population in recent years 
that implemented Medicare Part D.  The stratified population analyses show, however, 
that financial pressures, as measure by the financial characteristics of prescription drug 
coverage and income, were associated with experiencing new cost-related underuse of 
medical care in 2007 but not for differences between resolved and unresolved underuse 
of medical care or prescription drugs (as indicated by the adjusted Wald joint 
probabilities tests).     
Recent research102 has suggested that anticipatory drug behavior may have 
overestimated the effects of cost-related underuse of prescription drug prior to the 
implementation of Part D because Medicare beneficiaries knew benefit would start on 
January 1, 2006. Given that the Medicare Part D legislation passed in 2003 and the 2006 
implementation date was widely publicized in news outlets and beneficiary educational 
outreach materials, Medicare beneficiaries may have “anticipated” their enrollment in the 
period prior to implementation and modified their drug utilization behavior by forgoing 
non-essential medications to avoid the higher costs.102 The model findings for the 
stratified Medicare population that experienced cost-related underuse of prescription 
drugs in 2005 did not show that those with newly obtained drug coverage differed from 
those that did not in the likelihood of resolved or unresolved underuse and do not support 
the anticipatory behavior theory.  
 Perspective pieces marking Medicare’s 50th anniversary brought to light the 
contrast with a key provision of the Affordable Care Act that subsidizes medical 
coverage for low income populations under 65 while Medicare does not have an out-of-
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pocket limit on medical care.78,103 The findings from this study that show the differs by 
income in the likelihood of experiencing new cost-related underuse of medical care, 
although examining an historic period of the 2006 Part D implementation, add to the 
current policy discussions of how policy may affect cost-related underuse of medical care 
within the Medicare population by showing the association with income and coverage. 
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Figure 2: Study 1 Analytical Sample Construction 
  
 
2005-2007 MCBS retrospective cohort, 
complex survey full sample 
(unweighted N = 6,654;  
weighted N = 35,372,742) 
Long-term care, nursing home 
residents in 2005 or 2007 
(unweighted N = 478) 
Community-dwelling respondents 
(unweighted N = 6,176) 
Missing data response exclusion 
(unweighted N = 72) 
Analytical sample,  
complex survey subpopulation 
(unweighted N = 6,104; 
weighted N = 33,119,862) 
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Table 2: Question Wording of Measures Used to Construct Cost-Related Underuse 
Outcome Variables from the Medicare Current Beneficiary Survey 
MCBS Questionnaire 
Instrument 
Question 
Number 
Question Wording [response] 
Medical Care Underutilization Due to Cost  
Community Component, 
Health Status 
AC31 In the last year, have you delayed seeking 
medical care because you were worried about the 
cost? [yes, no, don’t know, refused] 
Prescription Drug Underutilization Due to Cost  
Community Component, 
Satisfaction with Care 
SC17 During the past year, were any medicines 
prescribed for you that you did not get? Which of 
these reasons explains why you did not obtain 
the medication? [thought it would cost too much, 
don’t know, refused] 
Community Component, 
Satisfaction with Care 
SC20c Please tell me how often during past year you 
have taken smaller doses of a medicine to make 
the medicine last longer? [often, sometimes, 
never, don’t know, refused] 
Community Component, 
Satisfaction with Care 
SC20d Please tell me how often during past year you 
have skipped doses to make the medicine last 
longer? [often, sometimes, never, don’t know, 
refused] 
Source: Medicare Current Beneficiary Survey (MCBS). 2005. MCBS Main Study – 
Round 43 – Fall Supplement 2005, Community Component. Baltimore, MD: Centers for 
Medicare and Medicaid Services. 
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Figure 3: Unadjusted Rates and 95% Confidence Interval Rates of Cost-Related 
Underuse of Prescription Drugs or Medical Care within the Continuously-Enrolled, 
Community-Dwelling Medicare Population from 2005-2007 
 
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Rates calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Differences in rates 
from 2005 to 2007 are significant at p<0.001.  
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Table 3: Unadjusted Rates of Cost-Related Underuse of Prescription Drugs in 2007 
for the Community-Dwelling Medicare Population Experiencing Cost-Related 
Underuse of Prescription Drugs in 2005 
Variable 
Unresolved 
Cost-
Related 
Underuse 
Resolved 
Cost-
Related 
Underuse 
Significance 
Level 
Financial Characteristics 
Drug Coverage 
Continued Coverage 52.0% 49.3% 0.112 
New Coverage 24.2% 21.5% 
No Coverage 14.3% 21.6% 
Lose Coverage 9.6% 7.7% 
Income 
Under $25K 71.0% 71.3% 0.935 
Over $25K 29.0% 28.7% 
Patient Characteristics 
Gender 
Female 67.2% 59.1% 0.052 
Male 32.8% 41.0% 
Race/Ethnicity 
White 70.1% 72.8% 0.156 
Black 17.3% 12.0% 
Hispanic 6.7% 10.5% 
Other 5.9% 4.8% 
Age 
Less than 45 years 12.2% 6.1% 0.000 
45 to 64 years 38.7% 19.7% 
65 to 69 years 17.1% 22.2% 
70 to 74 years 15.2% 19.3% 
75 years and over 16.8% 32.8% 
Education 
No High School 31.2% 36.7% 0.148 
High School 22.8% 25.9% 
Some College 32.0% 23.9% 
College Degree 14.0% 13.5% 
Current Employment 
Not Employed 90.4% 88.6% 0.500 
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Variable 
Unresolved 
Cost-
Related 
Underuse 
Resolved 
Cost-
Related 
Underuse 
Significance 
Level 
Employed 9.6% 11.4% 
Geography 
Urban 66.7% 75.5% 0.079 
Rural 33.3% 24.5% 
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health 83.7% 68.1% 0.000 
Good/Excellent Health 16.3% 31.9% 
Chronic Conditions 
None or One Chronic Condition 26.8% 27.4% 0.585 
Two or Three Conditions 46.2% 49.2% 
Four or More Conditions 27.0% 23.4% 
 
No Depression 52.1% 71.6% 0.000 
Depression 47.9% 28.4% 
Mobility 
Instrumental Activities of Daily Living (IADL) 
None 47.0% 61.0% 0.001 
One 23.7% 18.5% 
Two or more 29.3% 20.5% 
Activities of Daily Living (ADL) 
None 54.4% 63.4% 0.086 
One 16.9% 15.7% 
Two or more 28.7% 21.0% 
 
Weighted Population 1,211,449 3,007,675 
Percent of Total 28.7% 71.3%   
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Rates calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Significance level 
from chi-square test statistic reported. 
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Table 4: Logistic Regression of Resolved Cost-Related Underuse of Prescription 
Drugs in 2007 for the Community-Dwelling Medicare Population Experiencing 
Cost-Related Underuse of Prescription Drugs in 2005 
Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
Financial Characteristics 
Drug Coverage 
Continued Coverage reference 
New Coverage 1.14 0.517 0.76 1.70 
No Coverage 1.45 0.145 0.88 2.38 
Lose Coverage 0.73 0.279 0.40 1.30 
Income 
Over $25K 0.83 0.424 0.53 1.31 
Patient Characteristics 
Gender 
Male 1.48 0.053 1.00 2.21 
Race/Ethnicity 
White reference 
Black 0.77 0.362 0.44 1.35 
Hispanic 1.34 0.402 0.67 2.67 
Other 0.94 0.862 0.44 1.99 
Age 
Less than 45 years 0.36 0.004 0.18 0.72 
45 to 64 years 0.40 0.002 0.22 0.71 
65 to 69 years 0.78 0.427 0.43 1.43 
70 to 74 years 0.70 0.267 0.37 1.31 
75 years and over reference 
Education 
No High School reference 
High School 0.93 0.723 0.62 1.39 
Some College 0.61 0.051 0.37 1.00 
College Degree 0.62 0.117 0.34 1.13 
Current Employment 
Employed 0.94 0.851 0.51 1.75 
Geography 
Urban reference 
Rural 0.65 0.080 0.40 1.05 
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Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
     
     
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health reference 
Good/Excellent Health 1.88 0.002 1.26 2.79 
Chronic Conditions 
None or One Chronic Condition reference 
Two or Three Conditions 0.95 0.782 0.63 1.41 
Four or More Conditions 0.96 0.884 0.56 1.64 
 
Depression 0.66 0.036 0.44 0.97 
Mobility 
Instrumental Activities of Daily Living 
(IADL) 
None reference 
One 0.90 0.662 0.57 1.43 
Two or more 1.02 0.946 0.61 1.70 
Activities of Daily Living 
(ADL) 
None reference 
One 1.00 0.998 0.56 1.80 
Two or more 0.90 0.658 0.56 1.44 
Intercept 5.32 0.000 2.91 9.75 
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Model 
F(25,454)=3.74, P>|F|=0.000. Adjusted Wald test of joint probability for financial 
characteristics: F(4,475)=1.62, P>|F|=0.167; patient characteristics: F(13,466)=2.58, 
P>|F|=0.002; diagnosis characteristics: F(8,471)=2.22, P>|F|=0.025. 
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Table 5: Unadjusted Rates of Cost-Related Underuse of Prescription Drugs in 2007 
for the Community-Dwelling Medicare Population Not Experiencing Cost-Related 
Underuse of Prescription Drugs in 2005 
Variable 
No Cost-
Related 
Underuse 
New 
Cost-
Related 
Underuse 
Significance 
Level 
Financial Characteristics 
Drug Coverage 
Continued Coverage 60.7% 54.9% 0.255 
New Coverage 13.5% 15.0% 
No Coverage 17.8% 22.3% 
Lose Coverage 8.0% 7.8% 
Income 
Under $25K 53.5% 61.6% 0.013 
Over $25K 46.6% 38.4% 
Patient Characteristics 
Gender 
Female 54.0% 61.2% 0.023 
Male 46.0% 38.8% 
Race/Ethnicity 
White 80.5% 78.6% 0.047 
Black 7.5% 11.7% 
Hispanic 7.4% 4.6% 
Other 4.5% 5.1% 
Age 
Less than 45 years 3.0% 4.7% 0.000 
45 to 64 years 9.1% 20.0% 
65 to 69 years 23.0% 23.3% 
70 to 74 years 22.9% 20.3% 
75 years and over 42.0% 31.7% 
Education 
No High School 26.1% 27.7% 0.677 
High School 31.4% 33.5% 
Some College 24.4% 22.9% 
College Degree 18.1% 16.0% 
Current Employment 
Not Employed 86.1% 86.4% 0.888 
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Variable 
No Cost-
Related 
Underuse 
New 
Cost-
Related 
Underuse 
Significance 
Level 
Employed 13.9% 13.6% 
Geography 
Urban 77.0% 72.9% 0.121 
Rural 23.1% 27.1% 
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health 52.3% 70.5% 0.000 
Good/Excellent Health 47.7% 29.5% 
Chronic Conditions 
None or One Chronic 
Condition 32.7% 26.5% 0.089 
Two or Three Conditions 46.0% 47.4% 
Four or More Conditions 21.3% 26.2% 
 
No Depression 83.2% 70.3% 0.000 
Depression 16.8% 29.7% 
Mobility 
Instrumental Activities of Daily Living 
(IADL) 
None 73.0% 63.8% 0.004 
One 15.8% 21.1% 
Two or more 11.3% 15.1% 
Activities of Daily Living (ADL) 
None 74.1% 65.3% 0.007 
One 12.8% 14.9% 
Two or more 13.2% 19.8% 
 
Weighted Population 27,281,568 1,619,170 
Percent of Total 94.4% 5.6%   
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Rates calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Significance level 
from chi-square test statistic reported. 
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Table 6: Logistic Regression of New Cost-Related Underuse of Prescription Drugs 
in 2007 for the Community-Dwelling Medicare Population Not Experiencing Cost-
Related Underuse of Prescription Drugs in 2005  
Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
Financial Characteristics 
Drug Coverage 
Continued Coverage reference 
New Coverage 1.26 0.174 0.90 1.74 
No Coverage 1.52 0.017 1.08 2.14 
Lose Coverage 1.17 0.622 0.63 2.19 
Income 
Over $25K 0.88 0.400 0.65 1.19 
Patient Characteristics 
Gender 
Male 0.70 0.010 0.54 0.92 
Race/Ethnicity 
White reference 
Black 1.34 0.216 0.84 2.12 
Hispanic 0.55 0.053 0.30 1.01 
Other 1.16 0.642 0.62 2.15 
Age 
Less than 45 years 1.81 0.013 1.13 2.89 
45 to 64 years 2.20 0.000 1.50 3.23 
65 to 69 years 1.44 0.010 1.09 1.89 
70 to 74 years 1.26 0.210 0.88 1.81 
75 years and over reference 
Education 
No High School reference 
High School 1.02 0.891 0.75 1.40 
Some College 0.94 0.775 0.63 1.42 
College Degree 1.10 0.650 0.73 1.67 
Current Employment 
Employed 1.16 0.479 0.77 1.76 
Geography 
Urban reference 
Rural 1.11 0.476 0.83 1.48 
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Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
     
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health reference 
Good/Excellent Health 0.59 0.001 0.43 0.81 
Chronic Conditions 
None or One Chronic 
Condition reference 
Two or Three Conditions 1.20 0.303 0.85 1.69 
Four or More Conditions 1.22 0.302 0.84 1.77 
 
Depression 1.53 0.014 1.09 2.15 
Mobility 
Instrumental Activities of Daily Living 
(IADL) 
None reference 
One 1.12 0.494 0.81 1.53 
Two or more 0.85 0.425 0.57 1.27 
Activities of Daily Living 
(ADL) 
None reference 
One 1.07 0.742 0.73 1.56 
Two or more 1.26 0.265 0.84 1.91 
Intercept 0.05 0.000 0.03 0.08 
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Model 
F(25,454)=3.92, P>|F|=0.000. Adjusted Wald test of joint probability for financial 
characteristics: F(4,475)=1.82, P>|F|=0.123; patient characteristics: F(13,466)=2.68, 
P>|F|=0.001; diagnosis characteristics: F(8,471)=4.18, P>|F|=0.000. 
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Table 7: Adjusted Marginal Probability of Cost-Related Underuse of Prescription Drugs in 2007 for Community-Dwelling 
Medicare Population Stratified by Cost-Related Underuse of Prescription Drugs in 2005 
  
Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Prescription Drugs 
in 2005 
New Cost-Related Underuse Compared 
to No Cost-Related Underuse in 2007 
for Subpopulation with No Cost-
Related Underuse of Prescription Drugs 
in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
Financial Characteristics   
Drug Coverage   
Continued Coverage reference reference 
New Coverage 0.0217 0.509 -0.0427 0.0861 0.0117 0.188 -0.0057 0.0292 
No Coverage 0.0566 0.127 -0.0160 0.1291 0.0234 0.027 0.0026 0.0442 
Lose Coverage -0.0597 0.307 -0.1742 0.0549 0.0079 0.641 -0.0251 0.0408 
Income   
Over $25K -0.0307 0.434 -0.1076 0.0462 -0.0066 0.397 -0.0218 0.0087 
Patient Characteristics   
Gender   
Male 0.0640 0.050 0.0001 0.1280 -0.0180 0.008 -0.0313 -0.0047 
Race/Ethnicity   
White reference reference 
Black -0.0457 0.385 -0.1487 0.0574 0.0173 0.259 -0.0127 0.0474 
Hispanic 0.0443 0.364 -0.0513 0.1399 -0.0244 0.014 -0.0437 -0.0050 
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Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Prescription Drugs 
in 2005 
New Cost-Related Underuse Compared 
to No Cost-Related Underuse in 2007 
for Subpopulation with No Cost-
Related Underuse of Prescription Drugs 
in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
Other -0.0112 0.865 -0.1404 0.1180 0.0082 0.662 -0.0285 0.0448 
Age   
Less than 45 years -0.1884 0.006 -0.3240 -0.0528 0.0324 0.041 0.0014 0.0634 
45 to 64 years -0.1688 0.003 -0.2804 -0.0572 0.0473 0.002 0.0179 0.0766 
65 to 69 years -0.0368 0.430 -0.1284 0.0547 0.0178 0.016 0.0033 0.0324 
70 to 74 years -0.0555 0.281 -0.1563 0.0454 0.0107 0.231 -0.0068 0.0283 
75 years and over reference reference 
Education   
No High School reference reference 
High School -0.0107 0.724 -0.0702 0.0488 0.0011 0.891 -0.0152 0.0175 
Some College -0.0831 0.056 -0.1685 0.0022 -0.0030 0.773 -0.0232 0.0172 
College Degree -0.0787 0.130 -0.1804 0.0231 0.0051 0.653 -0.0173 0.0276 
Current Employment   
Employed -0.0098 0.853 -0.1139 0.0942 0.0081 0.501 -0.0156 0.0318 
Geography   
Urban reference reference 
Rural -0.0751 0.104 -0.1656 0.0154 0.0056 0.483 -0.0100 0.0211 
Diagnosis Characteristics   
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Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Prescription Drugs 
in 2005 
New Cost-Related Underuse Compared 
to No Cost-Related Underuse in 2007 
for Subpopulation with No Cost-
Related Underuse of Prescription Drugs 
in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
Self-Reported Health   
Fair/Poor Health reference reference 
Good/Excellent Health 0.1015 0.001 0.0404 0.1627 -0.0265 0.001 -0.0423 -0.0108 
Chronic Conditions   
None or One Chronic Condition reference reference 
Two or Three Conditions -0.0093 0.781 -0.0745 0.0559 0.0091 0.300 -0.0081 0.0262 
Four or More Conditions -0.0065 0.884 -0.0942 0.0812 0.0100 0.306 -0.0091 0.0291 
 
  
Depression -0.0744 0.044 -0.1468 -0.0020 0.0249 0.025 0.0031 0.0466 
Mobility   
Instrumental Activities of Daily Living 
(IADL)   
None reference reference 
One -0.0174 0.668 -0.0970 0.0622 0.0060 0.507 -0.0118 0.0238 
Two or more 0.0029 0.946 -0.0803 0.0861 -0.0079 0.404 -0.0264 0.0106 
Activities of Daily Living 
(ADL)   
None reference reference 
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Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Prescription Drugs 
in 2005 
New Cost-Related Underuse Compared 
to No Cost-Related Underuse in 2007 
for Subpopulation with No Cost-
Related Underuse of Prescription Drugs 
in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
One 0.0001 0.998 -0.0956 0.0958 0.0033 0.746 -0.0165 0.0230 
Two or more -0.0178 0.663 -0.0980 0.0623 0.0130 0.292 -0.0112 0.0371 
Note: AME is Average Marginal Effect, at means. Probabilities constructed from Tables 4 and 6 logistic regression model estimates 
with marginal effects calculated with other variables at mean values. Data from Medicare Current Beneficiary Survey (MCBS) Access 
to Care modules. Calculated using retrospective longitudinal survey weights. Variance corrected for complex survey design strata and 
clusters using Taylor Linearization. Predicted probability of resolved cost-related underuse of prescription drugs in 2007 is 0.77 (95% 
Confidence Interval (CI): 0.74-0.81, P>0.000). Predicted probability of new cost-related underuse of prescription drugs in 2007 is 0.06 
(95% CI: 0.06-0.07, P>0.000).
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Table 8: Unadjusted Rates of Cost-Related Underuse of Medical Care in 2007 for 
the Community-Dwelling Medicare Population Experiencing Cost-Related 
Underuse of Medical Care in 2005 
Variable 
Unresolved 
Cost-
Related 
Underuse 
Resolved 
Cost-
Related 
Underuse 
Significance 
Level 
Financial Characteristics 
Drug Coverage 
Continued Coverage 41.0% 48.0% 0.038 
New Coverage 25.3% 25.0% 
No Coverage 32.1% 21.4% 
Lose Coverage 1.6% 5.6% 
Income 
Under $25K 78.1% 79.4% 0.779 
Over $25K 21.9% 20.6% 
Patient Characteristics 
Gender 
Female 55.1% 58.5% 0.562 
Male 44.9% 41.5% 
Race/Ethnicity 
White 75.0% 69.0% 0.402 
Black 12.7% 15.5% 
Hispanic 6.0% 10.8% 
Other 6.4% 4.6% 
Age 
Less than 45 years 16.6% 11.1% 0.011 
45 to 64 years 42.1% 28.3% 
65 to 69 years 18.2% 29.1% 
70 to 74 years 13.3% 15.9% 
75 years and over 9.8% 15.7% 
Education 
No High School 29.4% 39.5% 0.295 
High School 25.7% 22.2% 
Some College 31.4% 28.4% 
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Variable 
Unresolved 
Cost-
Related 
Underuse 
Resolved 
Cost-
Related 
Underuse 
Significance 
Level 
College Degree 13.6% 10.0% 
    
Current Employment 
Not Employed 89.3% 87.5% 0.588 
Employed 10.8% 12.5% 
Geography 
Urban 70.0% 70.2% 0.983 
Rural 30.0% 29.9% 
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health 81.2% 76.1% 0.265 
Good/Excellent Health 18.8% 23.9% 
Chronic Conditions 
None or One Chronic Condition 36.6% 27.7% 0.090 
Two or Three Conditions 38.2% 51.3% 
Four or More Conditions 25.3% 21.0% 
 
No Depression 49.9% 61.0% 0.050 
Depression 50.1% 39.0% 
Mobility 
Instrumental Activities of Daily Living (IADL) 
None 45.2% 51.7% 0.416 
One 20.6% 20.3% 
Two or more 34.3% 28.1% 
Activities of Daily Living (ADL) 
None 48.6% 52.9% 0.153 
One 14.8% 20.3% 
Two or more 36.6% 26.8% 
 
Weighted Population 760,100 1,613,091 
Percent of Total 32.0% 68.0%   
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Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Rates calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Significance level 
from chi-square test statistic reported. 
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Table 9: Logistic Regression of Resolved Cost-Related Underuse of Medical Care in 
2007 for the Community-Dwelling Medicare Population Experiencing Cost-Related 
Underuse of Medical Care in 2005 
Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
Financial Characteristics 
Drug Coverage 
Continued Coverage 0.35 0.095 0.10 1.20 
New Coverage 0.29 0.063 0.79 1.07 
No Coverage 0.19 0.020 0.05 0.77 
Lose Coverage reference 
Income 
Over $25K 0.97 0.920 0.51 1.82 
Patient Characteristics 
Gender 
Male 0.96 0.848 0.60 1.53 
Race/Ethnicity 
White reference 
Black 1.28 0.586 0.53 3.08 
Hispanic 1.63 0.352 0.58 4.61 
Other 0.73 0.452 0.32 1.66 
Age 
Less than 45 years 0.53 0.203 0.20 1.41 
45 to 64 years 0.48 0.131 0.19 1.24 
65 to 69 years 1.11 0.826 0.44 2.78 
70 to 74 years 0.69 0.547 0.21 2.29 
75 years and over reference 
Education 
No High School reference 
High School 0.77 0.470 0.38 1.56 
Some College 0.84 0.618 0.42 1.67 
College Degree 0.58 0.159 0.27 1.24 
Current Employment 
Employed 0.95 0.887 0.48 1.88 
Geography 
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Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
Urban reference 
Rural 0.98 0.937 0.57 1.68 
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health reference 
Good/Excellent Health 0.94 0.844 0.51 1.73 
Chronic Conditions 
None or One Chronic 
Condition reference 
Two or Three Conditions 1.67 0.106 0.90 3.11 
Four or More Conditions 1.07 0.845 0.54 2.12 
 
Depression 0.73 0.248 0.42 1.25 
Mobility 
Instrumental Activities of Daily Living 
(IADL) 
None reference 
One 1.07 0.829 0.58 1.97 
Two or more 1.09 0.780 0.61 1.93 
Activities of Daily Living 
(ADL) 
None reference 
One 1.28 0.510 0.62 2.64 
Two or more 0.72 0.328 0.38 1.38 
Intercept 4.03 0.015 1.31 12.39 
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Model 
F(25,436)=2.10, P>|F|=0.002. Adjusted Wald test of joint probability for financial 
characteristics: F(4,457)=1.61, P>|F|=0.171; patient characteristics: F(13,448)=1.42, 
P>|F|=0.147; diagnosis characteristics: F(8,453)=0.94, P>|F|=0.480. 
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Table 10: Unadjusted Rates of Cost-Related Underuse of Medical Care in 2007 for 
the Community-Dwelling Medicare Population Not Experiencing Cost-Related 
Underuse of Medical Care in 2005 
Variable 
No Cost-
Related 
Underuse 
New 
Cost-
Related 
Underuse 
Significance 
Level 
Financial Characteristics 
Drug Coverage 
Continued Coverage 60.4% 50.2% 0.006 
New Coverage 13.6% 21.0% 
No Coverage 17.6% 22.3% 
Lose Coverage 8.4% 6.5% 
Income 
Under $25K 53.4% 81.3% 0.000 
Over $25K 46.6% 18.7% 
Patient Characteristics 
Gender 
Female 55.1% 59.1% 0.327 
Male 44.9% 40.9% 
Race/Ethnicity 
White 80.3% 71.6% 0.012 
Black 7.8% 14.9% 
Hispanic 7.4% 8.0% 
Other 4.5% 5.5% 
Age 
Less than 45 years 2.8% 8.4% 0.000 
45 to 64 years 9.1% 36.9% 
65 to 69 years 22.8% 15.2% 
70 to 74 years 22.9% 17.5% 
75 years and over 42.4% 22.0% 
Education 
No High School 26.6% 28.6% 0.002 
High School 31.5% 23.9% 
Some College 23.8% 35.1% 
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Variable 
No Cost-
Related 
Underuse 
New 
Cost-
Related 
Underuse 
Significance 
Level 
College Degree 18.1% 12.5% 
Current Employment 
Not Employed 86.3% 88.0% 0.521 
Employed 13.7% 12.0% 
Geography 
Urban 76.9% 70.5% 0.072 
Rural 23.1% 29.5% 
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health 53.4% 74.5% 0.000 
Good/Excellent Health 46.6% 25.5% 
Chronic Conditions 
None or One Chronic 
Condition 31.7% 32.7% 0.014 
Two or Three Conditions 46.7% 37.2% 
Four or More Conditions 21.7% 30.1% 
 
No Depression 83.0% 58.7% 0.000 
Depression 17.0% 41.3% 
Mobility 
Instrumental Activities of Daily Living 
(IADL) 
None 72.7% 53.5% 0.000 
One 16.1% 21.8% 
Two or more 11.2% 24.6% 
Activities of Daily Living (ADL) 
None 74.2% 54.6% 0.000 
One 12.8% 16.5% 
Two or more 13.1% 29.0% 
 
Weighted Population 29,689,844 1,056,827 
Percent of Total 96.6% 3.4%   
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Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Rates calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Significance level 
from chi-square test statistic reported. 
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Table 11: Logistic Regression of New Cost-Related Underuse of Medical Care in 
2007 for the Community-Dwelling Medicare Population Not Experiencing Cost-
Related Underuse of Medical Care in 2005  
Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
Financial Characteristics 
Drug Coverage 
Continued Coverage reference 
New Coverage 1.64 0.021 1.08 2.50 
No Coverage 1.73 0.010 1.14 2.62 
Lose Coverage 1.15 0.656 0.63 2.09 
Income 
Over $25K 0.32 0.000 0.22 0.49 
Patient Characteristics 
Gender 
Male 0.80 0.210 0.56 1.13 
Race/Ethnicity 
White reference 
Black 1.36 0.264 0.79 2.33 
Hispanic 0.81 0.459 0.46 1.42 
Other 1.15 0.704 0.55 2.40 
Age 
Less than 45 years 3.60 0.000 2.14 6.04 
45 to 64 years 4.82 0.000 2.81 8.28 
65 to 69 years 1.55 0.108 0.91 2.64 
70 to 74 years 1.72 0.044 1.02 2.92 
75 years and over reference 
Education 
No High School reference 
High School 0.89 0.563 0.60 1.32 
Some College 2.00 0.001 1.31 3.06 
College Degree 1.58 0.123 0.88 2.82 
Current Employment 
Employed 1.28 0.291 0.81 2.03 
Geography 
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Variable 
Adjusted 
Odds 
Ratio P>|t| 
95% Confidence 
Interval 
Urban reference 
Rural 1.23 0.328 0.81 1.86 
Diagnosis Characteristics 
Self-Reported Health 
Fair/Poor Health reference 
Good/Excellent Health 0.77 0.208 0.51 1.16 
Chronic Conditions 
None or One Chronic 
Condition reference 
Two or Three Conditions 0.80 0.288 0.53 1.21 
Four or More Conditions 1.10 0.692 0.69 1.74 
 
Depression 1.71 0.002 1.22 2.39 
Mobility 
Instrumental Activities of Daily Living 
(IADL) 
None reference 
One 1.07 0.709 0.76 1.49 
Two or more 1.06 0.827 0.61 1.85 
Activities of Daily Living 
(ADL) 
None reference 
One 1.37 0.244 0.81 2.31 
Two or more 1.75 0.059 0.98 3.14 
Intercept 0.02 0.000 0.01 0.03 
Note: Data from Medicare Current Beneficiary Survey (MCBS) Access to Care modules. 
Calculated using retrospective longitudinal survey weights. Variance corrected for 
complex survey design strata and clusters using Taylor Linearization. Model 
F(25,454)=12.16, P>|F|=0.000. Adjusted Wald test of joint probability for financial 
characteristics: F(4,475)=11.77, P>|F|=0.000; patient characteristics: F(13,466)=5.88, 
P>|F|=0.000; diagnosis characteristics: F(8,471)=5.41, P>|F|=0.000. 
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Table 12: Adjusted Marginal Probability of Cost-Related Underuse of Medical Care in 2007 for Community-Dwelling 
Medicare Population Stratified by Cost-Related Underuse of Medical Care in 2005 
  
Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Medical Care in 
2005 
New Cost-Related Underuse Compared to 
No Cost-Related Underuse in 2007 for 
Subpopulation with No Cost-Related  
Underuse of Medical Care in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
Financial Characteristics   
Drug Coverage   
Continued Coverage reference reference 
New Coverage -0.0374 0.495 -0.1448 0.0701 0.0124 0.043 0.0004 0.0243 
No Coverage -0.1273 0.051 -0.2550 0.0005 0.0139 0.017 0.0025 0.0254 
Lose Coverage 0.1371 0.032 0.0120 0.2621 0.0028 0.670 -0.0102 0.0159 
Income   
Over $25K -0.0060 0.921 -0.1236 0.1116 -0.0255 0.000 -0.0350 -0.0159 
Patient Characteristics   
Gender   
Male -0.0085 0.848 -0.0953 0.0784 -0.0051 0.211 -0.0132 0.0029 
Race/Ethnicity   
White reference reference 
Black 0.0433 0.563 -0.1033 0.1899 0.0081 0.312 -0.0076 0.0239 
 
 
 
 
7
2
 
  
Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Medical Care in 
2005 
New Cost-Related Underuse Compared to 
No Cost-Related Underuse in 2007 for 
Subpopulation with No Cost-Related  
Underuse of Medical Care in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
Hispanic 0.0813 0.291 -0.0695 0.2321 -0.0044 0.429 -0.0152 0.0065 
Other -0.0637 0.476 -0.2388 0.1114 0.0035 0.717 -0.0153 0.0223 
         
Age   
Less than 45 years -0.1275 0.183 -0.3150 0.0601 0.0377 0.001 0.0164 0.0591 
45 to 64 years -0.1460 0.108 -0.3239 0.0319 0.0545 0.000 0.0290 0.0801 
65 to 69 years 0.0169 0.829 -0.1365 0.1702 0.0082 0.128 -0.0024 0.0188 
70 to 74 years -0.0681 0.540 -0.2859 0.1498 0.0108 0.066 -0.0007 0.0223 
75 years and over reference reference 
Education   
No High School reference reference 
High School -0.0458 0.474 -0.1711 0.0796 -0.0021 0.571 -0.0093 0.0051 
Some College -0.0300 0.626 -0.1509 0.0908 0.0187 0.002 0.0071 0.0302 
College Degree -0.1031 0.175 -0.2520 0.0458 0.0108 0.148 -0.0038 0.0255 
Current Employment   
Employed -0.0092 0.889 -0.1376 0.1192 0.0063 0.329 -0.0064 0.0190 
Geography   
Urban reference reference 
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Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Medical Care in 
2005 
New Cost-Related Underuse Compared to 
No Cost-Related Underuse in 2007 for 
Subpopulation with No Cost-Related  
Underuse of Medical Care in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
Rural -0.0040 0.938 -0.1036 0.0957 0.0051 0.361 -0.0058 0.0160 
Diagnosis Characteristics   
Self-Reported Health   
Fair/Poor Health reference reference 
Good/Excellent Health -0.0113 0.845 -0.1241 0.1016 -0.0060 0.206 -0.0154 0.0033 
Chronic Conditions   
None or One Chronic Condition reference reference 
Two or Three Conditions 0.0945 0.120 -0.0246 0.2135 -0.0051 0.303 -0.0147 0.0046 
Four or More Conditions 0.0140 0.844 -0.1258 0.1538 0.0024 0.694 -0.0097 0.0145 
 
  
Depression -0.0616 0.255 -0.1677 0.0445 0.0147 0.008 0.0039 0.0255 
Mobility   
Instrumental Activities of Daily Living (IADL)   
None reference reference 
One 0.0124 0.826 -0.0981 0.1228 0.0015 0.711 -0.0064 0.0094 
Two or more 0.0150 0.776 -0.0883 0.1183 0.0014 0.830 -0.0117 0.0146 
Activities of Daily Living (ADL)   
None reference reference 
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Resolved Underuse Compared to 
Unresolved Cost-Related Underuse in 
2007 for Subpopulation with Cost-
Related Underuse of Medical Care in 
2005 
New Cost-Related Underuse Compared to 
No Cost-Related Underuse in 2007 for 
Subpopulation with No Cost-Related  
Underuse of Medical Care in 2005 
Variable AME P>|t| 
95% Confidence 
Interval AME P>|t| 
95% Confidence 
Interval 
One 0.0418 0.497 -0.0787 0.1622 0.0075 0.287 -0.0063 0.0212 
Two or more -0.0638 0.344 -0.1959 0.0683 0.0153 0.113 -0.0036 0.0341 
Note: AME is Average Marginal Effect, at means. Probabilities constructed from Tables 9 and 11 logistic regression model estimates 
with marginal effects calculated with other variables at mean values. Data from Medicare Current Beneficiary Survey (MCBS) Access 
to Care modules. Calculated using retrospective longitudinal survey weights. Variance corrected for complex survey design strata and 
clusters using Taylor Linearization. Predicted probability of resolved cost-related underuse of medical care in 2007 is 0.74 (95% 
Confidence Interval (CI): 0.67-0.80, P>0.000). Predicted probability of new cost-related underuse of medical care in 2007 is 0.04 
(95% CI: 0.04-0.05, P>0.000).
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Study 2: Drug Adherence Before and After Enrollment in Medicare 
Part D Partial Low Income Subsidy 
Summary for Study 2 
Objectives: To evaluate the Medicare Partial Low Income Subsidy (LIS) benefit and to 
determine its association with prescription drug adherence for three therapeutic cohorts of 
beneficiaries prescribed statins, oral anti-diabetic agents, or proton pump inhibitors. 
 
Background: The partial LIS benefit has three levels of premium subsidization (25%, 
50%, 75%) based on the beneficiary’s income level and enrollees face the same uniform 
15% coinsurance level and small deductible.  
 
Data: Medicare administrative enrollment and claims data are used from the national 5% 
enhanced sample from 2006 through 2010.  
 
Methods: Medicare beneficiaries continuously enrolled in the stand alone prescription 
drug plans in the Part D benefit that transition from the non-LIS to partial LIS enrollment 
at any time during the initial implementation of Part D in 2006 through the end of the 
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study data in December 2010 are the analytical cohort. Three therapeutic cohorts are 
selected from the enrollment analytical file based on having prescription drug fills in the 
pre- and post-partial LIS enrollment periods for proton pump inhibitors, statins, or oral 
anti-diabetic medications. Demographic measures, health risk adjusters, and Part D plan 
and benefit variables are used as explanatory variables. A regression analysis examines 
the relationship of the explanatory measures and before and after partial LIS enrollment 
change in prescription drug proportional days covered (PDC) adherence measure for each 
therapeutic cohort. 
 
Results: After enrollment in the partial LIS benefit, average unadjusted adherence levels 
increased 0.24 (95% confidence interval (CI), 0.21-0.27) for proton pump inhibitors 
(PPIs), 0.19 (95% CI, 0.17-0.21) for statins, and 0.12 (95% CI, 0.09-0.15) for oral anti-
diabetic medications. On average, the oral anti-diabetic therapeutic cohort was adherent, 
as measured by PDC greater than 0.80, post-partial LIS enrollment but the other two 
cohorts, although improved, were not at adherent levels on average. Comparing change in 
adherence among the three premium subsidization groups found insignificant differences 
for the statin and oral anti-diabetic cohorts, but the 25% premium subsidization group 
within the PPI cohort had a 0.07 (95% CI, 0.006-0.14) increase in adherence compared to 
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the 50% subsidization group, adjusted for other financial, patient, and diagnostic 
characteristics. Partial LIS enrollees residing in more competitive Part D plan markets 
had lower adjusted change in PPI adherence (β= -0.02; 95% CI, -0.06 - -0.0001), in statin 
adherence levels (β= -0.04; 95% CI, -0.06 - -0.02), and in oral anti-diabetic (β= -0.04; 
95% CI, -0.06 - -0.005) adherence, which suggests they may have experienced less cost 
pressure during the pre-transition period. 
 
Conclusions: Overall, partial LIS enrollees improved adherence rates following 
enrollment in the benefit in the three therapeutic classes most likely to have cost-related 
underuse.  
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Introduction 
 The Centers for Medicare and Medicaid Services (CMS) estimate that 
approximately 20 percent of Medicare beneficiaries eligible to receive extra help with 
premium subsidies and drug cost sharing have not applied for the Low Income Subsidy 
benefit.49 Cost-related underuse has had marginal declines within the Medicare 
population since the implementation of Part D, but a sizeable number of eligible 
beneficiaries have not enrolled within the LIS benefit and are experiencing higher out-of-
pocket costs when they may qualify for premium or cost-sharing assistance. A survey of 
potentially LIS eligible seniors found that 77% were not aware of the subsidy availability, 
83% did not know how to apply for it, and 48% were reluctant to apply for a “welfare” 
program,104 which suggests some Medicare beneficiaries may be experiencing higher cost 
sharing and monthly premiums for drug coverage that may unnecessarily lead to cost-
related underuse. Overall self-reported, cost-related underuse of prescription drugs has 
declined slightly within the Medicare populations since expansion of coverage and the 
implementation of Medicare Part D; however, Medicare beneficiaries with multiple 
chronic conditions and higher drug utilization remain vulnerable to skipping doses, 
splitting pills, or delaying refills due to limited income.82–84 In this study, we examine 
Part D enrollees’ prescription drug behavior before and after enrollment in the Partial 
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Low Income Subsidy program to evaluate whether premium assistance and reduced cost-
sharing provided by the benefit is associated with better adherence to prescribed drug 
therapy regimens. 
Policy Background of Partial Low Income Subsidy Program 
The Low Income Subsidy (LIS) program provides premium payment assistance 
and reduced cost-sharing/co-payment rates for Medicare Part D beneficiaries who qualify 
based on income and asset levels. The income limits for LIS qualification are up to 150% 
of the federal poverty limit (FPL) and, in 2011, assets that do not exceed $12,640 for 
individuals or $25,260 for married couples. Medicare beneficiaries who are dually 
enrolled in Medicaid, Medicare Savings Program (MSP), or Supplemental Security 
Income (SSI) are auto-enrolled or deemed into LIS and receive a full 100% premium 
subsidy. Non-deemed LIS recipients must apply for program enrollment and receive 
premium assistance on a sliding scale based on their income level. In addition to 
premium and cost-sharing assistance, LIS program enrollees do not experience the 
coverage gap during the year and may change drug plans at any time. 
Partial LIS enrollees are non-deemed LIS beneficiaries divided into three 
categories of premium subsidization amounts based on income. The 25%, 50%, and 75% 
premium subsidization categories are based on qualification into the categories by 5% 
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increments of income between 135% and 150% of the federal poverty level. Partial LIS 
enrollees have the same asset level threshold for qualification. All partial LIS 
beneficiaries have a uniform, small deductible (e.g., $63 in 2010) and 15% coinsurance 
rate for prescription drugs. Variation among the three groups is solely the differences in 
income levels and premium subsidization amounts. 
Health services research examining LIS has addressed enrollment differences and 
eligibility rates105–109 but has not examined specific prescription drug behavioral 
outcomes for the partial LIS program population. Instead, most research on the LIS 
population has been examined using it as a control population of Part D beneficiaries who 
do not face the coverage gap or donut hole and examined as a broad population rather 
than individual LIS categories.110–115 Examining the LIS population as a single group is 
similar to how Medicare/Medicaid dual eligible beneficiaries were examined before 
Medicare Part D and does not distinguish the programmatic differences within these two 
groups based on qualification differences in enrollment. Lin, et al.,116 notable for its 
analytical comparison of the LIS cost sharing groups, examine drug initiation of 
osteoporosis medications comparing full and partial LIS categories with non-LIS Part D 
beneficiaries and did not find differences in out-of-pocket expenses affecting initiation. 
Survey analysis of self-reported cost-related drug underuse has shown that LIS 
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enrollment is associated with reduced underuse,117,118 but prescription drug adherence has 
not been examined by LIS enrollment categories, such as the partial LIS benefit.  
Partial LIS enrollees are approximately 13% of all LIS beneficiaries, but it is 
estimated that only 40% of those eligible for the non-deemed LIS benefit are enrolled.109 
With 60% of the eligible population not enrolled, a large number of new partial LIS 
enrollees may be more likely to have experienced cost-related underuse of prescription 
drugs prior to enrolling for the benefit. 
 Given the relationship between cost-related underuse and Medicare beneficiaries 
with limited resources, the objective of this paper is to examine medication adherence 
levels before and after enrollment in the partial LIS benefit. The partial LIS benefit 
provides premium subsidization and cost-sharing assistance for the enrolled beneficiaries, 
and it is expected, therefore, that adherence, as measured by the proportion of days 
covered (PDC), will improve with partial LIS enrollment.  
Research Design 
Data  
 The Chronic Condition Warehouse (CCW) 5% enhanced sample from 2006 
through 2010 is used to examine prescription drug adherence for the non-deemed, partial 
LIS recipients with a comparison before and after enrollment. The administrative 
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Medicare files used in the analysis are the denominator data, prescription drug event 
(PDE) file, Minimum Data Set (MDS) long-term care assessment, MedPAR, and the plan 
characteristics data. The Part D Denominator file is used to identify enrollment in Part D 
and the partial LIS benefit and includes beneficiary demographic data. The MDS data are 
used to identify and exclude nursing home residents. MedPAR data are used for diagnosis 
and hospitalizations information. The PDE data are merged with RxNorm to determine 
the drug therapy cohorts and used to determine their corresponding adherence levels. 
Health risk adjusters are computed using the AHRQ comorbidity index constructed from 
the MedPAR data files. The plan characteristics data provide information on the types of 
Part D plans, such as enhanced benefit plans or stand-alone prescription drug plans 
(PDPs) and Medicare Advantage prescription drug plans (MAPDs). All Medicare claims 
data used in the analysis were obtained from the Centers from Medicare and Medicaid 
Services (CMS) prior to the current substance use disorder (SUD) suppression,119 and 
study results are not affected by missing SUD data. 
Study Sample 
 The analytical extracts for the enrollment cohorts selected all beneficiaries during 
the five years of data that were continuously enrolled first in the Part D program but not 
in the LIS benefit and then enrolled in the partial LIS benefit consecutively. Only those 
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beneficiaries who transition from non-LIS Part D enrollment one month to partial LIS 
status the next month are included in the analysis, but that transition may occur at any 
time during the 2006 to 2010 period. The post partial LIS enrollment period ends when 
the data ends in 2010 or if the beneficiary is no longer enrolled within the partial LIS 
categories due to disenrollment in Part D, transition to full LIS, return transition to non-
LIS Part D enrollment, or death. Beneficiaries who are not enrolled in the Part D benefit, 
are enrolled in an MA-PD, or are enrolled in the full LIS benefit prior to a transition into 
the partial LIS program are not included in the analysis. 
 Figure 4 provides a flow chart illustration of the construction of the analytical 
sample for Study 2. Within the enhanced 5% Medicare sample, there are 1,985,653 Part 
D Medicare beneficiaries from 2006 through 2010. Medicare beneficiaries who enter the 
partial LIS benefit at their initiation of their Part D enrollment are excluded from the 
analysis (n=38,488 beneficiaries), and beneficiaries who are deemed into the full LIS 
benefit without any preceding partial LIS transition from Part D are also excluded  
(n=780,974 beneficiaries). Long-term care and nursing home residents (n=160,918 
beneficiaries) are excluded because their prescription drug behavior is monitored by their 
residential institution. Lastly, MA-PD enrollees are excluded because their hospital 
encounter data are not fully included within the MedPAR data file that is used for 
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adjusting the outcome variable and determining chronic condition co-morbidities. The 
final analytical file is composed of 552,511 Medicare Part D beneficiaries who are 
community-dwelling, FFS-enrolled, and do not have any prior LIS transitions. From this 
analytical population, a total of 3,322 beneficiaries transition from Medicare Part D into 
the partial LIS program from 2006 through 2010. Of these 3,322 beneficiaries, 1,005 
have a proton pump inhibitor filled before and after the transition, 1,606 have a statin 
filled in both periods, and 747 beneficiaries have oral anti-diabetic medication fills pre- 
and post-partial LIS transition. The consecutive periods before and after enrollment in the 
partial LIS benefit are used for extracting the corresponding prescription drug data, 
demographic, plan, and enrollment variables. 
Therapeutic Classes 
Therapeutic classes were selected based on medications most likely to not be 
filled due to cost concerns. The Medicare Current Beneficiary Survey (MCBS) began 
asking about cost-related underuse in 1997 and collected the prescription drug name that 
was not filled due to concerns about the cost of the medication. By pooling this data from 
multiple years of MCBS, the frequency of top medication classes most likely to have 
cost-related underuse are: (1) gastrointestinal agents, (2) statins, (3) anti-depressants, and 
(4) oral anti-diabetics. After consultation with project advisors, the three therapeutic drug 
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classes examined in this study were selected as proton pump inhibitors, statins, and oral 
anti-diabetics.  
The selection of therapeutic beneficiary cohorts is from prescription drug data in 
the PDE data files that are merged with RxNorm to select three therapeutic classes of 
drugs - statins, oral anti-diabetics, and gastrointestinal agents - to use for comparison of 
clinical cohorts of the partial LIS beneficiary sample. RxNorm classifies the 11-digit 
national drug codes (NDCs) by common code for active ingredients.120 The active 
ingredients used to select the therapeutic cohorts are listed in Table 13. To be included in 
the clinical cohorts, beneficiaries had to have at least one prescription drug fill for the 
class in both the pre- and post-enrollment periods. 
Outcome Variables 
The proportional days covered (PDC) was calculated to measure the adherence 
level for each period and drug class.121–123 The construction of PDC started the counting 
clock with the first day of the period if the beneficiary had drug stock that carried over 
into the start of the period or on the first day of the first fill within the period for the 
medication. The pre-partial LIS period starts on the first month observed enrollment in 
the non-partial LIS Part D benefit and the post-partial LIS period starts in the first month 
of partial LIS enrollment. The PDC clock begins within each of the pre and post periods 
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with the first prescription fill for the therapeutic class and ends with the close of the 
period. Beneficiaries were limited to carrying a maximum of 30 days of surplus drug 
stock at any time during the period. Gap days occur whenever the beneficiary does not 
have days’ supply or surplus stock covered and are adjusted for hospitalizations.124 Gaps 
of 90 consecutive days are considered a discontinuation and the end of the PDC 
calculation period.125,126 If the drug is refilled during the pre- or post-transition period 
after discontinuation, then a second PDC period is calculated for the beneficiary and 
added to the first period for the adherence calculation.1 PDC ranges from greater than 0, 
perfect non-adherence, to 1, perfect adherence during the period. PDC levels greater than 
or equal to 0.80 are considered as adherent behavior.2,126–131 The post-transition PDC is 
subtracted from the pre-transition PDC to calculate the change in adherence before and 
after partial LIS enrollment as the outcome measure. 
Explanatory Measures 
Financial Characteristics. Two different measures of premium subsidization are 
created for analysis. The first one is an indicator variable for the partial LIS categories. 
The 25%, 50%, and 75% premium subsidy levels vary by income qualification in the 
range for the percent above federal poverty level (FPL) for the category, and it is 
expected that Medicare beneficiaries with higher incomes would have better adherence 
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rates. The second measure is an indicator variable if the beneficiary enrolls in a plan with 
a premium above the subsidy level. Partial LIS enrollees receive a subsidy amount up to 
the benchmark subsidy without their region. If they enroll in a plan with premiums above 
that amount, they pay 100 percent of the premium above the subsidy limit. Beneficiaries 
who enroll in plans above the subsidy level are expected to have better adherence because 
they have more financial resources to cover premium costs above the regional rate. 
Two measures of drug plan enrollment are created to capture differing 
expectations of their effects on adherence behavior: plan switching at the time of benefit 
enrollment and during the benefit enrollment period. Beneficiaries who switch plans at 
the transition change the Part D plan they are enrolled in between the last month of non-
partial LIS enrollment and the first month of partial LIS enrollment. The plan identifiers 
contained within the administrative data provided to academic researchers are encrypted 
specific to the calendar year and a crosswalk file provides plan identifier tracking from 
one year to the next. Plan switching at the time of enrollment is expected to be associated 
with improved adherence rates because the beneficiary is enrolling in a plan with a better 
suited formulary or cost sharing for their prescription drug therapies.132 Changing plans 
during the partial LIS enrollment period, listed as change plans within benefit in the 
tables, is coded as an indicator variable for one or more plan changes. Plan switching 
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within the benefit during the year is expected to be related to lower adherence levels 
because the beneficiary is enrolled in a poor quality plan or mismatched plan formulary. 
Another key plan measure captures the degree of competition within the Part D 
market for the beneficiary and measures the percent of plans offered as enhanced benefit 
plans within the beneficiary’s county. Karaca-Mandic, et al.20 found the level of plan 
generosity was associated with more competitive Part D markets. It is expected that 
beneficiaries residing in more competitive markets may have more generous plans 
benefits and thereby better adherence levels in the period prior to enrollment in the partial 
LIS benefit.  
Patient Characteristics. Demographic measures are created from the denominator 
data. Age is calculated for the beneficiary for the transition month. The denominator files 
from CMS changed the reference period for age provided in the annual files from January 
to December (begin of year to end of year switch) between the 2008 and 2009 files, so 
age was recalculated to be age at transition for this analysis. Gender is male or female sex 
from the denominator data. Race/ethnicity is from the Research Triangle Institute race 
variable in the denominator data.133 Black, non-Hispanic and Hispanic, all races 
beneficiaries are compared to White, non-Hispanic and Other, non-Hispanic beneficiaries 
in the regression estimation models. Other, non-Hispanic Medicare beneficiaries were not 
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examined separately due to the CMS data use agreement restrictions that limit cell size 
reporting. 
Diagnosis Characteristics. Chronic conditions are classified using the Healthcare 
Cost and Utilization Project (HCUP) algorithm.134 Using all of the diagnosis codes 
provided within the MedPAR data, the following chronic condition indicators are created 
by the algorithm: congestive heart failure, valvular disease, pulmonary circulation 
disease, peripheral vascular disease, hypertension, paralysis, other neurological disorders, 
chronic pulmonary disease, diabetes without chronic complications, diabetes with chronic 
complications, hypothyroidism, renal failure, liver disease, peptic ulcer disease and 
bleeding, acquired immune deficiency syndrome, lymphoma, metastatic cancer, solid 
tumor without metastasis, rheumatoid arthritis/collagen vas, coagulopathy, obesity, 
weight loss, fluid and electrolyte disorders, chronic blood loss anemia, deficiency 
anemias, alcohol abuse, drug abuse, psychoses, depression. The chronic condition 
indicators are summed to create a co-morbidity index and used in the analysis as a three 
category measure comparing beneficiaries with no co-morbidities, 1 to 2 co-morbidities, 
and 3 or more co-morbidities.70,135 Medicare beneficiaries with more chronic conditions 
or co-morbidities are expected to have poorer adherence levels from complicated 
management of polypharmacy or from poorer health limitations.  
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Exposure variable. The analysis examines transitions that may occur at any time 
during the period covered by available data. As control measures, the duration in 
enrollment months before and after transition are used in the regression models as pre and 
post-partial LIS exposure variables.  
Statistical Model 
Descriptive analysis of the single treatment-only cohort research design is tested 
by comparing the average adherence level, as measured by PDC, before and after 
enrollment in the partial LIS program. A paired t-Test for difference in means compares 
the unadjusted, pre-partial LIS PDC mean to the unadjusted, post-partial LIS PDC mean. 
For the bivariate analysis of the explanatory variables, the outcome measure was 
collapsed into two categories to compare Medicare beneficiaries with improved 
adherence with those that had the same or worse adherence. The outcome measure was 
recoded into two categories because it is a continuous variable measuring the individual’s 
change in PDC levels before and after partial LIS enrollment. The bivariate analysis of 
those with improved adherence following partial LIS enrollment and those that did not 
improve compares the explanatory measures of financial, patient, and diagnostic 
characteristics using χ2 test statistics for the categorical explanatory measures and a t-test 
for difference in means for the continuous explanatory measures. Heckman’s selection 
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model was estimated to correct for unobservable bias of the self-selection into the partial 
LIS program by the Medicare beneficiaries, but the Rho value from the two part model 
indicated that the correction was not needed and a regression model was suitable. The 
results of the Heckman selection model are provided in Appendix A. The financial, 
patient, and diagnostic explanatory measures are regressed on the continuous outcome 
measure of change in adherence before and after enrollment in the partial LIS program. 
The adjusted Wald test of joint probability of the variables for financial, patient, and 
diagnostics characteristics are equal to zero as a set is also tested for each regression 
model. The descriptive and bivariate statistics and regression model are estimated using 
Stata 12. All results with p<0.05 are discussed in the findings section. 
Findings  
 The findings section discussion is divided into each of the three therapeutic cohort 
analyses of the descriptive, bivariate, and regression results. 
Proton Pump Inhibitor Cohort 
 Enrollment in the partial LIS benefit does result in statistically significant 
improvement in levels of prescription drug adherence for those Medicare beneficiaries 
using prescribed proton pump inhibitors. As shown in Table 14, the average adherence 
level is 0.44 (95% confidence interval (CI), 0.42-0.47) before enrollment in the partial 
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LIS program when the Medicare beneficiary is enrolled in a stand-alone PDP in the 
regular Part D benefit and the average PDC level increases to 0.69 (95% CI, 0.67-0.70) in 
the period after enrolling in the partial LIS program. The differences between pre- and 
post-partial LIS enrollment is an improvement of 0.24 (95% CI, 0.21-0.27) in the average 
adherence level of PPIs. 
 Table 15 provides the bivariate statistics for the explanatory variables of financial, 
patient, and diagnostic characteristics with the exposure variable for duration of post-
partial LIS enrollment for the outcome measure divided into two categories to compare 
beneficiaries with improved adherence following the transition in the partial LIS program 
with those beneficiaries who did not improve. Within the PPI cohort, 68.3 percent 
improved their adherence levels following enrollment in the partial LIS program. 
Medicare beneficiaries in the highest income threshold from 145% to 150% of FPL with 
25% premium subsidy level were more likely to have improved adherence levels (37.2 
percent improved compared to 28.5 percent with same or worse adherence levels). 
Medicare beneficiaries with the 50% premium subsidy are a larger proportional share of 
the PPI cohort with same or worse adherence following partial LIS enrollment (39.8 
percent with same or worse PDC and 32.4 percent with improved PDC levels). The 
lowest income group with the highest level of premium subsidization, 75% premium 
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subsidy, have similar proportional shares with improved and worse adherence levels 
(31.7 percent with same or worse and 30.5 percent with improved). Differences between 
improved adherence and same or worse adherence for PPI medications were not 
statistically significant for the other financial characteristics or the patient and diagnosis 
characteristics. On average, Medicare beneficiaries in the PPI cohort with improved 
adherence had 6 more months of enrollment in the partial LIS benefit than those with 
same or worse adherence. For those Medicare beneficiaries with same or worse PPI 
adherence, they are enrolled an average of 24.1 months before the transition and 21.4 
months after the transition, and those with improved PPI adherence have been enrolled 
19.7 months, on average, before partial LIS enrollment and in the benefit 27.7 months on 
average following the partial LIS transition. 
 Table 16 provides the regression model results of financial, patient, and diagnosis 
characteristics on change in PPI adherence before and after partial LIS enrollment. 
Medicare beneficiaries with incomes between 140% and 145% FPL receiving the 50% 
premium subsidy had lower change in their PDC adherence levels before and after 
enrollment in the partial LIS benefit (β = -0.07; 95% CI, -0.14 - -0.006) than beneficiaries 
with income between 145% and 150% FPL. Medicare beneficiaries in more competitive 
Part D markets had lower change in PPI adherence levels before and after partial LIS 
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enrollment (β = -0.03; 95% CI, -0.06 - -0.0001). Medicare beneficiaries with 1-2 co-
morbidities had lower change in their PPI adherence levels than those with 3 or more co-
morbidities (β = -0.10; 95% CI, -0.18 - -0.02). Medicare beneficiaries enrolled longer in 
Medicare Part D before the partial LIS benefit for lower change in their adherence levels 
compared before and after enrollment (β = -0.003; 95% CI, -0.005 - -0.001). Medicare 
beneficiaries enrolled in the partial LIS benefit for longer periods have more 
improvement in their adherence levels compared to before and after enrollment (β = 
0.005; 95% CI, 0.003-0.007). The adjusted Wald tests on the joint probability that the set 
of variables for financial, patient, or diagnosis characteristics are equal to zero shows that 
the diagnosis characteristics are significantly different.  
Statin Cohort 
Similar to the PPI cohort, enrollment in the partial LIS benefit results in 
statistically significant improvement in levels of prescription drug adherence for those 
Medicare beneficiaries using prescribed statins. Table 17 shows the average unadjusted 
PDC levels for the statin cohort before and after enrolling in the partial LIS program. The 
average adherence level is 0.59 (95% CI, 0.57-0.61) before enrollment in the partial LIS 
program and the average PDC level increases to 0.78 (95% CI, 0.77-0.79) in the period 
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after enrolling in the partial LIS program. The difference before and after enrollment in 
the partial LIS benefit is 0.19 (95% CI, 0.17-0.21) in statin PDC levels. 
Bivariate statistics for the explanatory variables of financial, patient, and 
diagnostic characteristics with the exposure variable for duration of post-partial LIS 
enrollment for the outcome measure divided into two categories to compare beneficiaries 
with improved statin adherence following the transition in the partial LIS program with 
those beneficiaries who did not improve are provided in Table 18. Within the statin 
cohort, 63.0 percent had improved adherence levels following enrollment in the partial 
LIS benefit and 37.1 percent had the same or worse adherence. On average, Medicare 
beneficiaries with improved statin adherence are younger than those with the same or 
worse adherence. The average age of Medicare beneficiaries with improved statin 
adherence is 72.2 years, and the average age of those with same or worse adherence is 
73.8 years. Differences between improved adherence and same or worse adherence for 
statin medications were not statistically significant for the other financial, patient, or 
diagnosis characteristics. Medicare beneficiaries in the statin cohort with improved 
adherence had, on average, 4 more months enrolled in the partial LIS benefit than those 
with same or worse adherence. Medicare beneficiaries with improved statin adherence 
are enrolled in the Part D before the partial LIS benefit enrollment less time, on average, 
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than those with the same or worse adherence (23.1 months compared to 25.2 months, on 
average). For those Medicare beneficiaries with same or worse statin adherence, they are 
post-partial LIS enrolled an average of 20.9 months, and those with improved statin 
adherence have been enrolled in the benefit 25.0 months on average following the partial 
LIS transition. 
The regression model results of change in statin adherence levels with financial, 
patient, and diagnosis characteristics explanatory variables is provided in Table 19. 
Medicare beneficiaries residing in counties with more Part D plan competition as 
measured by a larger proportion with gap plans have lower change in their PDC levels (β 
= -0.04; 95% CI, -0.06 - -0.02). Controlling for all other explanatory measures, Medicare 
beneficiaries have 0.003 (95% CI, -0.01 - -0.001) lower change in their statin adherence 
levels for each year older, and male beneficiaries have 0.05 (95% CI, -0.09 - -0.004) 
lower change in their statin PDC levels than females. Similar to the PPI therapeutic 
cohort, partial LIS enrollees with longer periods within the partial LIS benefit have more 
improvement in the difference between their adherence levels before and after the 
transition (β = 0.006; 95% CI, 0.004-0.007) and those with longer periods prior to partial 
LIS enrollment in the Part D benefit have less improvement in statin adherence (β = -
0.003; 95% CI, -0.004 - -0.001). The adjusted Wald tests on the joint probability tests for 
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the financial, patient, or diagnosis characteristics show that the financial and patient 
characteristics are significantly different from zero. 
Oral Anti-Diabetics Cohort 
For those Medicare beneficiaries taking oral anti-diabetic medications, enrollment 
in the partial LIS benefit had statistically significant improvement in levels of 
prescription drug adherence. Table 20 shows the average unadjusted PDC levels for the 
oral anti-diabetic medication cohort before and after enrolling in the partial LIS program. 
The average adherence level is 0.68 (95% CI, 0.65-0.71) before enrollment in the partial 
LIS program and the average PDC level increases to 0.80 (95% CI, 0.78-0.82) in the 
period after enrolling in the partial LIS program. The pre- and post-enrollment difference 
of 0.12 (95% CI, 0.09-0.15) shows improved oral anti-diabetic adherence for partial LIS 
beneficiaries. Compared to the other two cohorts, this therapeutic cohort had the least 
amount of change before and after enrollment but qualitatively they are the only cohort 
that changed from an average, non-adherent level below 0.80 PDC to on average, 
adherent PDC levels after enrolling in the partial LIS program. The 0.80 average PDC 
level post-partial LIS is exactly on the adherence threshold but both the PPI and statin 
therapeutic cohorts were below this level before and after partial LIS enrollment. 
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Table 21 provides the bivariate statistics for the explanatory variables of financial, 
patient, and diagnostic characteristics with the exposure variable for duration of post-
partial LIS enrollment for the oral anti-diabetic cohort. For analytical purposes, the 
outcome measure is divided into two categories to compare beneficiaries with improved 
adherence to oral anti-diabetics following the transition in the partial LIS program with 
those beneficiaries who did not improve. Within the oral anti-diabetic cohort, 47.9 
percent had improved adherence levels following enrollment in the partial LIS benefit 
and 52.1 percent had the same or worse adherence. Similar to the statin therapeutic 
cohort, Medicare beneficiaries with improved adherence to oral anti-diabetic medications 
are, on average, younger than those with the same or worse adherence. The average age 
of Medicare beneficiaries with improved adherence to oral anti-diabetic medications is 
71.1 years, and the average age of those with same or worse adherence is 72.9 years. All 
other outcome category differences were not statistically significant for the other 
financial, patient, or diagnosis characteristics explanatory measures. On average, those 
Medicare beneficiaries with same or worse oral anti-diabetic adherence have been 
enrolled 21.3 months in the partial LIS benefit and 22.5 months before partial LIS, and 
those with improved adherence have been enrolled in the benefit 26.8 months and 19.8 
months, on average, before partial LIS enrollment. 
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Table 22 presents the regression model estimates of change in oral anti-diabetic 
medication PDC levels by financial, patient, and diagnosis characteristics explanatory 
variables. Similar to the statin drug therapeutic cohort, Medicare beneficiaries residing in 
counties with more gap plans competing within the Part D plan market have lower 
change in their oral anti-diabetic PDC levels (β = -0.04; 95% CI, -0.06 - -0.005). 
Controlling for all other explanatory measures, Medicare beneficiaries have 0.004 (95% 
CI, -0.01 - -0.001) lower change in their oral anti-diabetic adherence levels for each year 
older in age. Medicare beneficiaries with longer durations enrolled in the partial LIS 
benefit have more improvement in their post-LIS oral anti-diabetic adherence levels 
compared to their pre-LIS adherence (β = 0.005; 95% CI, 0.002-0.007).  
Discussion 
 The Partial Low Income Subsidy (LIS) provides Medicare beneficiaries, who 
have incomes between 135% and 150% of the federal poverty level and assets less than 
$12,640 for individuals or $25,260 for married couples in 2011, assistance with premium 
subsidization and lower cost-sharing for prescription drugs. The purpose of the analysis 
in this study was to examine if the financial assistance provided by the partial LIS benefit 
resulted in improvements to adherence of prescription drug therapies.  
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 One limitation of the findings from this analysis for purposes of an overall 
evaluation of the partial LIS benefit was the focus on three clinical cohorts of drug 
classes most likely to have cost-related underuse. To the extent that beneficiaries were 
experiencing cost-related underuse prior to enrolling in the partial LIS benefit, the 
selection of these three drug classes are more likely to show larger changes in adherence 
levels than drug classes less likely to have cost-related underuse.  In addition to being the 
drug categories most likely to have cost-related underuse reported, the three therapeutic 
classes are among the most common medications taken by the Medicare Part D 
population.50 
 Another important limitation is that the beneficiaries examined transitioned from 
non-LIS enrollment into the partial LIS benefit. Most partial LIS enrollees begin 
receiving the benefit at the same time they initiate Part D enrollment. Davidoff, Stuart, et 
al.108 found that the most vulnerable Medicare beneficiaries enroll in the LIS benefit at 
the initiation of Part D coverage. As shown in Figure 4, the numbers of Medicare 
beneficiaries who enroll in the partial LIS benefit directly are nearly 10 times more than 
the numbers who transition from non-LIS Part D into the partial LIS benefit. Therefore, 
the findings for those that transition onto the benefit may not be similar to those that 
enroll with Part D coverage initiation. More importantly, reducing the administrative 
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burden of re-enrollment once a beneficiary has enrolled within the partial LIS program 
may provide health benefits through improved adherence rates for the Medicare programs 
as shown by the common finding for all three drug therapy cohorts that the longer a 
beneficiary was enrolled within partial LIS, or exposed to the benefit, the better the 
adherence level. 
 Lastly, the findings are limited to the PDP Part D population and may not apply to 
the MA-PD population enrolled within the partial LIS program. As discussed in Figure 4, 
Medicare beneficiaries enrolled in PDP and MA-PD plans are roughly evenly split 
between the two categories of plans.  Since MA-PD plans provide prescription drug and 
medical care coverage, they may have more incentive to assist enrollees to have better 
prescription drug adherence to avoid more costly medical care utilization.136  
Williams, et al.137 find diabetes and cholesterol-lowering drugs were more likely 
to have cost-related non-adherence than symptom-relief drugs such as proton-pump 
inhibitors for Medicare Part D enrollees with diabetes. While this study was not limited 
to diabetic Medicare beneficiaries, the post-transition partial LIS adherence levels were 
larger and the cohort average adherence levels were at or near the 0.80 threshold of 
adherent prescription drug behavior for the diabetic and statin therapy groups compared 
to the PPI cohort. The results clearly suggest that following their transition the partial LIS 
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enrollees improved prescription drug adherence levels within three therapeutic classes 
most likely to have cost-related underuse and may in turn experience health gains that 
follow from improved drug adherence.  
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Figure 4: Study 2 Analytical Sample Construction 
 
  
 
1,985,653 Part D enrollees from 2006 to 
2010 in the 5% Enhanced Medicare 
Beneficiary Sample 
38,488 beneficiaries enroll directly into 
the Partial Low Income Subsidy 
program simultaneously when starting 
Part D enrollment 
1,947,165 beneficiaries who did not 
enroll in Part D and Partial LIS at same 
time 780,974 beneficiaries are deemed or 
enroll in full premium subsidy categories 
of Low Income Subsidy program without 
any preceding Partial LIS enrollment  
1,166,191 beneficiaries without prior 
LIS enrollment 
160,918 Part D enrolled beneficiaries 
with long-term care/nursing home stay 
1,005,273 community-dwelling 
beneficiaries without prior LIS 
3,322 beneficiaries transition into Partial 
LIS benefit from non-LIS Part D 
continuous enrollment  
549,189 beneficiaries who do not 
transition into Partial LIS benefit 
1,606 beneficiaries with statin filled before and after Partial LIS enrollment  
747 beneficiaries with oral anti-diabetic filled before and after Partial LIS 
1,005 beneficiaries with PPI filled before and after Partial LIS enrollment  
452,762 beneficiaries enrolled in MA-PD 
552,511 community-dwelling, FFS 
beneficiaries without prior LIS 
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Table 13: Active Ingredients of Selected Therapeutic Classes 
Therapeutic Class Active Ingredients 
Proton Pump Inhibitors 
(PPIs) 
Dexlansoprazole, Esomeprazole, Lansoprazole, 
Omeprazole, Pantoprazole, Rabeprazole  
Statins 
Atorvastatin, Cerivastatin, Fluvastatin, Lovastatin, 
Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin  
Oral Anti-Diabetics 
Acarbose, Acetohexamide, Chlorpropamide, 
Glibenclamide, Glimepiride, Glipizide, Glyburide, 
Meglitinides, Metformin, Miglitol, Nateglinide, 
Pioglitazone, Repaglinide, Rosiglitazone, Saxagliptin, 
Sitagliptin, Tolazamide, Tolbutamide 
Source: Food and Drug Administration (FDA). 2014. Orange Book: Approved Drug 
Products with Therapeutic Equivalence Evaluations. Silver Spring, MD: U.S. Department 
of Health & Human Services.  
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Table 14: Average Unadjusted Drug Adherence Levels of Proton Pump Inhibitors 
(PPIs) Before and After Medicare Part D Partial Low Income Subsidy (LIS) 
Enrollment for Continuously Enrolled in Stand-Alone Prescription Drug Plan 
(PDP), Community-Dwelling Medicare Beneficiaries 
Therapeutic 
Class 
Mean 
(95% Confidence Interval 
[CI]) 
Difference  
(95% CI) P>|t| 
Pre-Partial 
LIS 
Post-Partial 
LIS 
Proton 
Pump 
Inhibitors 
0.44 0.69 0.24 0.000 
(0.42,0.47) (0.67,0.70) (0.21,0.27)   
Note: Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 15: Bivariate Comparison Tests of Explanatory Variables and Improved 
Change in Adherence Levels of Proton Pump Inhibitors (PPIs) 
  
Change in Adherence 
Level    
Variable, Value Labels (units for mean, 
when applicable) 
Same or 
Worse Improved P value 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 31.7% 30.5% 0.016a 
50% Premium Subsidy 39.8% 32.4% 
25% Premium Subsidy 28.5% 37.2% 
    
Does not switch plans 99.7% 98.8% 0.182a 
Switch Plans at Transition 0.4% 1.2% 
    
Does not change plans 96.6% 96.8% 0.842a 
Change Plans Post-Enrollment 3.5% 3.2% 
    
Plan Premium Not Above Subsidy 66.5% 69.7% 0.305a 
Plan Premium Above Subsidy Level 33.5% 30.3% 
    
Market Percent of Gap Plans (µ, percent) 4.0 3.9 0.130b 
    
Patient Characteristics     
Age (µ, years) 72.4 72.1 0.752b 
    
Female 73.0% 75.4% 0.431a 
Male 27.0% 24.6% 
    
White/Other 89.0% 85.0% 0.128a 
Black 8.5% 10.1% 
Hispanic 2.5% 5.0% 
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Change in Adherence 
Level    
Variable, Value Labels (units for mean, 
when applicable) 
Same or 
Worse Improved P value 
Diagnosis Characteristics     
No Co-Morbidities 32.6% 32.2% 0.208a 
1-2 Co-morbidities 17.9% 13.9% 
3 or more Co-Morbidities 49.5% 53.9% 
    
Exposure variable     
Duration Before Transition (µ, months) 24.1 19.7 0.000b 
Duration After Transition (µ, months) 21.4 27.7 0.000b 
    
Number of Medicare Beneficiaries 319 686 
Percent 31.7% 68.3%   
Note: Statistical test denoted by a is chi-square test and by b is paired t-test of difference 
in means. Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 16: Regression Model Results of Financial, Patient, and Diagnosis 
Characteristics on Change in PPI Adherence Levels Before and After Partial LIS 
Enrollment 
Variable 
Parameter 
Coefficient 
Significance 
Level 
95% Confidence 
Interval 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy -0.0348 0.324 -0.1038 0.0343 
50% Premium Subsidy -0.0728 0.034 -0.1399 -0.0056 
25% Premium Subsidy reference 
Switch Plans at Transition 0.2121 0.164 -0.0864 0.5107 
Change Plans Post-Enrollment -0.0502 0.530 -0.2069 0.1066 
Plan Premium Above Subsidy Level -0.0388 0.212 -0.0998 0.0221 
Market Percent of Gap Plans -0.0284 0.049 -0.0566 -0.0001 
Patient Characteristics 
Age -0.0003 0.817 -0.0031 0.0024 
Female reference 
Male -0.0072 0.831 -0.0736 0.0592 
White/Other reference 
Black 0.0043 0.929 -0.0913 0.1000 
Hispanic 0.0036 0.960 -0.1365 0.1437 
Diagnosis Characteristics 
No Co-Morbidities -0.0355 0.270 -0.0986 0.0276 
1-2 Co-morbidities -0.1013 0.015 -0.1826 -0.0199 
3 or more Co-Morbidities reference 
Exposure Variable 
Duration Before Transition -0.0032 0.004 -0.0054 -0.0010 
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Variable 
Parameter 
Coefficient 
Significance 
Level 
95% Confidence 
Interval 
Duration After Transition 0.0050 0.000 0.0028 0.0073 
Intercept 0.3287 0.005 0.1006 0.5567 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. Model 
statistics: F(14,987)=6.79, P>|F|=0.000; R-squared=0.09; Adjusted R-squared=0.08. 
Adjusted Wald test of joint probability for financial characteristics: F(6,987)=2.10, 
P>|F|=0.051; patient characteristics: F(4,987)=0.20, P>|F|=0.990; diagnosis 
characteristics: F(2,987)=3.06, P>|F|=0.047. 
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Table 17: Average Unadjusted Drug Adherence Levels of Statins Before and After 
Medicare Part D Partial Low Income Subsidy (LIS) Enrollment for Continuously 
Enrolled in Stand-Alone Prescription Drug Plan (PDP), Community-Dwelling 
Medicare Beneficiaries 
Therapeutic 
Class 
Mean 
(95% Confidence Interval 
[CI]) 
Difference  
(95% CI) P>|t| 
Pre-Partial 
LIS 
Post-Partial 
LIS 
Statins 
0.59 0.78 0.19 0.000 
(0.57,0.61) (0.77,0.79) (0.17,0.21)   
Note: Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 18: Bivariate Comparison Tests of Explanatory Variables and Improved 
Change in Adherence Levels of Statins 
  
Change in Adherence 
Level    
Variable, Value Labels (units for mean, 
when applicable) 
Same or 
Worse Improved P value 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 32.8% 31.0% 0.232a 
50% Premium Subsidy 36.5% 34.1% 
25% Premium Subsidy 30.8% 34.9% 
    
Does not switch plans 99.5% 98.9% 0.224a 
Switch Plans at Transition 0.5% 1.1% 
    
Does not change plans 96.5% 97.9% 0.078a 
Change Plans Post-Enrollment 3.5% 2.1% 
    
Plan Premium Not Above Subsidy 71.4% 67.5% 0.097a 
Plan Premium Above Subsidy Level 28.6% 32.5% 
    
Market Percent of Gap Plans (µ, percent) 4.2 4.0 0.050b 
    
Patient Characteristics     
Age (µ, years) 73.8 72.2 0.003b 
    
Female 71.8% 72.3% 0.816a 
Male 28.2% 27.7% 
    
White/Other 85.2% 82.9% 0.177a 
Black 11.4% 11.8% 
Hispanic 3.4% 5.3% 
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Change in Adherence 
Level    
Variable, Value Labels (units for mean, 
when applicable) 
Same or 
Worse Improved P value 
Diagnosis Characteristics     
No Co-Morbidities 36.8% 38.2% 0.760a 
1-2 Co-morbidities 18.8% 17.5% 
3 or more Co-Morbidities 44.4% 44.3% 
    
Exposure variable     
Duration Before Transition (µ, months) 25.2 23.1 0.023b 
Duration After Transition (µ, months) 20.9 25.0 0.000b 
    
Number of Medicare Beneficiaries 595 1,011 
Percent 37.1% 63.0%   
Note: Statistical test denoted by a is chi-square test and by b is paired t-test of difference 
in means. Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 19: Regression Model Results of Financial, Patient, and Diagnosis 
Characteristics on Change in Statin Adherence Levels Before and After Partial LIS 
Enrollment 
Variable 
Parameter 
Coefficient 
Significance 
Level 
95% Confidence 
Interval 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy -0.0341 0.163 -0.0820 0.0138 
50% Premium Subsidy -0.0318 0.183 -0.0787 0.0150 
25% Premium Subsidy reference 
Switch Plans at Transition 0.0555 0.601 -0.1527 0.2638 
Change Plans Post-Enrollment -0.0242 0.698 -0.1466 0.0981 
Plan Premium Above Subsidy Level 0.0204 0.344 -0.0219 0.0627 
Market Percent of Gap Plans -0.0380 0.000 -0.0577 -0.0184 
Patient Characteristics 
Age -0.0030 0.006 -0.0051 -0.0009 
Female reference 
Male -0.0490 0.032 -0.0937 -0.0043 
White/Other reference 
Black 0.0050 0.872 -0.0555 0.0655 
Hispanic 0.0811 0.086 -0.0114 0.1737 
Diagnosis Characteristics 
No Co-Morbidities -0.0155 0.479 -0.0586 0.0275 
1-2 Co-morbidities -0.0193 0.482 -0.0732 0.0346 
3 or more Co-Morbidities reference 
Exposure Variable 
Duration Before Transition -0.0027 0.000 -0.0041 -0.0012 
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Variable 
Parameter 
Coefficient 
Significance 
Level 
95% Confidence 
Interval 
Duration After Transition 0.0055 0.000 0.0039 0.0071 
Intercept 0.4393 0.000 0.2620 0.6166 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. Model 
statistics: F(14,1588)=14.08, P>|F|=0.000; R-squared=0.11; Adjusted R-squared=0.10. 
Adjusted Wald test of joint probability for financial characteristics: F(6,1588)=3.08, 
P>|F|=0.005; patient characteristics: F(4,1588)=3.24, P>|F|=0.012; diagnosis 
characteristics: F(2,1588)=0.36, P>|F|=0.695. 
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Table 20: Average Unadjusted Drug Adherence Levels of Oral Anti-Diabetic 
Medications Before and After Medicare Part D Partial Low Income Subsidy (LIS) 
Enrollment for Continuously Enrolled in Stand-Alone Prescription Drug Plan 
(PDP), Community-Dwelling Medicare Beneficiaries 
Therapeutic 
Class 
Mean 
(95% Confidence Interval 
[CI]) 
Difference  
(95% CI) P>|t| 
Pre-Partial 
LIS 
Post-Partial 
LIS 
Oral Anti-
Diabetics 
0.68 0.80 0.12 0.000 
(0.65,0.71) (0.78,0.82) (0.09,0.15)   
Note: Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 21: Bivariate Comparison Tests of Explanatory Variables and Improved 
Change in Adherence Levels of Oral Anti-Diabetic Medications 
  
Change in 
Adherence Level    
Variable, Value Labels (units for mean, 
when applicable) 
Same 
or 
Worse Improved P value 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 27.8% 33.0% 0.098a 
50% Premium Subsidy 36.8% 38.6% 
25% Premium Subsidy 35.5% 28.5% 
Does not switch plans 98.2% 99.2% 0.253a 
Switch Plans at Transition 1.8% 0.8% 
    
Does not change plans 95.6% 96.7% 0.472a 
Change Plans Post-Enrollment 4.4% 3.4% 
    
Plan Premium Not Above Subsidy 69.4% 70.7% 0.707a 
Plan Premium Above Subsidy Level 30.6% 29.3% 
Market Percent of Gap Plans (µ, percent) 4.2 3.9 0.055b 
Patient Characteristics 
Age (µ, years) 72.9 71.1 0.014b 
Female 68.1% 69.8% 0.614a 
Male 31.9% 30.2% 
White/Other 79.7% 80.5% 0.668a 
Black 14.4% 12.6% 
Hispanic 5.9% 7.0% 
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Change in 
Adherence Level    
Variable, Value Labels (units for mean, 
when applicable) 
Same 
or 
Worse Improved P value 
Diagnosis Characteristics 
No Co-Morbidities 36.3% 37.4% 0.478a 
1-2 Co-morbidities 14.1% 11.2% 
3 or more Co-Morbidities 49.6% 51.4% 
Exposure variable 
Duration Before Transition (µ, months) 22.5 19.8 0.030b 
Duration After Transition (µ, months) 21.3 26.8 0.000b 
Number of Medicare Beneficiaries 389 358 
Percent 52.1% 47.9%   
Note: Statistical test denoted by a is chi-square test and by b is paired t-test of difference 
in means. Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 22: Regression Model Results of Financial, Patient, and Diagnosis 
Characteristics on Change in Oral Anti-Diabetic Adherence Levels Before and After 
Partial LIS Enrollment 
Variable 
Parameter 
Coefficient 
Significance 
Level 
95% Confidence 
Interval 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 0.0589 0.126 -0.0166 0.1344 
50% Premium Subsidy 0.0205 0.575 -0.0512 0.0921 
25% Premium Subsidy reference 
Switch Plans at Transition 0.0192 0.885 -0.2423 0.2808 
Change Plans Post-Enrollment 0.0913 0.253 -0.0653 0.2480 
Plan Premium Above Subsidy Level -0.0394 0.247 -0.1060 0.0273 
Market Percent of Gap Plans -0.0351 0.021 -0.0649 -0.0053 
Patient Characteristics 
Age -0.0043 0.011 -0.0076 -0.0010 
Female reference 
Male -0.0165 0.632 -0.0840 0.0510 
White/Other reference 
Black -0.0312 0.489 -0.1197 0.0573 
Hispanic 0.0540 0.388 -0.0686 0.1765 
Diagnosis Characteristics 
No Co-Morbidities 0.0189 0.568 -0.0461 0.0839 
1-2 Co-morbidities -0.0436 0.359 -0.1369 0.0496 
3 or more Co-Morbidities reference 
Exposure Variable 
Duration Before Transition -0.0018 0.116 -0.0039 0.0004 
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Variable 
Parameter 
Coefficient 
Significance 
Level 
95% Confidence 
Interval 
Duration After Transition 0.0047 0.000 0.0024 0.0070 
Intercept 0.4079 0.003 0.1364 0.6794 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. Model 
statistics: F(14,731)=4.87, P>|F|=0.000; R-squared=0.09; Adjusted R-squared=0.07. 
Adjusted Wald test of joint probability for financial characteristics: F(6,731)=1.81, 
P>|F|=0.094; patient characteristics: F(4,731)=2.02, P>|F|=0.090; diagnosis 
characteristics: F(2,731)=0.80, P>|F|=0.448.  
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Study 3: Income and Race/Ethnicity Effects on Drug Adherence of the 
Medicare Part D Low Income Partial Subsidy Population 
Summary for Study 3 
Objective: To examine income and race/ethnicity and their association with prescription 
drug adherence within the Medicare Part D Partial Low Income Subsidy (LIS) for three 
selected therapeutic cohorts that frequently experience cost-related underuse. 
 
Background: Health services research has demonstrated the association of income 
gradients and race/ethnicity differences on health behaviors. However, these effects have 
not been examined for prescription drug behavior within the national Medicare 
population for partial low-income elderly beneficiaries nor by race/ethnicity.  
 
Data and Methods: Medicare administrative data from 2006 through 2010 is used to 
determine Partial LIS continuous, calendar year enrollees within the 5% enhanced 
national sample for statin, proton pump inhibitors (PPI), and oral anti-diabetic therapeutic 
classes. The unit of analysis is the beneficiary-year. Logistic regression analysis with 
robust standard errors for individual-level panel effects is used to examine adherent 
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(proportional days covered >= 0.80) prescription drug behavior and the association to 
financial, demographic, and diagnostic explanatory measures. 
 
Findings: For PPI cohort, the 25 percent subsidy group has a higher probability of 
adherence than the 75 percent subsidy group (AME = 0.04; 95% confidence interval (CI), 
0.01-0.07). All three therapeutic cohorts have race/ethnicity differences in likelihood of 
adherent behavior. In comparison to white, non-Hispanic partial LIS enrollees, black, 
non-Hispanic beneficiaries had lower probability of adherence (PPI AME = -0.14; 95% 
CI, -0.18 - -0.10; statin AME = -0.15; 95% CI, -0.18 - -0.12; oral anti-diabetic AME = -
0.11; 95% CI, -0.15 - -0.07) as did Hispanic beneficiaries (PPI AME = -0.16; 95% CI, -
0.21 - -0.11; statin AME = -0.15; 95% CI, -0.19 - -0.10; oral anti-diabetic AME = -0.09; 
95% CI, -0.14 - -0.04). 
 
Conclusions: Within the partial low income subsidy program even modest income 
differences may affect drug adherence for some therapeutic classes, but race/ethnicity 
differences are common across all three clinical cohorts. 
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Introduction  
The Medicare Part D benefit provided numerous plan design options for demand 
side approaches to limiting prescription drug costs, such as deductibles and varying out-
of-pocket cost sharing by formulary. To mitigate some of these approaches for low-
income beneficiaries, Medicare provided lower cost-sharing and premium subsidization 
within the existing Medicare Shared Savings Programs (MSP, also known as dual 
Medicare-Medicaid program) and an expansion coverage program for incomes up to 
150% poverty and limited assets that would not qualify above the threshold within the 
existing MSP income and asset limits. The expanded coverage group is provided 
premium subsidies based on income level and reduced cost sharing and deductible 
amounts. Similar approaches to premium subsidization and cost-sharing assistance for 
low-income populations have been provided within the Affordable Care Act (ACA) 
insurance exchange options. 
Health services research has demonstrated the effects of income gradients on 
health behaviors138–143 and price sensitivity in response to out-of-pocket cost 
sharing.3,144,145 However, these effects have not been examined within the national 
Medicare population for low-income elderly beneficiaries. Examination of the Medicare 
Part D partial low-income program enrollees allows a comparison of narrow income 
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segments facing the same benefit design for cost sharing and deductibles and their 
corresponding health behaviors measured by prescription drug adherence. 
Differences in health behaviors and health care utilization patterns by racial and 
ethnic groups have been closely examined by health services researchers to develop 
health policy and programs to increase health equity.146,147 Given Medicare’s prominent 
role in assisting with desegregation of hospitals in the 1960s when the program was first 
implemented,148 it is important to examine the role the implementation of Medicare Part 
D, the largest expansion of its program benefits in recent history, as a policy and program 
for reducing race/ethnicity differences in prescription drug behavior within the Medicare 
population,149–152 especially enrollment within the low income subsidy program.153 Long-
standing problems associated with the coding of race/ethnicity within Medicare 
administrative claims data are discussed below to highlight current updates to improve 
the validity and reliability of its measurement. 
Literature Background on Income and Race/Ethnicity Association with Prescription 
Adherence within the Medicare Population 
 The low-income subsidy program for Medicare Part D enrollees is now renamed 
Extra Help and includes reduced cost sharing and premium assistance for beneficiaries 
who qualify based on income and asset levels. Lower socioeconomic status groups are 
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less likely to adhere to long-term treatments for chronic conditions.154 When faced with 
tighter budget constraints, lower income populations may cut back on needed care and 
experience adverse health.155 Increased drug and office visit co-pays caused increased 
hospitalization for elderly patients with chronic diseases.156 While income may affect 
responses to differing cost sharing, another large difference for elderly Medicare 
beneficiaries are asset levels, especially differences by racial and ethnic groups. Median 
asset levels among white Medicare beneficiaries ($89K) were more than eight times 
higher than non-white beneficiaries ($10K).157  
 Findings on the relationship between prescription drug adherence and 
race/ethnicity has been shown to be mixed at the population level,158 but within the 
elderly population non-white racial groups or Hispanic ethnic groups tend to have poorer 
adherence.2,35,159–162 In their study of elderly Medicare beneficiaries following an episode 
of acute myocardial infarction, Lauffenburger et al.160 found no difference in the 
initiation of drug therapies post-discharge but Hispanic and Black beneficiaries had lower 
adherence levels than White patients. Medicare Part D has had mixed results on reducing 
cost-related nonadherence163 and drug spending149,150 by race/ethnicity but has been 
shown to reduce the offset differences in other medical care.164,165 While the probability 
of having drug coverage did not differ by race/ethnicity before or after Part D,166 non-
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White racial and ethnic groups have been shown to have greater price sensitivity in the 
Part D coverage gap.151  
Programmatic Background of Race/Ethnicity Coding in Medicare Enrollment Data 
Problems with Medicare race/ethnicity coding are well documented within the 
academic literature.167–172 Arday, et al.171 have found that the iterative updates to the 
CMS race/ethnicity data have had marked improvements in accuracy. Comparing data 
from before and after the 1997 update, Arday et al.171 found that sensitivity for white 
persons was 97 percent, 95 percent for black persons, and less than 60 percent for all 
others, but these groups had the largest improvements in specificity following the update.  
There are at least two issues that need to be addressed when attempting to describe the 
accuracy of the race code in CMS data files: administrative error and self-report bias. 
Historically, race data coding in the Medicare enrollment data are transferred 
from the Social Security Administration (SSA) or the Railroad Retirement Board (RRB).  
The RRB does not collect information on race and, therefore, many of the CMS 
enrollment records coded as “unknown” race are RRB beneficiaries.  The majority of 
enrollment records, however, are derived from the SSA's Master Beneficiary Record File. 
The SSA collects race on an application form called the SS-5.173  From 1936 to 
1980, the SS-5 form included three categories for race (white, black, and other).  This 
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information was transferred to a SSA database called the master beneficiary record file, 
which had four categories of white, black, other, and unknown.  In November 1980, the 
race choice on the SS-5 form was expanded in order to comply with a federal directive.  
As a result of the federal directive, the “other” category on the SS-5 form was replaced 
by the following three categories: Asian, Asian American, or Pacific Islander; Hispanic; 
and Northern American Indian or Alaskan Native. This directive did not, however, 
require a differentiation between race and ethnicity (i.e., Hispanic is listed as a choice for 
a single race/ethnicity question).  Unfortunately, the SSA did not restructure their Master 
Beneficiary Record database to accommodate these new choices; instead the new race 
categories were collapsed into one of the original four choices 
(White/Black/Other/Unknown).   
In regard to those with Hispanic race/ethnicity, prior to 1980, Hispanics may have 
identified their racial category as white, black, or other; whereas, after 1980, Hispanic 
was a category choice but administratively it was collapsed into the “other” category.  As 
a result, Hispanic individuals constituted a large portion of the “other” category, and 
some Hispanic individuals may have continued in the White/Black categories. 
In addition to problems associated with collapsed codes, the SSA master beneficiary data 
stores demographic information associated with the SSN that the person claims benefits 
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under.  Approximately 20 percent of total beneficiaries qualify for social security benefits 
based on their relation to another wage earner (e.g., spouses or disabled children), and for 
this group the race/ethnicity variable listed for this beneficiary is that of the qualifying 
wage earner. 
Administrative errors in the race/ethnicity coding in CMS data may result from 
the SSA and RRB data from which it is compiled.  As such, CMS has initiated corrective 
remedies on three different occasions.  In 1994, CMS sent a mailing to all those 
beneficiaries classified as “other” or “unknown” in the database asking them to self-
report their race.  In 1997 and 2001, CMS changed the SSA database source they were 
transferring race data from the Master beneficiary record file (collapsed fields) to the SS-
5 file directly. 174,175 The effect was that those individuals that had marked themselves as 
Hispanic, Asian, or Native American after 1980 in the SS-5 file would be changed in the 
CMS enrollment file to these matching codes.176  In addition, spouses or disabled 
children qualifying for social security benefits under a different wage earner would have 
their data corrected with their original SSN category. 
The new, updated race/ethnicity measure that was released by the Centers for 
Medicare and Medicaid (CMS) in 2007 was created from a project sponsored by the 
Agency for Healthcare Research and Quality (AHRQ).133,177   Using surname recoding 
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and probability modeling, the new race/ethnicity variable released with the administrative 
data was seen as corrective for mainframe administrative race variable.178  Known as the 
Research Triangle Institute Race Code, the new measure has an estimated Kappa value of 
0.79 and improved sensitivity (greater than 77%) compared to the administrative race 
variable.133  
Study Design 
Data  
 The administrative data used in this analysis was obtained from the Chronic 
Condition Warehouse for the 5% enhanced sample from 2006 through 2010. The 
analytical sample was created from Medicare administrative claims, assessment, and 
enrollment data files including beneficiary enrollment data, prescription drug event 
(PDE) file, Minimum Data Set (MDS) long-term care assessment, MedPAR, and the Part 
D plan characteristics data. The Part D enrollment file is used to identify enrollment in 
Part D and the partial LIS benefit and includes beneficiary demographic data. The MDS 
data are used to identify and exclude nursing home residents for the calendar year. 
MedPAR data are used for capturing co-morbidity diagnoses and to adjust drug 
adherence for hospitalization periods. The PDE data are merged with RxNorm to 
determine the drug therapy cohorts by active ingredients and the adherence levels within 
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those drug cohorts. RxNorm is produced by National Medical Library association and 
classifies each drug entity by the individual nation drug code (NDC). Health risk 
adjusters are computed using the AHRQ comorbidity index constructed from diagnoses 
in the MedPAR data files. The plan characteristics data provide information on 
characteristics of Part D plans, such as enhanced benefit plans, plan types such as stand-
alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans 
(MAPDs), benchmark status, premiums, and drug tier information. All Medicare claims 
data used in the analysis were obtained from the Centers from Medicare and Medicaid 
Services (CMS) prior to the current substance use disorder (SUD) suppression,119 and the 
findings are not limited from missing SUD data. 
The historical 5% Medicare sample is extracted from the CMS administrative 
enrollment data in the same manner every year by pulling the same two-digit set from the 
11-digit beneficiary identifier. The first 9 digits of a beneficiary Medicare identifier are 
the Social Security Number (SSN) from which the person claims Social Security 
payments. Since the last 4 digits of the SSN are random digits, the systematic sampling of 
five sets of the last two digits pulls a 5% random sample from the Medicare population. 
One limitation of a random sample from a systematic pull for longitudinal analysis is that 
Medicare beneficiaries may change their Medicare identifier (for reasons, such as, 
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identity theft). For the one to two percent that change identifier, the new identifier may 
not have the two-digits that belong in the set pulled for the sample. To correct this 
limitation, the Chronic Condition Warehouse (CCW) created the 5% enhanced Medicare 
sample, where once a beneficiary meets the criterion for inclusion in the sample they are 
retained in the prospective cohort regardless of whether the current identifier meets the 
sample pull conditions. 
The benefits of using the CMS administrative data are that a large, representative 
sample is used and that the data contain the actual programmatic measures of utilization. 
The limitations are that the data quality of the PDE is still relatively untested and 
measures that can be examined are limited to variables that are collected for enrollment 
or payment reconciliation. The unknown data quality of the PDE are due to differences in 
how plans reported the information to CMS and due to possible prescription drug 
omissions if the beneficiary does not file a paper claim for reimbursement from an out-of-
network pharmacy or a fill for a cash-only generic. Possible prescription omissions would 
result in an upward bias of non-adherence or an overestimation of non-adherence as 
calculated from the PDE data. Since the analysis is focusing on the LIS enrolled group, 
this bias is expected to be less because the group does not encounter the benefit gap.  
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Study Sample 
The analytical extracts for the enrollment cohorts selected all beneficiaries during 
the five years of data that were continuously enrolled during the calendar year within the 
partial LIS benefit, were not nursing home residents, were not enrolled in MA-PDs, and 
had a prescription drug fill within the selected clinical cohorts. The unit of analysis is the 
beneficiary-year observation. The PDE data are merged with RxNorm to select three 
therapeutic classes of drugs following the same procedures outlined in Study 2 for statin, 
oral anti-diabetic, and proton pump inhibitor drugs, the drug therapies most commonly 
associated with cost-related underuse within the Medicare population. To be included in 
the clinical cohorts, beneficiaries had to have at least one prescription drug fill for the 
class during the calendar year.  
Figure 5 shows the flow chart illustration of the construction steps followed to 
create the analytical cohorts for Study 3. Within the 2006 through 2010 enhanced 5% 
sample of Medicare beneficiaries, there are 107,100 beneficiary-year combinations with 
partial LIS enrollment. Beneficiary-year combinations are excluded for any year the 
beneficiary is not continuously enrolled within any of the partial LIS benefit categories 
for the entire calendar year (n=41,502 beneficiary-years). If beneficiaries transition 
between partial LIS categories, they are still included for that year, but if they transition 
 
 
 
132 
 
 
 
out of the partial LIS benefit, disenroll from Medicare Part D, or die at any time during 
the year, they would be excluded. Next partial LIS beneficiaries are excluded if they 
reside in a nursing home (n=2,545 beneficiary-years) during the calendar year because 
they receive monitored care within the facility setting. The final exclusion is partial LIS 
beneficiaries enrolled within an MA-PD during the calendar year (n=23,934 beneficiary-
years). The resulting analytical population is 39,119 beneficiary-years with continuous 
partial LIS enrollment during the calendar year that reside in the community and are 
covered by FFS for the year. From this analytical population, subpopulations are selected 
for the therapeutic cohorts based on prescription drugs filled during the year: 10,468 
beneficiary-years have a proton pump inhibitor fill during the year; 16,872 beneficiary-
years have a statin; and 8,625 beneficiary-years use oral anti-diabetic medications. 
Outcome Variable 
The proportional days covered (PDC) was calculated to measure the adherence 
level for each drug class during the calendar year. The same methodology for calculating 
PDC in Study 2 was followed for the calculation of calendar year PDC levels for Study 3. 
The construction of the PDC started the counting clock with the first day of the calendar 
year if the beneficiary had drug stock that carried over into the start of the year or on the 
first day of the first fill within the calendar year for the medication. Beneficiaries were 
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limited to carrying a maximum of 30 days of surplus drug stock at any time during the 
year. Gap days occur whenever the beneficiary does not have days supply or surplus 
stock covered and are adjusted for hospitalizations. Gaps of 90 consecutive days are 
considered a discontinuation and the end of the PDC calculation period. If the drug is 
refilled during the calendar year after discontinuation, then a second PDC period is 
calculated for the beneficiary and added to the first period for the calendar year adherence 
calculation. PDC ranges from greater than 0, perfect non-adherence, to 1, perfect 
adherence during the period. PDC levels greater than or equal to 0.80 are considered as 
adherent behavior. The outcome measure is coded as an indicator variable for adherent 
(PDC >= 0.80) prescription drug behavior. 
Explanatory Measures 
Financial Characteristics. The partial low income subsidy group allows a 
comparison of a narrow income gradient between 135% and 150% of the federal poverty 
level. The social gradient of morbidity and mortality has been shown to persistent into 
retirement,142 and the steep inverse relationship is such that even those in the middle of 
the distribution have an association with poorer health than those above them.140,143,179 
Thus, it is expected that Medicare beneficiaries in the 75% premium subsidy group will 
have poorer adherence levels than those in the 25% premium subsidy group, with the 
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50% premium subsidy group in between them, based on differences in income levels. 
The partial LIS category is the based on the December enrollment category. 
Partial LIS enrollees may enroll in plans with premiums above the subsidy 
amount and pay the full premium amount above the subsidy level. It is expected that 
beneficiaries who enroll in plans with premiums above the subsidy level may have more 
resources in income or assets than those they enroll in plans at or below the premium 
subsidy amount and may have better adherence rates given the additional resources. 
Key control variables measure plan switching during the re-enrollment period or 
from one year to the next and during the benefit enrollment period.180 The plan identifiers 
contained within the administrative data provided to academic researchers are encrypted 
specific to the calendar year and a crosswalk file provides plan identifier tracking from 
one year to the next. Changing plans during the partial LIS enrollment period, listed as 
change plans during year in the tables, is coded as an indicator variable for one or more 
plan changes. 
Another key plan measure captures the degree of competition within the Part D 
market for the beneficiary and measures the percent of plans offered as enhanced benefit 
plans within the beneficiary’s county. Karaca-Mandic, et al.20 found this measure to be a 
useful instrument for capturing the level of plan generosity offered within competitive 
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Part D markets. It is expected that beneficiaries residing in more competitive markets 
may have more generous plans benefits and thereby better adherence levels.  
Patient Characteristics. Demographic measures are created from the denominator 
data. Age is calculated based on the end of the year. The denominator files from CMS 
changed the reference period for age provided in the annual files from January to 
December (begin of year to end of year switch) between the 2008 and 2009 files, so age 
was recalculated to be age at end of year to be at the same time point. Gender is male or 
female sex from the denominator data. Race/ethnicity is from the Research Triangle 
Institute race variable133 in the denominator data and divided into four groups for 
analysis: white, non-Hispanic; black, non-Hispanic; Hispanic, all races; and other, non-
Hispanic.  
Diagnosis Characteristics. Chronic conditions are classified using the Healthcare 
Cost and Utilization Project (HCUP) algorithm.134 Using all of the diagnosis codes 
provided within the MedPAR data, the chronic condition indicators are created and then 
summed to create a co-morbidity index and used in the analysis as a three category 
measure comparing beneficiaries with no co-morbidities, 1 to 2 co-morbidities, and 3 or 
more co-morbidities.70,135 Medicare beneficiaries with more chronic conditions or co-
 
 
 
136 
 
 
 
morbidities are expected to have poorer adherence levels from complicated management 
of polypharmacy or from poorer health limitations.  
Statistical Model 
  The bivariate analysis of the adherent (PDC>=0.80) outcome measure compared 
for the explanatory measures of financial, patient, and diagnostic characteristics using χ2 
test statistics for the categorical explanatory measures and a t-test for difference in means 
for the continuous explanatory measures. The panel data cohort is tested using logistic 
regression analysis with indicator variables for calendar year and robust standard errors 
clustered by individual beneficiaries. The unit of analysis is the beneficiary-year, and 
three drug therapy classes are run as separate models. The logistic regression model 
estimates the effects of the financial, patient, and diagnostic characteristics on the 
calendar year measure of prescription drug adherence with PDC levels greater than or 
equal to 0.80 and those below that level. The adjusted Wald test of joint probability of the 
variables for financial, patient, and diagnostics characteristics are equal to zero as a set is 
also tested for each logistic regression model. The average marginal probabilities at the 
means of the explanatory variables are calculated from the logistic regression models to 
allow comparisons of financial, patient, and diagnostic variables across the three 
therapeutic drug cohorts. The bivariate statistics, logistic regression models, and marginal 
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effects are estimated using Stata 12. All results with p<0.05 are discussed in the findings 
section. 
Findings 
 The bivariate statistics and logistic regression model of adherent behavior for 
each of the three drug classes are discussed by therapeutic cohort below and followed by 
a discussion of the marginal effects calculated from the logistic regression models and 
compared across all cohorts. 
Proton Pump Inhibitor Cohort 
 Table 23 presents the bivariate comparison statistics for PPI adherent behavior by 
financial, patient, and diagnostic explanatory variables. For partial LIS enrollees in stand-
alone PDPs and continuously enrolled for the calendar year, 51.2 percent of the PPI 
cohort have PDC levels greater than or equal to 0.80 and are considered adherent and 
48.9 percent of the cohort is non-adherent.  
For the PPI cohort, adherence is related to the financial characteristics for 
premium subsidy level and plan switching behavior. Medicare beneficiaries with higher 
income levels and receiving the 25% premium subsidy are more likely to be adherent 
(30.0 percent adherent, 27.7 percent non-adherent). Medicare beneficiaries receiving the 
50% premium subsidy are equally divided with 35.3 percent non-adherent and 35.7 
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percent adherent. Beneficiaries with the lowest income levels receiving the 75% premium 
subsidy are less likely to be adherent (37.0 percent non-adherent, 34.2 percent adherent). 
For those Medicare beneficiaries who change drug plans during the year, 3.9 percent are 
non-adherent compared to 2.9 percent that are adherent. 
All patient characteristics are related to PPI adherence in the bivariate 
comparisons. PPI adherent beneficiaries have an average age of 72.7 years and non-
adherent beneficiaries have an average age of 70.4 years. Males are more likely to be 
non-adherent (28.8 percent) than adherent (27.1 percent). White non-Hispanic Medicare 
beneficiaries have a higher proportional share adherent (86.9 percent) than non-adherent 
(78.1 percent). Black, non-Hispanic beneficiaries have a larger proportional share that is 
non-adherent (13.8 percent) than adherent (8.4 percent). Similar to Black, non-Hispanic 
beneficiaries, partial LIS enrollees with race/ethnicity of Hispanic, all races (non-
adherent 7.1 percent; adherent 4.1 percent) and other, non-Hispanic (non-adherent 1.1 
percent; adherent 0.6 percent).  
The bivariate comparison shows that diagnosis characteristics are related to PPI 
adherence. Medicare beneficiaries with 3 or more co-morbidities are more likely to be 
adherent than non-adherent (non-adherent 52.1 percent; adherent 55.8 percent). Those 
with 1 to 2 co-morbidities have 15.7 percent non-adherent and 14.9 percent adherent. 
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Medicare beneficiaries without any co-morbidities have a higher share non-adherent, 32.3 
percent, than adherent, 29.3 percent. 
 Table 24 provides the logistic regression results for the PPI therapeutic cohort 
estimating adherence by financial, patient, and diagnosis explanatory variables. Financial 
characteristics for the subsidy level and plan changing during the year are associated PPI 
adherence. Partial LIS enrollees with highest incomes levels and receiving the 25% 
premium subsidy (AOR = 1.2; 95% CI, 1.0-1.3) are more likely to be adherent than those 
with the lowest income levels and receiving the 75% premium subsidy. Beneficiaries 
who change drug plans during the year are less likely to be adherent (AOR = 0.8; 95% 
CI, 0.6-1.0). Older Medicare beneficiaries are more likely to be adherent to PPIs (AOR = 
1.0; 95% CI, 1.0-1.0). In comparison with white, non-Hispanic Medicare beneficiaries, 
other race/ethnicity groups are less likely to be adherent to PPIs (Black AOR = 0.6; 95% 
CI, 0.5-0.7; Hispanic AOR = 0.5; 95% CI, 0.4-0.7; Other AOR = 0.5; 95% CI, 0.3-0.9). 
Unlike the bivariate findings, gender and co-morbidities are not significantly related to 
PPI adherence when the other financial and patient characteristics are controlled for in 
the model. The adjusted Wald statistics shows that the financial and patient 
characteristics, as a group, are related to PPI adherent behavior. 
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Statin Cohort 
 The bivariate comparison statistics for the statin drug therapy cohort are listed in 
Table 25. For the statin therapeutic cohort, 61.4 percent are adherent with PDC levels 
above the 0.80 threshold and 38.6 percent are non-adherent. Changing prescription drugs 
plans during the year have a larger proportional share non-adherent, 3.4 percent, than 
adherent, 2.8 percent, and this explanatory variable is the only financial characteristic 
related to statin adherence. The average age for partial LIS enrollees that are adherent, 
72.8 years, is older than the average age of the non-adherent group, 70.7 years. Similar to 
the PPI cohort, adherence to statin drugs varies by race/ethnicity group. White, non-
Hispanic beneficiaries are a larger proportion of adherent, 84.5 percent, than non-
adherent, 74.2 percent. Black, non-Hispanic beneficiaries have a higher share non-
adherent, 17.1 percent than adherent, 10.0 percent. Hispanic Medicare beneficiaries are 
more likely to be non-adherent, 7.1 percent, to statin drugs than adherent, 4.3 percent. 
Other, non-Hispanic beneficiaries are more likely to be non-adherent, 1.5 percent, but the 
proportional share adherent, 1.3 percent, is close to the same rate. 
Table 26 provides the logistic regression results for the statin therapeutic cohort 
predicting PDC levels greater than 0.80 or adherent by financial, patient, and diagnosis 
explanatory variables. The adjusted Wald test statistics show that patient characteristics 
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are the only set of explanatory measures that as a group are related to statin adherent 
behavior for the partial LIS enrollees. Older Medicare beneficiaries are more likely to be 
adherent (AOR = 1.0; 95% CI, 1.0-1.0). In comparison with white, non-Hispanic 
Medicare beneficiaries, black beneficiaries (AOR = 0.5; 95% CI, 0.5-0.6) and Hispanic 
beneficiaries (AOR = 0.5; 95% CI, 0.5-0.7) are less likely to be adherent. Controlling for 
all other financial and patient characteristics, Medicare beneficiaries with 3 or more co-
morbidities (AOR = 0.9; 95% CI, 0.8-1.0) are less likely to be adherent with statin drug 
therapies than beneficiaries without any co-morbidities. 
Oral Anti-Diabetics Cohort 
Table 27 shows the bivariate comparison statistics for oral anti-diabetic adherence 
groups by financial, patient, and diagnostic explanatory variables. For partial LIS 
enrollees taking oral anti-diabetic medications, 70.5 percent have PDC levels greater than 
or equal to 0.80 and are considered adherent and 29.5 percent of the cohort is non-
adherent.  
Financial characteristics related to adherent behavior for the oral anti-diabetic 
cohort include for premium subsidy level and drug plan market competition as measured 
by the percent of gap plan offerings. Medicare beneficiaries receiving the 25% premium 
subsidy have the highest income levels among partial LIS enrollees and are more likely to 
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be adherent (29.9 percent adherent, 26.9 percent non-adherent). Medicare beneficiaries 
receiving the 50% premium subsidy have a higher proportion with non-adherent, 36.0 
percent, than adherent, 34.7 percent. Beneficiaries with the lowest income levels among 
partial LIS enrollees are receiving the 75% premium subsidy and are less likely to be 
adherent (37.1 percent non-adherent, 35.4 percent adherent). The average market portion 
of gap plan offerings for adherent oral anti-diabetic medications (average 4.1 percent) is 
higher than non-adherents (average 4.0 percent). 
Patient characteristics related to oral anti-diabetic adherence in the bivariate 
comparisons include age and race/ethnicity. Oral anti-diabetic adherent beneficiaries have 
an average age of 71.5 years and non-adherent beneficiaries have an average age of 69.4 
years. White non-Hispanic partial LIS enrollees have a higher proportional share adherent 
(78.7 percent) than non-adherent (69.6 percent). Black, non-Hispanic beneficiaries have a 
larger proportional share that is non-adherent (19.5 percent) than adherent (12.9 percent). 
Hispanic beneficiaries also have a larger percent who are non-adherent, 9.1 percent, than 
adherent, 6.8 percent. Other, non-Hispanic partial LIS enrollees have similar shares in the 
oral anti-diabetic adherence groups with 1.8 percent non-adherent and 1.6 percent 
adherent. 
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 Diagnosis characteristics are also related to oral anti-diabetic adherent behavior. 
Medicare beneficiaries with more chronic conditions are less likely to be adherent on oral 
anti-diabetic medications. Partial LIS enrollees with 3 or more co-morbidities are 56.4 
percent of non-adherent and 50.0 percent of adherent group. Those with 1 to 2 co-
morbidities have more evenly distributed in each of the two statin adherent behavior 
groups with 11.2 percent non-adherent and 11.4 percent adherent. Medicare beneficiaries 
with no co-morbidities have a higher share adherent, 38.6 percent, than non-adherent, 
32.4 percent. 
Table 28 presents the adjusted odds ratio from the logistic regression results for 
the oral anti-diabetic therapeutic cohort. The adjusted Wald test statistics show that 
patient and diagnosis characteristics are related to oral anti-diabetic adherence. The 
likelihood of adherent oral anti-diabetic behavior increases with age (AOR = 1.0; 95% 
CI, 1.0-1.0). In comparison with white, non-Hispanic beneficiaries, black, non-Hispanic 
partial LIS enrollees are likely to be adherent to oral anti-diabetic drug therapies (AOR = 
0.6; 95% CI, 0.5-0.7). Hispanic beneficiaries are also less likely to be adherent (AOR = 
0.7; 95% CI, 0.5-0.8). Medicare beneficiaries with 1 to 2 co-morbidities, in reference to 
those with no co-morbidities, are less likely to be adherent (AOR = 0.8; 95% CI, 0.6-1.0), 
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and those with 3 or more co-morbidities are less likely to be adherent (AOR = 0.7; 95% 
CI, 0.6-0.8). 
Marginal Effects Comparison of Clinical Cohorts 
Table 29 shows the adjusted marginal probability of adherent prescription drug 
behavior by financial, patient, and diagnostic characteristics for each of the therapeutic 
drug cohorts as estimated from their corresponding logistic regression results presented in 
Tables 24, 26, and 28. The average marginal effect (AME) is the estimated change in 
probability for the measure holding all other model variables at their mean values.  
Financial characteristics are associated with adherent behavior for the PPI cohort. 
Partial LIS enrollees with the 25% premium subsidy have a 0.04 (95% CI, 0.01-0.07) 
increase in probability of adherent behavior than the 75% premium subsidy group. 
Beneficiaries than change plans during the year have a 0.07 (95% CI, -0.12 - -0.01) lower 
probability than those that do not change plans. 
Age and race/ethnicity are patient characteristics related to adherent behavior 
within all three cohorts. For each additional year in age, the probability of adherent drug 
behavior increases 0.004 for all three drug therapy cohorts (PPI CI, 0.003-0.005; statin 
CI, 0.003-0.01; oral anti-diabetic CI, 0.003-0.01). Non-white race/ethnicity groups in 
reference to the white, non-Hispanic group have lower probability of adherence within all 
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three therapeutic classes. For the statin and oral anti-diabetic cohorts, Medicare 
beneficiaries who are black, non-Hispanic (statin AME = -0.15; 95% CI, -0.18 - -0.12; 
oral anti-diabetic AME = -0.11; 95% CI, -0.15 - -0.07) have lower probabilities of 
adherence than Hispanic beneficiaries (statin AME = -0.15; 95% CI, -0.19 - -0.10; oral 
anti-diabetic AME = -0.09; 95% CI, -0.14 - -0.04). Within the PPI cohort, Hispanic 
beneficiaries (AME = -0.16; 95% CI, -0.21 - -0.11) and other, non-Hispanic partial LIS 
enrollees (AME = -0.16; 95% CI, -0.29 - -0.02) have lower probabilities of adherence 
than black, non-Hispanic beneficiaries (AME = -0.14; 95% CI, -0.18 - -0.10). 
Diagnostic characteristics are related to the probability of statin and oral anti-
diabetic adherence but are not associated with PPI adherent behavior. In reference to 
beneficiaries with no co-morbidities, beneficiaries with 1 to 2 co-morbidities have a 
lower probability of oral anti-diabetic adherence (AME = -0.05; 95% CI, -0.09 - -0.004) 
while beneficiaries with 3 or more co-morbidities have a lower probability of statin 
adherence (AME = -0.02; 95% CI, -0.05 - -0.00) and oral anti-diabetic adherence (AME 
= -0.08; 95% CI, -0.11 - -0.05).  
Discussion 
 The study shows that within the partial low income subsidy program even modest 
income differences between the highest and lowest income thresholds may affect drug 
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adherence, but these differences only statistical significance for the PPI cohort, the 
therapeutic cohort most likely to be associated with self-reported, cost-related underuse. 
The more recent facilitated plan enrollment for the partial LIS group181 making it 
comparable to the same offering of facilitated enrollment for full LIS beneficiaries in low 
quality or discontinued plans should be beneficial for the PPI cohort changing plans 
during the year. 
Race/ethnicity differences for black and Hispanic Medicare beneficiaries are 
common across all three clinical cohorts. Race/ethnicity differences may be related to 
long-term factors that do not have readily available policy solutions to address, such as 
cost-sharing and premium subsidization for difference in income and assets. Previous 
research examining race/ethnicity difference in adherence following heart failure found 
similar persistent effects,159 but that study population included disabled and aged 
Medicare qualified beneficiaries who have different confounding influences.  The 
findings, controlling for specifically identified income groups, from this study for an 
aged-qualified Medicare population suggest additional research is needed to understand if 
improvements in pharmacy access issues or better physician-patient relationships would 
provide more targeted solutions to address the racial and ethnic differences in adherence 
for this low income Medicare population. 
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Testing of income effects has been limited due to the confounding effects of 
differences in benefit designs linked to income levels. By focusing on the partial low 
income subsidy group, marginal differences in income levels can be tested among 
beneficiaries who face the same coinsurance rates. The main contribution of this study is 
the analysis of income and race/ethnicity effects on adherence while controlling for 
benefit design features with the Medicare population. 
One of the key features of the ACA is premium subsidization for lower income 
populations. The Medicare Part D partial Low Income Subsidy program provides a useful 
scale comparison, with the limitation of focus on an elderly population, of subsidization 
based on income levels for an expansion population. The findings from this study show 
income effects have been minimized, but race/ethnicity differences remain. 
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Figure 5: Study 3 Analytical Sample Construction 
 
107,100 beneficiary-years with partial 
LIS enrollment in 2006-2010 enhanced 
5% Medicare pooled, calendar year 
samples 
41,502 beneficiary-years with less than 
12 months continuous partial LIS 
enrollment 
65,598 beneficiary-years with 
continuous partial LIS enrollment 
during calendar year 
2,545 beneficiary-years with long-term 
care or nursing home stays during the 
calendar year 
39,119 beneficiary-years with 
continuous partial LIS enrollment, FFS, 
and community-dwelling residence 
during calendar year 
16,872 beneficiary-years with filled statin during calendar year 
8,625 beneficiary-years with filled oral anti-diabetic during 
calendar year 
10,468 beneficiary-years with filled PPI during calendar year 
63,053 beneficiary-years with 
continuous partial LIS enrollment, FFS, 
and community-dwelling residence 
during calendar year 
23,934 beneficiary-years enrolled in an 
MA-PD during calendar year 
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Table 23: Bivariate Comparison Statistics of Explanatory Variables by Proton 
Pump Inhibitor (PPI) Adherence Behavior for Community-Dwelling Medicare 
Beneficiaries Enrolled in the Part D Partial Low Income Subsidy (LIS) Program 
and in Stand-Alone Prescription Drug Plans 
Variable 
Nonadherent 
PDC < 0.8 
Adherent 
PDC >= 
0.8 P value 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 37.0% 34.2% 0.005a 
50% Premium Subsidy 35.3% 35.7% 
25% Premium Subsidy 27.7% 30.0% 
    
Does not change plans 96.1% 97.2% 0.003a 
Change Plans During Year 3.9% 2.9% 
    
Does not switch plans 89.0% 88.0% 0.117a 
Switch Plans at Re-Enrollment 11.0% 12.0% 
    
Plan Premium Not Above Subsidy 81.7% 81.0% 0.393a 
Plan Premium Above Subsidy Level 18.3% 19.0% 
    
Market Percent of Gap Plans (µ, 
percent) 3.9 4.0 0.815b 
    
Patient Characteristics     
Age (µ, years) 70.4 72.7 0.000b 
    
Female 71.2% 73.0% 0.042a 
Male 28.8% 27.1% 
    
White 78.1% 86.9% 0.000a 
Black 13.8% 8.4% 
 
 
 
150 
 
 
 
Variable 
Nonadherent 
PDC < 0.8 
Adherent 
PDC >= 
0.8 P value 
Hispanic 7.1% 4.1% 
Other 1.1% 0.6% 
    
Diagnosis Characteristics     
No Co-Morbidities 32.3% 29.3% 0.001a 
1-2 Co-morbidities 15.7% 14.9% 
3 or more Co-Morbidities 52.1% 55.8% 
    
Number of Beneficiary-Years 5,120 5,361 
Percent 48.9% 51.2%   
Note: Statistical test denoted by a is chi-square test and by b is paired t-test of difference 
in means. Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 24: Logistic Regression of Financial, Patient, and Diagnosis Characteristics on 
PPI Adherent Behavior for Community-Dwelling Partial LIS Medicare 
Beneficiaries Enrolled in Stand-Alone PDPs 
Variable 
Adjusted 
Odds 
Ratio P>|z| 
95% Confidence 
Interval 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy reference 
50% Premium Subsidy 1.08 0.177 0.96 1.22 
25% Premium Subsidy 1.16 0.020 1.02 1.31 
Change Plans During Year 0.76 0.016 0.61 0.95 
Switch Plans at Re-Enrollment 1.11 0.113 0.98 1.26 
Plan Premium Above Subsidy Level 1.02 0.753 0.90 1.15 
Market Percent of Gap Plans 1.00 0.834 0.98 1.02 
Patient Characteristics 
Age 1.01 0.000 1.01 1.02 
Female reference 
Male 1.04 0.518 0.92 1.17 
White reference 
Black 0.58 0.000 0.49 0.68 
Hispanic 0.53 0.000 0.42 0.66 
Other 0.53 0.030 0.30 0.94 
Diagnosis Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities 0.98 0.806 0.83 1.15 
3 or more Co-Morbidities 1.08 0.192 0.96 1.21 
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Variable 
Adjusted 
Odds 
Ratio P>|z| 
95% Confidence 
Interval 
Control Variables 
2006 reference 
2007 0.83 0.021 0.71 0.97 
2008 0.98 0.802 0.83 1.16 
2009 0.97 0.709 0.83 1.13 
2010 0.79 0.004 0.68 0.93 
Intercept 0.41 0.000 0.29 0.59 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. The unit 
of analysis is the beneficiary-year. Robust standard errors clustered by individual 
beneficiaries. Model statistics: Wald χ2(17)=174.88, P>|χ2|=0.000; Pseudo R-
squared=0.0185. Adjusted Wald test of joint probability for financial characteristics: 
χ2(6)=13.88, P>|χ2|=0.031; patient characteristics: χ2(5)=122.26, P>|χ2|=0.000; diagnosis 
characteristics: : χ2(2)=2.69, P>|χ2|=0.260. 
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Table 25: Bivariate Comparison Statistics of Explanatory Variables by Statin 
Adherence Behavior for Community-Dwelling Medicare Beneficiaries Enrolled in 
the Part D Partial Low Income Subsidy (LIS) Program and in Stand-Alone 
Prescription Drug Plans 
Variable 
Nonadherent 
PDC < 0.8 
Adherent 
PDC >= 
0.8 P value 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 36.3% 35.1% 0.077a 
50% Premium Subsidy 36.0% 35.6% 
25% Premium Subsidy 27.7% 29.3% 
    
Does not change plans 96.6% 97.2% 0.025a 
Change Plans During Year 3.4% 2.8% 
    
Does not switch plans 89.9% 89.3% 0.173a 
Switch Plans at Re-Enrollment 10.1% 10.7% 
    
Plan Premium Not Above Subsidy 82.2% 81.1% 0.053a 
Plan Premium Above Subsidy Level 17.8% 19.0% 
    
Market Percent of Gap Plans (µ, 
percent) 4.1 4.0 0.083b 
    
Patient Characteristics     
Age (µ, years) 70.7 72.8 0.000b 
    
Female 67.1% 68.4% 0.088a 
Male 32.9% 31.7% 
    
White 74.2% 84.5% 0.000a 
Black 17.1% 10.0% 
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Variable 
Nonadherent 
PDC < 0.8 
Adherent 
PDC >= 
0.8 P value 
Hispanic 7.1% 4.3% 
Other 1.5% 1.3% 
    
Diagnosis Characteristics     
No Co-Morbidities 38.8% 39.4% 0.744a 
1-2 Co-morbidities 15.8% 15.7% 
3 or more Co-Morbidities 45.4% 44.9% 
    
Number of Beneficiary-Years 6,518 10,373 
Percent 38.6% 61.4%   
Note: Statistical test denoted by a is chi-square test and by b is paired t-test of difference 
in means. Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
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Table 26: Logistic Regression of Financial, Patient, and Diagnosis Characteristics on 
Statin Adherent Behavior for Community-Dwelling Partial LIS Medicare 
Beneficiaries Enrolled in Stand-Alone PDPs 
Variable 
Adjusted 
Odds 
Ratio P>|z| 
95% Confidence 
Interval 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy reference 
50% Premium Subsidy 1.01 0.875 0.92 1.11 
25% Premium Subsidy 1.08 0.136 0.98 1.19 
Change Plans During Year 0.86 0.105 0.71 1.03 
Switch Plans at Re-Enrollment 1.06 0.303 0.95 1.18 
Plan Premium Above Subsidy Level 1.06 0.280 0.96 1.17 
Market Percent of Gap Plans 1.00 0.631 0.98 1.01 
Patient Characteristics 
Age 1.02 0.000 1.01 1.02 
Female reference 
Male 1.08 0.079 0.99 1.19 
White reference 
Black 0.53 0.000 0.47 0.60 
Hispanic 0.54 0.000 0.45 0.65 
Other 0.72 0.060 0.51 1.01 
Diagnosis Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities 0.91 0.143 0.81 1.03 
3 or more Co-Morbidities 0.90 0.024 0.82 0.99 
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Variable 
Adjusted 
Odds 
Ratio P>|z| 
95% Confidence 
Interval 
Control Variables 
2006 reference 
2007 0.95 0.443 0.84 1.08 
2008 1.08 0.233 0.95 1.24 
2009 1.10 0.128 0.97 1.24 
2010 1.02 0.725 0.90 1.16 
Intercept 0.49 0.000 0.36 0.67 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. The unit 
of analysis is the beneficiary-year. Robust standard errors clustered by individual 
beneficiaries. Model statistics: Wald χ2(17)=256.55, P>|χ2|=0.000; Pseudo R-
squared=0.0188. Adjusted Wald test of joint probability for financial characteristics: 
χ2(6)=7.96, P>|χ2|=0.241; patient characteristics: χ2(5)=229.69, P>|χ2|=0.000; diagnosis 
characteristics: : χ2(2)=5.41, P>|χ2|=0.067. 
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Table 27: Bivariate Comparison Statistics of Explanatory Variables by Oral Anti-
Diabetic Medication Adherence Behavior for Community-Dwelling Medicare 
Beneficiaries Enrolled in the Part D Partial Low Income Subsidy (LIS) Program 
and in Stand-Alone Prescription Drug Plans 
Variable 
Nonadherent 
PDC < 0.8 
Adherent 
PDC >= 
0.8 P value 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy 37.1% 35.4% 0.024a 
50% Premium Subsidy 36.0% 34.7% 
25% Premium Subsidy 26.9% 29.9% 
    
Does not change plans 96.7% 96.7% 0.986a 
Change Plans During Year 3.3% 3.3% 
    
Does not switch plans 89.5% 89.2% 0.751a 
Switch Plans at Re-Enrollment 10.6% 10.8% 
    
Plan Premium Not Above Subsidy 81.4% 81.7% 0.745a 
Plan Premium Above Subsidy Level 18.6% 18.3% 
    
Market Percent of Gap Plans (µ, 
percent) 4.0 4.1 0.038b 
    
Patient Characteristics     
Age (µ, years) 69.4 71.5 0.000b 
    
Female 65.0% 65.7% 0.523a 
Male 35.0% 34.3% 
    
White 69.6% 78.7% 0.000a 
Black 19.5% 12.9% 
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Variable 
Nonadherent 
PDC < 0.8 
Adherent 
PDC >= 
0.8 P value 
Hispanic 9.1% 6.8% 
Other 1.8% 1.6% 
    
Diagnosis Characteristics     
No Co-Morbidities 32.4% 38.6% 0.000a 
1-2 Co-morbidities 11.2% 11.4% 
3 or more Co-Morbidities 56.4% 50.0% 
    
Number of Beneficiary-Years 2,550 6,085 
Percent 29.5% 70.5%   
Note: Statistical test denoted by a is chi-square test and by b is paired t-test of difference 
in means. Data from enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
  
 
 
 
159 
 
 
 
Table 28: Logistic Regression of Financial, Patient, and Diagnosis Characteristics on 
Oral Anti-Diabetic Adherent Behavior for Community-Dwelling Partial LIS 
Medicare Beneficiaries Enrolled in Stand-Alone PDPs 
Variable 
Adjusted 
Odds 
Ratio P>|z| 
95% Confidence 
Interval 
Financial Characteristics 
Partial LIS Income/Subsidy Category 
75% Premium Subsidy reference 
50% Premium Subsidy 0.98 0.820 0.86 1.13 
25% Premium Subsidy 1.13 0.107 0.97 1.31 
Change Plans During Year 1.02 0.897 0.78 1.32 
Switch Plans at Re-Enrollment 1.01 0.867 0.86 1.19 
Plan Premium Above Subsidy Level 0.97 0.680 0.84 1.12 
Market Percent of Gap Plans 1.02 0.119 1.00 1.04 
Patient Characteristics 
Age 1.02 0.000 1.01 1.03 
Female reference 
Male 1.10 0.160 0.96 1.25 
White reference 
Black 0.60 0.000 0.51 0.71 
Hispanic 0.65 0.000 0.52 0.81 
Other 0.74 0.215 0.46 1.19 
Diagnosis Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities 0.79 0.026 0.64 0.97 
3 or more Co-Morbidities 0.67 0.000 0.59 0.77 
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Variable 
Adjusted 
Odds 
Ratio P>|z| 
95% Confidence 
Interval 
Control Variables 
2006 reference 
2007 0.73 0.001 0.60 0.88 
2008 0.70 0.001 0.57 0.86 
2009 0.76 0.006 0.63 0.92 
2010 0.61 0.000 0.50 0.74 
Intercept 1.06 0.821 0.66 1.69 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. The unit 
of analysis is the beneficiary-year. Robust standard errors clustered by individual 
beneficiaries. Model statistics: Wald χ2(17)=156.43, P>|χ2|=0.000; Pseudo R-
squared=0.0227. Adjusted Wald test of joint probability for financial characteristics: 
χ2(6)=6.65, P>|χ2|=0.355; patient characteristics: χ2(5)=98.76, P>|χ2|=0.000; diagnosis 
characteristics: : χ2(2)=33.97, P>|χ2|=0.000. 
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Table 29: Adjusted Marginal Probability of Adherent Prescription Drug Behavior by Drug Therapy Class Cohorts 
  
Proton Pump Inhibitor 
Therapeutic Class 
Cohort 
Statin Therapeutic 
Class Cohort 
Oral Anti-Diabetic 
Therapeutic Class 
Cohort 
Variable 
AME  
(95% CI) P>|z| 
AME  
(95% CI) P>|z| 
AME  
(95% CI) P>|z| 
Financial Characteristics       
Partial LIS Income/Subsidy Category    
75% Premium Subsidy reference reference reference 
50% Premium Subsidy 0.0201 0.177 0.0018 0.875 -0.0033 0.820 
(-0.01,0.05)   (-0.02,0.02)   (-0.03,0.03) 
25% Premium Subsidy 0.0366 0.020 0.0181 0.135 0.0249 0.106 
(0.01,0.07)   (-0.01,0.04)   (-0.01,0.06) 
    
Change Plans During Year -0.0680 0.015 -0.0365 0.110 0.0036 0.897 
(-0.12,-0.01)   (-0.08,0.01)   (-0.05,0.06) 
Switch Plans at Re-Enrollment 0.0256 0.112 0.0133 0.300 0.0028 0.866 
(-0.01,0.06)   (-0.01,0.04)   (-0.03,0.04) 
Plan Premium Above Subsidy Level 0.0048 0.753 0.0131 0.277 -0.0063 0.681 
(-0.03,0.03)   (-0.01,0.04)   (-0.04,0.02) 
Market Percent of Gap Plans -0.0005 0.834 -0.0009 0.631 0.0036 0.119 
(-0.01,0.004)   (-0.004,0.003)   (-0.001,0.01) 
       
Patient Characteristics       
Age 0.0036 0.000 0.0042 0.000 0.0040 0.000 
(0.003,0.005)   (0.003,0.01)   (0.003,0.01) 
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Proton Pump Inhibitor 
Therapeutic Class 
Cohort 
Statin Therapeutic 
Class Cohort 
Oral Anti-Diabetic 
Therapeutic Class 
Cohort 
Variable 
AME  
(95% CI) P>|z| 
AME  
(95% CI) P>|z| 
AME  
(95% CI) P>|z| 
Female reference reference reference 
Male 0.0096 0.518 0.0190 0.078 0.0189 0.157 
(-0.02,0.04)   (-0.002,0.04)   (-0.01,0.05) 
    
White reference reference reference 
Black -0.1365 0.000 -0.1542 0.000 -0.1095 0.000 
(-0.18,-0.10)   (-0.18,-0.12)   (-0.15,-0.07) 
Hispanic -0.1571 0.000 -0.1479 0.000 -0.0927 0.000 
(-0.21,-0.11)   (-0.19,-0.10)   (-0.14,-0.04) 
Other -0.1560 0.024 -0.0784 0.067 -0.0634 0.241 
(-0.29,-0.02)   (-0.16,0.01)   (-0.17,0.04) 
    
Diagnosis Characteristics    
No Co-Morbidities reference reference reference 
1-2 Co-morbidities -0.0051 0.806 -0.0214 0.144 -0.0462 0.031 
(-0.05,0.04)   (-0.05,0.01)   (-0.09,-0.004) 
3 or more Co-Morbidities 0.0193 0.192 -0.0247 0.024 -0.0800 0.000 
  (-0.01,0.05)   (-0.05,0.00)   (-0.11,-0.05)   
Note: AME is Average Marginal Effect, at means. CI is Confidence Interval. Probabilities are constructed from Tables 24, 26, and 28 
logit model estimates by therapeutic class cohorts. Data are Medicare claims and enrollment for the enhanced 5% standard sample, 
2006-2010. Predicted probability of PPI adherence is 0.51 (95% CI: 0.50-0.52, P>0.000). Predicted probability of statin adherence is 
0.61 (95% CI: 0.60-0.62, P>0.000). Predicted probability of oral anti-diabetic adherence is 0.70 (95% CI: 0.69-0.72, P>0.000).
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Project Conclusions 
The three research aims of this project examined cost-related underuse of 
prescription drugs and medical care within the Medicare population and explored how 
financial, patient, and diagnostic characteristics were associated with those health 
behaviors.  
Summary of Research Aims 
The first research aim examined the relationship between prescription drug 
coverage and medical care cost underutilization. The primary purpose was to examine 
rates of health care underutilization within the Medicare population and to compare these 
rates before and after the implementation of the Medicare Part D benefit. 
Cost-related underuse is a concern within the Medicare population with limited 
household budgets and no additional financial resources. The implementation of 
Medicare Part D resulted in a reduction of cost-related nonadherence to prescription 
drugs during the initial years, but the relationship to cost-related underuse of medical care 
within the household has not received the same attention. 
The findings demonstrated that the implementation of Medicare Part D benefit 
reduced the rates of cost-related underuse of medical care and prescription drugs. 
Nonetheless, the analysis of the stratified, subpopulations based on underuse behavior in 
2005 showed that prescription drug coverage was not associated with resolving cost-
related underuse of prescription drugs or medical care.  Instead, the findings highlighted 
differences between Medicare beneficiaries that continued to have no drug coverage 
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following the implementation of Part D and those that had continued drug coverage in 
both 2005 and 2007 by showing that those without coverage were associated with an 
increased probability of experiencing new cost-related underuse of prescription drugs or 
medical care in comparison to those Medicare beneficiaries that did not have any self-
reported underuse in 2005 or 2007. 
The strengths of this study are the use of a nationally representative longitudinal 
sample of community-dwelling Medicare beneficiaries that allows comparison of 
behaviors before and after the implementation of Part D. One weakness of the study is 
that it measures association and not causality. 
While cost related underuse of drugs has been examined following the Part D 
implementation, the phenomenon of medical care underutilization due to cost has not 
received the same attention. The main contribution this study makes is the comparison 
with medical care underuse and prescription drug underuse. 
The second research aim evaluated the effects of the Medicare Partial Low 
Income Subsidy benefit on drug adherence. The purpose of this aim was to evaluate the 
Medicare Partial Low Income Subsidy (LIS) benefit and to determine its effect on 
prescription drug adherence for three therapeutic cohorts of beneficiaries prescribed 
statins, anti-diabetic agents, or proton pump inhibitors (PPIs). 
After enrollment in the partial LIS benefit, adherence levels increased on average 
within all three therapeutic cohorts. Comparing the three premium subsidization groups 
found insignificant differences for the statin and oral anti-diabetic cohorts, but small 
differences between the subsidization groups were statistically significant for the PPI 
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cohort, which found that the highest income group had more improvement in adherence 
levels. For all three of the therapeutic cohorts, Medicare beneficiaries residing in more 
competitive Part D plan markets may have experienced less cost pressure from plans with 
more generous benefits. 
Overall, partial LIS enrollees improved adherence rates in the three therapeutic 
classes most likely to have cost-related underuse following enrollment in the benefit. This 
suggests that the partial LIS benefit may be offering financial protections for Medicare 
beneficiaries with out-of-pocket spending for prescription drugs.  
The strengths of this study are the use of national claims data for the 5 percent 
Medicare sample for community-dwelling beneficiaries. The weaknesses of the study are 
the findings are limited to the three drug classes and may not generalize to other partial 
LIS enrollees that do not transition into the benefit from Part D or are enrolled in 
Medicare Advantage plans. 
The partial low income subsidy group has not received much specific attention 
within the literature to date, most likely due to the relatively small size, but this study 
provides an important first step by examining the basic question of enrollee adherence. 
The main contribution of this study is the application of existing health services research 
hypotheses and theory onto an understudied programmatic area. 
The partial low income subsidy extended subsidized benefits to a Medicare 
population that previously did not have any additional assistance, essentially serving as 
an expansion population. The findings from this study suggest that the additional 
assistance has provided clinical improvement, as measured by increased adherence, for 
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these three therapeutic cohorts.  In addition, the finding within all three drug therapy 
cohorts that increased exposure or longer enrollment within the partial LIS benefit was 
associated with better adherence levels suggests that process changes that reduce the 
administrative burden of re-enrollment may improve the health of the Medicare 
population with low incomes. 
The third research aim analyzed the effects of differing subsidization levels by 
income levels and race/ethnicity. The purpose was to examine income effects within the 
Medicare Part D Low Income Partial Subsidy and their effect on prescription drug 
adherence within three selected therapeutic cohorts that frequently experience cost-
related underuse. 
Health services research has demonstrated the effects of income gradients on 
health behaviors and price sensitivity in response to out-of-pocket cost sharing. However, 
these effects have not been examined within the national Medicare population for partial 
low-income subsidy.  
For the PPI cohorts, the 25 percent subsidy group had a higher probability of 
adherent behavior than the 75 percent subsidy group, but the 50 percent subsidy group 
was not significantly different. For the statin and oral anti-diabetic medication cohorts, 
the financial characteristics were not significant. Across all three therapeutic cohorts 
race/ethnicity differences remained and decreased the likelihood of adherent behavior. 
Within the partial low income subsidy program even small income differences may affect 
drug adherence for some therapeutic classes, but race/ethnicity differences are 
statistically significant for all three clinical cohorts. 
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The strengths of this study are the partial low income subsidy groups face the 
same benefit design so that the income effects may be isolated. The weaknesses are the 
findings are examine by selected therapeutic class and need to be replicated for other 
drug therapies. 
Testing of income effects has been limited due to the confounding effects of 
differences in benefit designs linked to income levels. By focusing on the partial low 
income subsidy group, marginal differences in income levels can be tested among 
beneficiaries who face the same coinsurance rates. The main contribution of this study is 
the analysis of income and race/ethnicity effects on adherence while controlling for 
benefit design features with the Medicare population. The Affordable Care Act (ACA) 
eliminated assets restrictions by using modified adjusted gross income (MAGI) 
eligibility, but Medicare savings programs (Medicare-Medicaid duals) and the LIS 
benefit continue to use assets. The limited findings on income differences in this study 
but the sharp contrasts by race/ethnicity may be capturing these asset differences. Within 
the Medicare population, the spend down of asset levels is most frequently associated 
with needing Medicaid wrap-around coverage for nursing home care as a result of 
declining health that requires long term care assistance. Eliminating the asset 
qualification would provide Part D cost sharing assistance for the beneficiary, and the 
reduced financial pressure may maintain and increase health within Medicare population 
with low incomes.  
One of the key features of the ACA is premium subsidization for lower income 
populations. The Medicare Part D partial Low Income Subsidy program provides a useful 
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scale comparison, with the limitation of focus on an elderly population, of subsidization 
based on income levels for an expansion population. The findings from this study show 
that income effects have been minimized, but race/ethnicity differences remain.  
A summary of financial, patient, and diagnosis characteristics across the three 
studies are listed in Table 30. The application of the conceptual model from Piette’s et 
al.51 development of cost-related non-adherence in Study 1, which directly measure self-
reported cost-related underuse, shows a comparison of the financial characteristics by the 
stratification of the Medicare population based on underuse and no underuse were only 
significant for those experiencing new cost-related underuse of medical care. For the 
other subpopulations, resolved underuse or new cost-related prescription drug underuse 
was associated with patient characteristics and their diagnosis characteristics. For Studies 
2 and 3, the use of therapeutic classes most likely to have cost-related underuse to 
examine adherence within a low-income Medicare population was an attempt to keep the 
same framework, but financial characteristics were not significant for either Study 2 or 
3’s oral anti-diabetic cohorts and were not significant for Study 2’s PPI cohort or Study 
3’s statin cohort. It may be the case that medically-sensitive therapeutic classes would 
show different results. 
Policy Implications 
The LIS program provides premium payment assistance and reduced cost-sharing 
for Medicare Part D beneficiaries who qualify based on income and asset levels. The 
income limits for LIS qualification are up to 150% of the federal poverty limit (FPL) and, 
in 2011, assets that do not exceed $12,640 for individuals or $25,260 for married couples. 
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Medicare beneficiaries who are dually enrolled in Medicaid are auto-enrolled or deemed 
into LIS and receive a full 100% premium subsidy. Non-deemed LIS recipients must 
apply for program enrollment and receive partial premium assistance on a sliding scale 
based on their income level and a set 15% co-insurance rate. In addition to premium and 
cost-sharing assistance, LIS program enrollees do not experience the coverage gap during 
the year and may change drug plans at any time. The findings from Study 1 suggest that 
programs that target those without drug coverage to enroll in the Part D benefit would 
help to reduce new cost-related underuse of prescription drugs or medical care. The 
implications of the study 2 findings suggest that efforts to improve awareness of the 
availability of the LIS program to increase enrollment will benefit Medicare population 
health by improving adherence levels for drugs most likely to have cost-related underuse. 
From Study 3, the findings suggest the importance of targeting programs and policy 
changes to improve patient-physician communication about prescription drug treatment 
efficacy to increase drug adherence levels and reduce differences by race/ethnicity. 
Future Research 
Additional research related to these research aims includes examining how 
financial, patient, and diagnostic characteristics affect additional outcomes, study 
populations, and time periods. 
Following from the first research aim examining how cost-related underuse of 
medical care was affected by reduced financial constraints from obtaining drug coverage, 
it is important to test the model during other time periods to examine how changes in 
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drug coverage that are not from a nationwide benefit expansion may affect underuse of 
medical care. 
The next top priority following from the findings of the second research aim on 
the transition into the partial LIS program is to examine other outcomes, such as drug 
initiation and discontinuation, and other therapeutic classes, such as medications for 
medically sensitive conditions. In addition based on understanding the dynamic 
enrollment patterns of the partial LIS beneficiaries learned in creating the analytical 
dataset for Study 2, a new research aim examining preventable hospital admissions and 
readmissions for medication sensitive conditions comparing partial LIS beneficiaries who 
enroll and disenroll in the Part D benefit is an important area of future study. 
Adding the Medicare Advantage population is the next step for the third research 
aim study. Schneeweiss, et al.182 have shown using the New Jersey Medicaid population 
that prescription drug therapeutic risk adjusters are adequate substitutes for diagnosis 
developed adjusters. With the use of a commercial therapeutic classification of 
prescription drugs to create risk adjusters for the diagnostic characteristic measures, the 
Medicare Advantage and stand-alone prescription drug populations could be studied 
together for a more complete picture of the partial LIS program and further examination 
of the race/ethnicity differences within the partial LIS enrollment population. 
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Table 30: Project Summary of Adjusted Wald Test of Financial, Patient, and 
Diagnosis Characteristics Model Findings on Cost-Related Underuse and 
Therapeutic Drug Classes More Likely to have Cost-Related Underuse 
Study, Outcome (Table) 
Financial 
Characteristics 
Patient 
Characteristics 
Diagnosis 
Characteristics 
Study 1: Cost-Related 
Underuse of Prescription 
Drugs in 2007 for those 
Experiencing Cost-
Related Underuse of 
Prescription Drugs in 
2005 (Table 4) 
Not Significant Significant Significant 
Study 1: Cost-Related 
Underuse of Prescription 
Drugs in 2007 for those 
Not Experiencing Cost-
Related Underuse of 
Prescription Drugs in 
2005 (Table 6) 
Not Significant Significant Significant 
Study 1: Cost-Related 
Underuse of Medical 
Care in 2007 for those 
Experiencing Cost-
Related Underuse of 
Medical Care in 2005 
(Table 9) 
Not Significant Not Significant Not Significant 
Study 1: Cost-Related 
Underuse of Medical 
Care in 2007 for those 
Not Experiencing Cost-
Related Underuse of 
Medical Care in 2005  
(Table 11) 
Significant Significant Significant 
Study 2: PPI Adherence 
Before and After Partial 
LIS Enrollment (Table 
16) 
Not Significant Not Significant Significant 
Study 2: Statin 
Adherence Before and 
After Partial LIS 
Enrollment (Table 19) 
Significant Significant Not Significant 
 172 
 
Study, Outcome (Table) 
Financial 
Characteristics 
Patient 
Characteristics 
Diagnosis 
Characteristics 
Study 2: Oral Anti-
Diabetic Adherence 
Before and After Partial 
LIS Enrollment (Table 
22) 
Not Significant Not Significant Not Significant 
Study 3: PPI Adherence 
for Continuous Partial 
LIS Enrollees During 
Calendar Year (Table 24)  
Significant Significant Not Significant 
Study 3: Statin 
Adherence for 
Continuous Partial LIS 
Enrollees During 
Calendar Year (Table 26) 
Not Significant Significant Not Significant 
Study 3: Oral Anti-
Diabetic Adherence for 
Continuous Partial LIS 
Enrollees During 
Calendar Year (Table 28) 
Not Significant Significant Significant 
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Appendix A for Study 2 
The single treatment-only cohort research design is tested using Heckman’s 
selection model with the observational data. The two-part model tests for unobservable 
bias of the self-selection into the partial Low Income Subsidy (LIS) program by the 
Medicare beneficiaries. The first part of the model is a discrete model of enrollment in 
partial LIS for all Part D enrollees within each therapeutic drug cohort. Two variables 
included within this discrete model, in addition to the financial, personal, and diagnostic 
explanatory variables, are a measure of hospitalizations and a measure of full LIS 
enrollment by three-digit zip code or ZCTA (zip code tabulation area). These two 
measures are expected to capture the increased likelihood that a beneficiary may 
transition into LIS enrollment. The second part of the model is a regression analysis of 
the change in adherence level before and after partial LIS enrollment. Heckman’s two-
part selection model is performed using SAS 9.4.  
Appendix Figure A-1 shows the final stages of the analytical sample construction 
for the selection data model analyses. The 552,511 Medicare beneficiaries from the 
enhanced 5% Medicare sample that have not previously transitioned into the LIS 
program, are community-dwelling, and continuously enrolled in stand-alone Medicare 
Part D prescription drug plans (PDPs) form the basis for the analytical sample. A total of 
3,322 Medicare beneficiaries transition into the partial LIS program from this core group, 
and the remaining 549,189 beneficiaries do not have any transitions before the end of the 
study period in December, 2010. The three therapeutic cohorts from these two groups of 
partial LIS transition and non-transition are then selected based on prescription drug fills 
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for proton pump inhibitors, statins, or oral anti-diabetic medications within the claims 
data.  
Full selection model results by therapeutic class are provided in Appendix Tables 
A-1 through A-3. Based on the lack of statistical significance of the Rho computation 
from the selection models, the model results for Study 2 are run using regression and the 
Heckman model is not needed for estimation of a correction for self-selection into the 
partial LIS program. 
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Figure A-1: Heckman Selection Model Analytical Sample Construction 
 
  
 
3,322 beneficiaries transition into 
Partial LIS benefit from non-LIS Part D 
continuous enrollment  
549,189 beneficiaries continuously 
enrolled in Part D that do not 
transition into Partial LIS benefit 
1,606 beneficiaries with 
statin filled before and 
after Partial LIS 
enrollment  
747 beneficiaries with 
oral anti-diabetic filled 
before and after Partial 
LIS enrollment  
1,005 beneficiaries with 
PPI filled before and after 
Partial LIS enrollment  
552,511 community-dwelling, FFS Part D 
beneficiaries without prior LIS 
196,595 beneficiaries 
with PPI filled while 
Part D enrolled 
309,399 beneficiaries 
with statin filled 
while Part D enrolled 
105,955 beneficiaries 
with oral anti-
diabetic filled while 
Part D enrolled 
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Appendix Table A-1: Heckman Selection Model Results of Discrete Choice of 
Transition into Partial Low Income Subsidy (LIS) Program and Continuous 
Measure of Change in Adherence Before and After Partial LIS Enrollment for 
2006-2010 Cohort of 5% Enhanced Sample of Medicare Beneficiaries Taking 
Proton Pump Inhibitors (PPIs) Medications 
Variable Name Parameter 
Standard 
Error P-value 
Discrete Choice Model, Part 1 
Intercept -1.126 0.090 <.0001 
Transition Measures 
Hospitalization in Prior 6 
Months -0.277 0.029 <.0001 
ZCAT Full LIS Enrollment Rate -0.146 0.011 <.0001 
Financial Characteristics 
Market Percent of Gap Plans 0.212 0.016 <.0001 
Patient Characteristics 
Age -0.022 0.001 <.0001 
Female reference 
Male -0.199 0.026 <.0001 
White reference 
Black 0.309 0.044 <.0001 
Hispanic 0.010 0.062 0.8781 
Other Race/Ethnicity -0.232 0.131 0.0768 
Disease Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities -0.019 0.053 0.7268 
3 or more Co-Morbidities 0.270 0.028 <.0001 
Regression Model, Part 2 
Intercept 0.437 0.184 0.0176 
Financial Characteristics 
75% Premium Subsidy reference 
50% Premium Subsidy -0.040 0.035 0.2530 
25% Premium Subsidy 0.030 0.035 0.3976 
Switch Plans at Transition 0.221 0.151 0.1439 
Change Plans Post-Enrollment -0.046 0.079 0.5580 
Market Percent of Gap Plans -0.046 0.021 0.0250 
Plan Premium Above Subsidy 
Level -0.042 0.031 0.1712 
Patient Characteristics 
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Variable Name Parameter 
Standard 
Error P-value 
Age 0.002 0.002 0.4439 
Female reference 
Male 0.010 0.037 0.7770 
White reference 
Black -0.019 0.053 0.7155 
Hispanic -0.015 0.071 0.8341 
Other Race/Ethnicity -0.140 0.170 0.4122 
Disease Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities -0.099 0.069 0.1560 
3 or more Co-Morbidities 0.004 0.034 0.9095 
Control Variable 
Duration Before Transition -0.003 0.001 0.0033 
Duration After Transition 0.005 0.001 <.0001 
Rho -0.222 0.182 0.2210 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010.  
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Appendix Table A-2: Heckman Selection Model Results of Discrete Choice of 
Transition into Partial Low Income Subsidy (LIS) Program and Continuous 
Measure of Change in Adherence Before and After Partial LIS Enrollment for 
2006-2010 Cohort of 5% Enhanced Sample of Medicare Beneficiaries Taking Statin 
Medications 
Variable Name Parameter 
Standard 
Error P-value 
Discrete Choice Model, Part 1 
Intercept -1.385 0.081 <.0001 
Transition Measures 
Hospitalization in Prior 6 
Months -0.291 0.025 <.0001 
ZCAT Full LIS Enrollment Rate -0.140 0.009 <.0001 
Financial Characteristics 
Market Percent of Gap Plans 0.283 0.013 <.0001 
Patient Characteristics 
Age -0.021 0.001 <.0001 
Female reference 
Male -0.241 0.020 <.0001 
White reference 
Black 0.407 0.032 <.0001 
Hispanic 0.076 0.048 0.1157 
Other Race/Ethnicity -0.152 0.092 0.0996 
Disease Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities 0.138 0.037 0.0002 
3 or more Co-Morbidities 0.339 0.022 <.0001 
Regression Model, Part 2 
Intercept 0.221 0.144 0.1239 
Financial Characteristics 
75% Premium Subsidy reference 
50% Premium Subsidy 0.002 0.024 0.9292 
25% Premium Subsidy 0.033 0.024 0.1764 
Switch Plans at Transition 0.056 0.106 0.5959 
Change Plans Post-Enrollment -0.022 0.062 0.7224 
Market Percent of Gap Plans -0.016 0.018 0.3511 
Plan Premium Above Subsidy 
Level 0.022 0.021 0.3149 
Patient Characteristics 
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Variable Name Parameter 
Standard 
Error P-value 
Age -0.005 0.002 0.0024 
Female reference 
Male -0.070 0.027 0.0099 
White reference 
Black 0.034 0.037 0.3520 
Hispanic 0.084 0.047 0.0744 
Other Race/Ethnicity -0.059 0.106 0.5736 
Disease Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities -0.018 0.041 0.6677 
3 or more Co-Morbidities 0.033 0.024 0.1749 
Control Variable 
Duration Before Transition -0.003 0.001 0.0002 
Duration After Transition 0.006 0.001 <.0001 
Rho 0.226 0.143 0.1149 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010.  
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Appendix Table A-3: Heckman Selection Model Results of Discrete Choice of 
Transition into Partial Low Income Subsidy (LIS) Program and Continuous 
Measure of Change in Adherence Before and After Partial LIS Enrollment for 
2006-2010 Cohort of 5% Enhanced Sample of Medicare Beneficiaries Taking Oral 
Anti-Diabetic Medications 
Variable Name Parameter 
Standard 
Error P-value 
Discrete Choice Model, Part 1 
Intercept -1.209 0.118 <.0001 
Transition Measures 
Hospitalization in Prior 6 Months -0.305 0.036 <.0001 
ZCAT Full LIS Enrollment Rate -0.149 0.013 <.0001 
Financial Characteristics 
Market Percent of Gap Plans 0.250 0.018 <.0001 
Patient Characteristics 
Age -0.020 0.002 <.0001 
Female reference 
Male -0.265 0.030 <.0001 
White reference 
Black 0.271 0.044 <.0001 
Hispanic 0.095 0.062 0.1268 
Other Race/Ethnicity -0.213 0.131 0.1028 
Disease Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities 0.073 0.087 0.4012 
3 or more Co-Morbidities 0.240 0.033 <.0001 
Regression Model, Part 2 
Intercept 0.604 0.197 0.0022 
Financial Characteristics 
75% Premium Subsidy reference 
50% Premium Subsidy -0.039 0.037 0.2837 
25% Premium Subsidy -0.061 0.038 0.1117 
Switch Plans at Transition 0.021 0.132 0.8747 
Change Plans Post-Enrollment 0.096 0.079 0.2237 
Market Percent of Gap Plans -0.049 0.022 0.0283 
Plan Premium Above Subsidy Level -0.037 0.034 0.2676 
Patient Characteristics 
Age -0.003 0.002 0.1349 
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Variable Name Parameter 
Standard 
Error P-value 
Female reference 
Male 0.001 0.040 0.9771 
White reference 
Black -0.048 0.048 0.3179 
Hispanic 0.047 0.062 0.4529 
Other Race/Ethnicity -0.015 0.157 0.9252 
Disease Characteristics 
No Co-Morbidities reference 
1-2 Co-morbidities -0.108 0.098 0.2695 
3 or more Co-Morbidities -0.032 0.033 0.3342 
Control Variable 
Duration Before Transition -0.002 0.001 0.1278 
Duration After Transition 0.005 0.001 <.0001 
Rho -0.159 0.191 0.4063 
Note: Data from the enhanced 5% sample of Medicare beneficiaries, 2006-2010. 
 
 
